| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:3373.)
© 2002 American Heart Association, Inc.
ATP III Final Report |
References
 |
References |
|---|
 Top References |
|---|
1. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. NIH Pub. No. 93-3095. Bethesda, MD: National Heart, Lung, and Blood Institute, 1993; 180 pages.
2. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation1994; 89:1333 -445.[Medline] [Order article via Infotrieve]
3. Report of the National Cholesterol Education Program Expert Panel
on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults:
the Expert Panel. Arch Intern Med1988; 148:36
-69.
4. National Cholesterol Education Program. High Blood Cholesterol in Adults: Report of the Expert Panel on Detection, Evaluation, and Treatment. NIH Pub. No. 88-2925. Bethesda, MD: National Heart, Lung, and Blood Institute, 1988; 87 pages.
5. National Cholesterol Education Program. Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction. NIH Pub. No. 90-3046. Bethesda, MD: National Heart, Lung, and Blood Institute,1990; 139 pages.
6. Report of the Expert Panel on Population Strategies for Blood
Cholesterol Reduction. A statement from the National Cholesterol Education
Program, National Heart, Lung, and Blood Institute, National Institutes of
Health. Circulation1991; 83:2154
-232.
7. Cleeman JI, Lenfant C. The National Cholesterol Education Program:
progress and prospects. JAMA1998; 280:2099
-104.
8. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol
homeostasis. Science1986; 232:34
-47.
9. Glueck CJ, Gartside PF, Fallart RW, Sielski J, Steiner PM. Longevity syndromes: familial hypobeta and familial hyperalpha lipoproteinemia. J Lab Clin Med1976; 88:941 -57.[Medline] [Order article via Infotrieve]
10. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H,
Kannel WB. Prediction of coronary heart disease using risk factor categories.
Circulation1998; 97:1837
-47.
11. Stamler J, Wentworth D, Neaton JD, for the MRFIT Research Group. Is
relationship between serum cholesterol and risk of premature death from
coronary heart disease continuous and graded? Findings in 356 222 primary
screenees of the Multiple Risk Factor Intervention Trial (MRFIT).
JAMA 1986;256:2823
-8.
12. Lipid Research Clinics Program. The Lipid Research Clinics Coronary
Primary Prevention Trial results. I: Reduction in the incidence of coronary
heart disease. JAMA1984; 251:351
-64.
13. Lipid Research Clinics Program. The Lipid Research Clinics Coronary
Primary Prevention Trial results. II: The relationship of reduction in
incidence of coronary heart disease to cholesterol lowering.
JAMA 1984;251:365
-74.
14. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med1990; 323:1112 -9.[Medline] [Order article via Infotrieve]
15. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, Tyroler HA. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med1990; 322:1700 -7.[Abstract]
16. Wong ND, Wilson PWF, Kannel WB. Serum cholesterol as a prognostic
factor after myocardial infarction: the Framingham Study. Ann
Intern Med 1991;115:687
-93.
17. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet1999; 353:89 -92.[CrossRef][Medline] [Order article via Infotrieve]
18. McGill HC Jr. Introduction to the geographic pathology of atherosclerosis. Lab Invest1968; 18:465 -7.[Medline] [Order article via Infotrieve]
19. Keys A, Arvanis C, Blackburn H. Seven countries: a multivariate analysis of death and coronary heart disease. Cambridge, MA: Harvard University Press, 1980;381 .
20. Keys A, Menotti A, Aravanis C, Blackburn H, Djordjevic BS, Buzina R, Dontas AS, Fidanza F, Karvonen MJ, Kimura N, Mohacek I, Nedeljkovic S, Puddu V, Punsar S, Taylor HL, Conti S, Kromhout D, Toshima H. The Seven Countries Study: 2,289 deaths in 15 years. Prev Med1984; 13:141 -54.[CrossRef][Medline] [Order article via Infotrieve]
21. Kagan A, Harris BR, Winkelstein W Jr, Johnson KG, Kato H, Syme SL, Rhoads GG, Gay ML, Nichaman MZ, Hamilton HB, Tillotson J. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii, and California: demographic, physical, dietary and biochemical characteristics. J Chron Dis1974; 27:345 -64.[CrossRef][Medline] [Order article via Infotrieve]
22. Toor M, Katchalsky A, Agmon J, Allalouf D. Atherosclerosis and
related factors in immigrants to Israel. Circulation1960; 22:265
-79.
23. Law MR, Wald NJ, Thompson SG. By how much and how quickly does
reduction in serum cholesterol concentration lower risk of ischaemic heart
disease? BMJ1994; 308:367
-72.
24. Law MR. Lowering heart disease risk with cholesterol reduction: evidence from observational studies and clinical trials. Eur Heart J Suppl 1999;(suppl S):S3 -S8.
25. Grundy SM, Wilhelmsen L, Rose G, Campbell RWF, Assmann G. Coronary
heart disease in high-risk populations: lessons from Finland. Eur
Heart J 1990;11:462
-71.
26. People's Republic of China-United States Cardiovascular and
Cardiopulmonary Epidemiology Research Group. An epidemiological study of
cardiovascular and cardiopulmonary disease risk factors in four populations in
the People's Republic of China: baseline report from the P.R.C.-U.S.A.
Collaborative Study. Circulation1992; 85:1083
-96.
27. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of
reducing serum cholesterol. BMJ1994; 308:373
-9.
28. Law MR, Wald NJ, Wu T, Hackshaw A, Bailey A. Systematic
underestimation of association between serum cholesterol concentration and
ischaemic heart disease in observational studies: data from the BUPA study.
BMJ 1994;308:363
-6.
29. McGill HC Jr, McMahan CA, Malcom GT, Oalmann MC, Strong JP, for the
PDAY Research Group. Effects of serum lipoproteins and smoking on
atherosclerosis in young men and women. Arterioscler Thromb Vasc
Biol 1997;17:95
-106.
30. McGill HC Jr, McMahan CA, and the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Determinants of atherosclerosis in the young. Am J Cardiol1998; 82:30T -6T.[Medline] [Order article via Infotrieve]
31. McGill HC Jr, McMahan CA, Zieske AW, Sloop GD, Walcott JV,
Troxclair DA, Malcom GT, Tracy RE, Oalmann MC, Strong JP, for the
Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research
Group. Associations of coronary heart disease risk factors with the
intermediate lesion of atherosclerosis in youth. Arterioscler
Thromb Vasc Biol 2000;20:1998
-2004.
32. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30
years of follow-up from the Framingham Study. JAMA1987; 257:2176
-80.
33. Klag MJ, Ford DE, Mead LA, He J, Whelton PK, Liang K-Y, Levine DM.
Serum cholesterol in young men and subsequent cardiovascular disease.
N Engl J Med1993; 328:313
-8.
34. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton
JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of
younger men to long-term coronary, cardiovascular, and all-cause mortality and
to longevity. JAMA2000; 284:311
-8.
35. Stary HC, Blankenhorn DH, Chandler AB, Glagov S, Insull WR Jr,
Richardson M, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW. A
definition of the intima of human arteries and of its atherosclerosisprone
regions: a report from the Committee on Vascular Lesions of the Council on
Arteriosclerosis, American Heart Association.
Circulation1992; 85:391
-405.
36. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld
ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW. A definition of initial,
fatty streak, and intermediate lesions of atherosclerosis: a report from the
Committee on Vascular Lesions of the Council on Arteriosclerosis, American
Heart Association. Arterioscler Thromb1994; 14:840
-56.
37. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W
Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced
types of atherosclerotic lesions and a histological classification of
atherosclerosis: a report from the Committee on Vascular Lesions of the
Council on Arteriosclerosis, American Heart Association.
Circulation1995; 92:1355
-74.
38. Libby P. Molecular bases of the acute coronary syndromes.
Circulation1995; 91:2844
-50.
39. Libby P, Schoenbeck U, Mach F, Selwyn AP, Ganz P. Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. Am J Med1998; 104(2A):14S -8S.[Medline] [Order article via Infotrieve]
40. Fuster V, Fayad ZA, Badimon JJ. Acute coronary syndromes: biology. Lancet1999; 353(suppl II):SII5 -SII9.[Medline] [Order article via Infotrieve]
41. Théroux P, Fuster V. Acute coronary syndromes: unstable
angina and non-Q-wave myocardial infarction.
Circulation1998; 97:1195
-206.
42. Brown BG, Stewart BF, Zhao X-Q, Hillger LA, Poulin D, Albers JJ. What benefit can be derived from treating normocholesterolemic patients with coronary artery disease? Am J Cardiol1995; 76:93C -7C.[CrossRef][Medline] [Order article via Infotrieve]
43. Brown BG, Zhao XQ. Lipid therapy to stabilize the vulnerable atherosclerotic plaque: new insights into the prevention of cardiovascular events. In: Grundy SM, ed. Cholesterol-lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker, Inc.,2000 : 249-72.
44. Grundy SM. Cholesterol-lowering trials: a historical perspective. In: Grundy SM, ed. Cholesterol lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker Inc., 2000:1 -329.
45. Gordon DJ. Cholesterol lowering reduces mortality: the statins. In: Grundy SM, ed. Cholesterol-lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker Inc., 2000:299 -311.
46. Holmes CL, Schulzer M, Mancini GB. Angiographic results of lipid-lowering trials: a systematic review and meta-analysis. In: Grundy SM, ed. Cholesterol-lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker Inc., 2000:191 -220.
47. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM,
Keech A, Packard C, Simes J, Byington R, Furberg CD, for the Prospective
Pravastatin Pooling Project Investigators Group. Effect of pravastatin on
coronary disease events in subgroups defined by coronary risk factors: the
Prospective Pravastatin Pooling Project. Circulation2000; 102:1893
-900.
48. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas
FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J, for the Veterans
Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Gemfibrozil for the secondary prevention of coronary heart disease in men with
low levels of high-density lipoprotein cholesterol. N Engl J
Med 1999;341:410
-8.
49. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol1998; 81:7B -12B.[CrossRef][Medline] [Order article via Infotrieve]
50. Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J1998; 19(suppl M):M8 -M14.[Medline] [Order article via Infotrieve]
51. Hulley SB, Rosenman RH, Bawol RD, Brand RJ. Epidemiology as a guide to clinical decisions: the association between triglyceride and coronary heart disease. N Engl J Med1980; 302:1383 -9.[Abstract]
52. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol1998; 81:18B -25B.[CrossRef][Medline] [Order article via Infotrieve]
53. Havel RJ. Role of triglyceride-rich lipoproteins in progression of
atherosclerosis. Circulation1990; 81:694
-6.
54. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol1998; 81:13B -7B.[CrossRef][Medline] [Order article via Infotrieve]
55. Nordestgaard BG, Lewis B. Intermediate density lipoprotein levels are strong predictors of the extent of aortic atherosclerosis in the St. Thomas's Hospital rabbit strain. Atherosclerosis1991; 87:39 -46.[CrossRef][Medline] [Order article via Infotrieve]
56. Breslow JL. Mouse models of atherosclerosis. Science 1996;272:685 -8.[Abstract]
57. Weisgraber KH, Innerarity TL, Rall SC Jr, Mahley RW. Atherogenic lipoproteins resulting from genetic defects of apolipoproteins B and E. Ann NY Acad Sci1990; 598:37 -48.[Medline] [Order article via Infotrieve]
58. Mahley RW, Weisgraber KH, Innerarity TL, Rall SC Jr. Genetic
defects in lipoprotein metabolism: elevation of atherogenic lipoproteins
caused by impaired catabolism. JAMA1991; 265:78
-83.
59. Tatami R, Mabuchi H, Ueda K, Ueda R, Haba T, Kametani T, Ito S,
Koizumi J, Ohta M, Miyamoto S, Nakayama A, Kanaya H, Oiwake H, Genda A, Takeda
R. Intermediate-density lipoprotein and cholesterol-rich very low density
lipoprotein in angiographically determined coronary artery disease.
Circulation1981; 64:1174
-84.
60. Steiner G, Schwartz L, Shumak S, Poapst M. The association of
increased levels of intermediate-density lipoproteins with smoking and with
coronary artery disease. Circulation1987; 75:124
-30.
61. Krauss RM, Lindgren FT, Williams PT, Kelsey SF, Brensike J, Vranizan K, Detre KM, Levy RI. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolemic men. Lancet 1987;2:62 -6.[CrossRef][Medline] [Order article via Infotrieve]
62. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and
progression of coronary artery disease evaluated by angiography and clinical
events. Circulation1993; 88:2762
-70.
63. Tornvall P, Bavenholm P, Landou C, de Faire U, Hamsten A. Relation
of plasma levels and composition of apolipoprotein B-containing lipoproteins
to angiographically defined coronary artery disease in young patients with
myocardial infarction. Circulation1993; 88[part 1]:2180
-9.
64. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L,
Hemphill LC, Kramsch DM, Blankenhorn DH. Triglyceride- and cholesterol-rich
lipoproteins have a differential effect on mild/moderate and severe lesion
progression as assessed by quantitative coronary angiography in a controlled
trial of lovastatin. Circulation1994; 90:42
-9.
65. Koren E, Corder C, Mueller G, Centurion H, Hallum G, Fesmire J, McConathy WD, Alaupovic P. Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease. Atherosclerosis1996; 122:105 -15.[CrossRef][Medline] [Order article via Infotrieve]
66. Karpe F, Boquist S, Tang R, Bond GM, de Faire U, Hamsten A. Remnant
lipoproteins are related to intima-media thickness of the carotid artery
independently of LDL cholesterol and plasma triglycerides. J Lipid
Res 2001;42:17
-21.
67. Takeichi S, Yukawa N, Nakajima Y, Osawa M, Saito T, Seto Y, Nakano T, Saniabadi AR, Adachi M, Wang T, Nakajima K. Association of plasma triglyceride-rich lipoprotein remnants with coronary atherosclerosis in cases of sudden cardiac death. Atherosclerosis1999; 142:309 -15.[CrossRef][Medline] [Order article via Infotrieve]
68. Thompson GR. Angiographic evidence for the role of triglyceride-rich lipoproteins in progression of coronary artery disease. Eur Heart J1998; 19(suppl H):H31 -H36.[Medline] [Order article via Infotrieve]
69. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ,
Pfeffer MA, Braunwald E. VLDL, apolipoproteins B, CIII, and E, and risk of
recurrent coronary events in the Cholesterol and Recurrent Events (CARE)
trial. Circulation2000; 102:1886
-92.
70. Kuchinskiene Z, Carlson LA. Composition, concentration, and size of low density lipoproteins and of subfractions of very low density lipoproteins from serum of normal men and women. J Lipid Res1982; 23:762 -9.[Abstract]
71. Miller KW, Small DM. Surface-to-core and interparticle equilibrium
distributions of triglyceride-rich lipoprotein lipids. J Biol
Chem 1983;258:13772
-84.
72. Bjorkegren J, Boquist S, Samnegard A, Lundman P, Tornvall P,
Ericsson C-G, Hamsten A. Accumulation of apolipoprotein C-I-rich and
cholesterol-rich VLDL remnants during exaggerated postprandial triglyceridemia
in normolipidemic patients with coronary artery disease.
Circulation2000; 101:227
-30.
73. Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am 1994;78:117 -41.[Medline] [Order article via Infotrieve]
74. Chait A, Brunzell JD. Acquired hyperlipidemia (secondary dyslipoproteinemias). Endocrinol Metab Clin North Am1990; 19:259 -78.[Medline] [Order article via Infotrieve]
75. Heiss G, Tamir I, Davis CE, Tyroler HA, Rifkind BM, Schonfeld G,
Jacobs D, Frantz ID Jr. Lipoprotein-cholesterol distributions in selected
North American populations: the Lipid Research Clinics Program Prevalence
Study. Circulation1980; 61:302
-15.
76. Denke MA, Sempos CT, Grundy SM. Excess body weight: an
underrecognized contributor to high blood cholesterol levels in white American
men. Arch Intern Med1993; 153:1093
-103.
77. Denke MA, Sempos CT, Grundy SM. Excess body weight: an
under-recognized contributor to dyslipidemia in white American women.
Arch Intern Med1994; 154:401
-10.
78. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. NIH Pub. No. 98-4083. Bethesda, MD: National Heart, Lung and Blood Institute, 1998;228 pages.
79. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. Obesity Res1998; 6(suppl 2):51S -209S.[Medline] [Order article via Infotrieve]
80. Hardman AE. Physical activity, obesity and blood lipids. Int J Obes Relat Metab Disord1999; 23(suppl 3):S64 -S71.
81. Berg A, Halle M, Franz I, Keul J. Physical activity and lipoprotein metabolism: epidemiological evidence and clinical trials. Eur J Med Res 1997;2:259 -64.[Medline] [Order article via Infotrieve]
82. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest1973; 52:1544 -68.[Medline] [Order article via Infotrieve]
83. Havel RJ. Remnant lipoproteins as therapeutic targets. Curr Opin Lipidol2000; 11:615 -20.[CrossRef][Medline] [Order article via Infotrieve]
84. Wilson MA, Vega GL, Gylling H, Grundy SM. Persistence of
abnormalities in metabolism of apolipoproteins B-100 and A-I after weight
reduction in patients with primary hypertriglyceridemia.
Arteriosclerosis Thrombosis1992; 12:976
-84.
85. Vega GL, Grundy SM. Gemfibrozil therapy in primary
hypertriglyceridemia associated with coronary heart disease.
JAMA 1985;253:2398
-403.
86. Vega GL, Grundy SM. Management of primary mixed hyperlipidemia with
lovastatin. Arch Intern Med1990; 150:1313
-9.
87. Vega GL, Grundy SM. Lipoprotein responses to treatment with
lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with
hypoalphalipoproteinemia. Arch Intern Med1994; 154:73
-82.
88. Mostaza JM, Schulz I, Vega GL, Grundy SM. Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia. Am J Cardiol1997; 79:1298 -301.[CrossRef][Medline] [Order article via Infotrieve]
89. Reardon MF, Nestel PJ, Craig IH, Harper RW. Lipoprotein predictors
of the severity of coronary artery disease in men and women.
Circulation1985; 71:881
-8.
90. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP,
Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein
cholesterol and cardiovascular disease: four prospective American studies.
Circulation1989; 79:8
-15.
91. Frost PH, Havel RJ. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol1998; 81:26B -31B.[CrossRef][Medline] [Order article via Infotrieve]
92. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik
PS, Bush TL. Non-high-density lipoprotein cholesterol level as a predictor of
cardiovascular disease mortality. Arch Intern Med2001; 161:1413
-9.
93. Vega GL, Grundy SM. Does measurement of apolipoprotein B have a
place in cholesterol management[Editorial]?
Arteriosclerosis1990; 10:668
-71.
94. Abate N, Vega GL, Grundy SM. Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. Atherosclerosis1993; 104:159 -71.[CrossRef][Medline] [Order article via Infotrieve]
95. Sedlis SP, Schechtman KB, Ludbrook PA, Sobel BE, Schonfeld G.
Plasma apoproteins and the severity of coronary artery disease.
Circulation1986; 73:978
-86.
96. Sniderman AD. Apolipoprotein B and apolipoprotein AI as predictors of coronary artery disease. Can J Cardiol1988; 4(suppl A):24A -30A.[Medline] [Order article via Infotrieve]
97. Marcovina S, Zoppo A, Graziani MS, Vassanelli C, Catapano AL. Evaluation of apolipoproteins A-I and B as markers of angiographically assessed coronary artery disease. La Ric Clin Lab1988; 18:319 -28.[CrossRef][Medline] [Order article via Infotrieve]
98. Reinhart RA, Gani K, Arndt MR, Broste SK. Apolipoproteins A-I and B
as predictors of angiographically defined coronary artery disease.
Arch Intern Med1990; 150:1629
-33.
99. Sniderman A, Vu H, Cianflone K. Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels. Atherosclerosis1991; 89:109 -16.[CrossRef][Medline] [Order article via Infotrieve]
100. Levinson SS, Wagner SG. Measurement of apolipoprotein B-containing lipoproteins for routine clinical laboratory use in cardiovascular disease. Arch Pathol Lab Med1992; 116:1350 -4.[Medline] [Order article via Infotrieve]
101. Kwiterovich PO Jr, Coresh J, Smith HH, Bachorik PS, Derby CA, Pearson TA. Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men and women with premature coronary artery disease. Am J Cardiol1992; 69:1015 -21.[CrossRef][Medline] [Order article via Infotrieve]
102. Westerveld HT, Roeters van Lennep JE, Roeters van Lennep HW, Liem
A-H, de Boo JA, van der Schouw YT, Erkelens W. Apolipoprotein B and coronary
artery disease in women: a cross-sectional study in women undergoing their
first coronary angiography. Arterioscler Thromb Vasc
Biol 1998;18:1101
-7.
103. Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S,
Jou JY, Langendörfer A, Beere PA, Watson DJ, Downs JR, de Cani JS.
Relation between baseline and on-treatment lipid parameters and first acute
major coronary events in the Air Force/Texas Coronary Atherosclerosis
Prevention Study (AFCAPS/TexCAPS). Circulation2000; 101:477
-84.
104. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard P-M, Dagenais
GR, Despres J-P. Apolipoprotein A-I and B levels and the risk of ischemic
heart disease during a five-year follow-up of men in the Quebec Cardiovascular
Study. Circulation1996; 94:273
-8.
105. Lemieux I, Pascot A, Couillard C, Lamarche B, T chernof A, Almeras
N, Bergeron J, Gaudet D, Tremblay G, Prud'homme D, Nadeau A, Despres J-P.
Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad
(hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?
Circulation2000; 102:179
-84.
106. Lipid Research Clinics Program Epidemiology Committee. Plasma lipid
distributions in selected North American populations: the Lipid Research
Clinics Program Prevalence Study. Circulation1979; 60:427
-39.
107. Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes
on survival following myocardial infarction in men vs women: the Framingham
Study. JAMA1988; 260:3456
-60.
108. Wilson PW, Garrison RJ, Castelli WP, Feinleib M, McNamara PM, Kannel WB. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol1980; 46:649 -54.[CrossRef][Medline] [Order article via Infotrieve]
109. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis1996; 124(suppl 6):S11 -S20.[CrossRef][Medline] [Order article via Infotrieve]
110. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature1991; 353:265 -7.[CrossRef][Medline] [Order article via Infotrieve]
111. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene
expression increases high density lipoprotein and suppresses atherosclerosis
in apolipoprotein E-deficient mouse. Proc Natl Acad Sci
USA 1994;91:9607
-11.
112. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Puré E, Rader
DJ. Regression of atherosclerosis induced by liver-directed gene transfer of
apolipoprotein A-I in mice. Circulation1999; 100:1816
-22.
113. Tall AR. An overview of reverse cholesterol transport. Eur Heart J1998; 19(suppl A):A31 -A35.[Medline] [Order article via Infotrieve]
114. van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response: loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995;96:2758 -67.[Medline] [Order article via Infotrieve]
115. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD,
Reddy ST, Sevanian A, Fonarow GC, Fogelman AM. Normal high density lipoprotein
inhibits three steps in the formation of mildly oxidized low density
lipoprotein: steps 2 and 3. J Lipid Res2000; 41:1495
-508.
116. Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L,
Subbanagounder G, Faull KF, Reddy ST, Miller NE, Fogelman AM. Normal high
density lipoprotein inhibits three steps in the formation of mildly oxidized
low density lipoprotein: step 1. J Lipid Res2000; 41:1481
-94.
117. Ng DS, Vezina C, Wolever TS, Kuksis A, Hegele RA, Connelly PW.
Apolipoprotein A-I deficiency: biochemical and metabolic characteristics.
Arterioscler Thromb Vasc Biol1995; 15:2157
-64.
118. Miller M, Aiello D, Pritchard H, Friel G, Zeller K. Apolipoprotein
A-I Zavalla (Leu159
Pro): HDL cholesterol
deficiency in a kindred associated with premature coronary artery disease.
Arterioscler Thromb Vasc Biol1998; 18:1242
-7.
119. Römling R, von Eckardstein A, Funke H, Motti C, Fragiacomo GC,
Noseda G, Assmann G. A nonsense mutation in the apolipoprotein A-I gene is
associated with high-density lipoprotein deficiency and periorbital
xanthelasmas. Arterioscler Thromb1994; 14:1915
-22.
120. Takata K, Saku K, Ohta T, Takata M, Bai H, Jimi S, Liu R, Sato H,
Kajiyama G, Arakawa K. A new case of Apo A-I deficiency showing codon 8
nonsense mutation of the Apo A-I gene without evidence of coronary heart
disease. Arterioscler Thromb Vasc Biol1995; 15:1866
-74.
121. Miccoli R, Bertolotto A, Navalesi R, Odoguardi L, Boni A, Wessling
J, Funke H, Wiebusch H, von Eckardstein A, Assmann G. Compound heterozygosity
for a structural apolipoprotein A-I variant, apo A-I (L141R) Pisa,
and an apolipoprotein A-I null allele in patients with absence of HDL
cholesterol, corneal opacifications, and coronary heart disease.
Circulation1996; 94:1622
-8.
122. Vega GL, Grundy SM. Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Curr Opin Lipidol 1996;7:209 -16.[Medline] [Order article via Infotrieve]
123. Schaefer EJ, Lamon-Fava S, Ordovas JM, Cohn SD, Schaefer MM, Castelli WP, Wilson PWF. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res1994; 35:871 -82.[Abstract]
124. Phillips NR, Havel RJ, Kane JP. Levels and interrelationships of
serum and lipoprotein cholesterol and triglycerides: association with
adiposity and the consumption of ethanol, tobacco, and beverages containing
caffeine. Arteriosclerosis1981; 1:13
-24.
125. Austin MA, King M-C, Vranizan KM, Krauss RM. Atherogenic
lipoprotein phenotype: a proposed genetic marker for coronary heart disease
risk. Circulation1990; 82:495
-506.
126. Luc G, Bard JM, Poulain P, Arveiler D, Evans AE, Cambien F, Fruchart JC, Ducimetiere P. Relationship between low-density lipoprotein size and apolipoprotein A-I-containing particles: the ECTIM Study. Eur J Clin Invest 1997;27:242 -7.[CrossRef][Medline] [Order article via Infotrieve]
127. Rainwater DL. Lipoprotein correlates of LDL particle size. Atherosclerosis2000; 148:151 -8.[CrossRef][Medline] [Order article via Infotrieve]
128. Austin MA, Rodriguez BL, McKnight B, McNeely MJ, Edwards KL, Curb JD, Sharp DS. Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. Am J Cardiol2000; 86:412 -6.[CrossRef][Medline] [Order article via Infotrieve]
129. Krauss RM. Regulation of high density lipoprotein levels. Med Clin North Am1982; 66:403 -30.[Medline] [Order article via Infotrieve]
130. Cohen JC, Wang Z, Grundy SM, Stoesz MR, Guerra R. Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels. J Clin Invest1994; 94:2377 -84.[Medline] [Order article via Infotrieve]
131. Brown CD, Higgins M, Donato KA, Rohde FC, Garrison R, Obarzanek E, Ernst ND, Horan M. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res2000; 8:605 -19.[Medline] [Order article via Infotrieve]
132. Nie L, Wang J, Clark LT, Tang A, Vega GL, Grundy SM, Cohen JC. Body
mass index and hepatic lipase gene (LIPC) polymorphism jointly influence
postheparin plasma hepatic lipase activity. J Lipid
Res 1998;39:1127
-30.
133. Carr MC, Hokanson JE, Deeb SS, Purnell JQ, Mitchell ES, Brunzell
JD. A hepatic lipase gene promoter polymorphism attenuates the increase in
hepatic lipase activity with increasing intra-abdominal fat in women.
Arterioscler Thromb Vasc Biol1999; 19:2701
-7.
134. Tato F, Vega GL, Grundy SM. Bimodal distribution of cholesteryl
ester transfer protein activities in normotriglyceridemic men with low HDL
cholesterol concentrations. Arterioscler Thromb Vasc
Biol 1995;15:446
-51.
135. Karhapää P, Malkki M, Laakso M. Isolated low HDL cholesterol: an insulin-resistant state. Diabetes1994; 43:411 -7.[Abstract]
136. Lamarche B, Despres J-P, Pouliot M-C, Prud'homme D, Moorjani S,
Lupien PJ, Nadeau A, Tremblay A, Bouchard C. Metabolic heterogeneity
associated with high plasma triglyceride or low HDL cholesterol levels in men.
Arterioscler Thromb1993; 13:33
-40.
137. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol1992; 70:733 -7.[CrossRef][Medline] [Order article via Infotrieve]
138. Martin-Jadraque R, Tato F, Mostaza JM, Vega GL, Grundy SM.
Effectiveness of low-dose crystalline nicotinic acid in men with low
high-density lipoprotein cholesterol levels. Arch Intern
Med 1996;156:1081
-8.
139. Frick MH, Elo MO, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med1987; 317:1237 -45.[Abstract]
140. Kastelein JJP, Isaacsohn JL, Ose L, Hunninghake DB, Frohlich J, Davidson MH, Habib R, Dujovne CA, Crouse JR, Liu M, Melino MR, O'Grady L, Mercuri M, Mitchel YB for the Simvastatin Atorvastatin HDL Study Group. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol 2000;86:221 -3.[CrossRef][Medline] [Order article via Infotrieve]
141. Coronary Drug Project Research Group. Clofibrate and niacin in
coronary heart disease. JAMA1975; 231:360
-81.
142. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss
RM. Low-density lipoprotein subclass patterns and risk of myocardial
infarction. JAMA1988; 260:1917
-21.
143. Verges BL. Dyslipidaemia in diabetes mellitus: review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. Diabetes Metab1999; 25(suppl 3):32 -40.[Medline] [Order article via Infotrieve]
144. Durrington PN. Diabetic dyslipidaemia. Baillière's Clin Endocrinol Metab1999; 13:265 -78.[CrossRef][Medline] [Order article via Infotrieve]
145. Kreisberg RA. Diabetic dyslipidemia. Am J Cardiol 1998;82:67U -73U.[CrossRef][Medline] [Order article via Infotrieve]
146. Kokkinos PF, Fernhall B. Physical activity and high density lipoprotein cholesterol levels: what is the relationship? Sports Med 1999;28:307 -14.[CrossRef][Medline] [Order article via Infotrieve]
147. Guyton JR, Blazing MA, Hagar J, Kashyap ML, Knopp RH, McKenney JM,
Nash DT, Nash SD, for the Niaspan-Gemfibrozil Study Group. Extended-release
niacin vs. gemfibrozil for the treatment of low levels of high-density
lipoprotein cholesterol. Arch Intern Med2000; 160:1177
-84.
148. Zema MJ. Gemfibrozil, nicotinic acid and combination therapy in
patients with isolated hypoalphalipoproteinemia: a randomized, open-label,
crossover study. J Am Coll Cardiol2000; 35:640
-6.
149. Committee of Principal Investigators. A co-operative trial in the
primary prevention of ischemic heart disease using clofibrate: Report from the
Committee of Principal Investigators. Br Heart J1978; 40:1069
-118.
150. Group of Physicians of the Newcastle upon Tyne Region. Trial of
clofibrate in the treatment of ischaemic heart disease: five year study by a
group of physicians of the New Castle upon Tyne region.
BMJ 1971;4:767
-75.
151. Research Committee of the Scottish Society of Physicians. Ischaemic
heart disease: a secondary prevention trial using clofibrate.
BMJ 1971;4:775
-84.
152. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand1988; 223:405 -18.[Medline] [Order article via Infotrieve]
153. Bezafibrate Infarction Prevention (BIP) Study Group. Secondary
prevention by raising HDL cholesterol and reducing triglycerides in patients
with coronary artery disease. Circulation2000; 102:21
-7.
154. Ericsson C-G, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849 -53.[CrossRef][Medline] [Order article via Infotrieve]
155. Frick MH, Syvänne M, Nieminen MS, Kauma H, Majahalme S,
Virtanen V, Kesäniemi YA, Pasternack A, Taskinen M-R, for the Lopid
Coronary Angiography Trial (LOCAT) Study Group. Prevention of the angiographic
progression of coronary and vein-graft atherosclerosis by gemfibrozil after
coronary bypass surgery in men with low levels of HDL cholesterol.
Circulation1997; 96:2137
-43.
156. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905 -10.[CrossRef][Medline] [Order article via Infotrieve]
157. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP,
Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on
coronary atherosclerosis and coronary venous bypass grafts.
JAMA 1987;257:3233
-40.
158. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin J-T, Kaplan C, Zhao X-Q, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med1990; 323:1289 -98.[Abstract]
159. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy
AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ. Simvastatin and
niacin, antioxidant vitamins, or the combination for the prevention of
coronary disease. N Engl J Med2001; 345:1583
-92.
160. JNC VI. The sixth report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
Arch Intern Med1997; 157:2413
-46.
161. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Sixth Report. NIH Pub. No. 98-4080. Bethesda, MD: Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute,1997; 70.
162. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease: part 1: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765 -74.[CrossRef][Medline] [Order article via Infotrieve]
163. Selmer R. Blood pressure and twenty-year mortality in the city of
Bergen, Norway. Am J Epidemiol1992; 136:428
-40.
164. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and
diastolic, and cardiovascular risks: U.S. population data. Arch
Intern Med 1993;153:598
-615.
165. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older persons with isolated systolic hypertension. Lancet 1997;1:757 -64.
166. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure
useful in predicting risk for coronary heart disease? The Framingham Heart
Study. Circulation1999; 100:354
-60.
167. van den Hoogen PCW, Feskens EJM, Nagelkerke NJD, Menotti A,
Nissinen A, Kromhout D, for the Seven Countries Research Group. The relation
between blood pressure and mortality due to coronary heart disease among men
in different parts of the world. N Engl J Med2000; 342:1
-8.
168. Rodgers A, MacMahon S. Blood pressure and the global burden of cardiovascular disease. Clin Exp Hypertens1999; 21:543 -52.[CrossRef][Medline] [Order article via Infotrieve]
169. Vasan RS, Larson MG, Evans JC, O'Donnell CJ, Levy D. High normal blood pressure and risk of cardiovascular disease: the Framingham Heart Study. Circulation1999; 100(18 suppl 1):34 .
170. Cutler JA, Psaty BM, MacMahon S, Furberg CD. Public health issues in hypertension control: what has been learned from clinical trials. In: Laragh JH, Brenner BM eds. Hypertension: pathophysiology, diagnosis, and management. 2nd ed. New York: Raven Press, 1995:253 -70.
171. SHEP Cooperative Research Group. Prevention of stroke by
antihypertensive drug treatment in older persons with isolated systolic
hypertension: final results of the Systolic Hypertension in the Elderly
Program (SHEP). JAMA1991; 265:3255
-64.
172. Working Group Report on Management of Patients with Hypertension and High Blood Cholesterol. NIH Pub. No. 90-2361. Bethesda, MD: National Heart, Lung, and Blood Institute, 1990;30 pages.
173. Working Group on Management of Patients with Hypertension and High
Blood Cholesterol. National Education Programs Working Group Report on the
Management of Hypertension and High Blood Cholesterol. Ann Intern
Med 1991;114:224
-37.
174. Meigs JB, D'Agostino RB Sr, Wilson PWF, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes1997; 46:1594 -600.[Abstract]
175. Doll R, Peto R. Mortality in relation to smoking: 20 years'
observations on male British doctors. BMJ1976; 2:1525
-36.
176. Doll R, Gray R, Hafner B, Peto R. Mortality in relation to smoking:
22 years' observations on female British doctors. BMJ1980; 280:967
-71.
177. Kannel WB, Neaton JD, Wentworth D, Thomas HE, Stamler J, Hulley SB, Kjelsberg MO, for the MRFIT Research Group. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Am Heart J1986; 112:825 -36.[CrossRef][Medline] [Order article via Infotrieve]
178. Colditz GA, Bonita R, Stampfer MJ, Willett WC, Rosner B, Speizer FE, Hennekens CH. Cigarette smoking and risk of stroke in middle-aged women. N Engl J Med1988; 318:937 -41.[Abstract]
179. Wolf PA, D'Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette
smoking as a risk factor for stroke: the Framingham Study.
JAMA 1988;259:1025
-9.
180. U.S. Department of Health and Human Services. Reducing the health consequences of smoking: 25 years of progress. A Report of the Surgeon General. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. DHHS pub. No. (CDC) 89-8411. Bethesda, MD: 1989; 703 pages.
181. Willett WC, Green A, Stampfer MJ, Speizer FE, Colditz GA, Rosner B, Monson RR, Stason W, Hennekens CH. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med 1987;317:1303 -9.[Abstract]
182. LaCroix AZ, Lang J, Scherr P, Wallace RB, Cornoni-Huntley J, Berkman L, Curb JB, Evans D, Hennekens CH. Smoking and mortality among older men and women in three communities. N Engl J Med1991; 324:1619 -25.[Abstract]
183. McBride PE. The health consequences of smoking; cardiovascular diseases. Med Clin North Am1992; 76:333 -53.[Medline] [Order article via Infotrieve]
184. Jonas MA, Oates JA, Ockene JK, Hennekens CH. Statement on smoking
and cardiovascular disease for health care professionals.
Circulation1992; 86:1664
-9.
185. Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D, on behalf of the Task Force. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis1994; 110:121 -61.[CrossRef][Medline] [Order article via Infotrieve]
186. U.S. Department of Health and Human Services. The health benefits of smoking cessation. A Report of the Surgeon General. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. DHHS pub. No. (CDC) 90-8416, Washington, D.C.: U.S. Department of Health and Human Services, 1990.627 pages.
187. Hjermann I, Holme I, Velve BK, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease: report from the Oslo Study Group of a randomised trial in healthy men. Lancet 1981;2:1303 -10.[CrossRef][Medline] [Order article via Infotrieve]
188. Rose G, Hamilton PJS, Colwell L, Shipley MJ. A randomised
controlled trial of anti-smoking advice: 10-year results. J
Epidemiol Community Health1982; 36:102
-8.
189. Multiple Risk Factor Intervention Trial Research Group. Multiple
Risk Factor Intervention Trial: risk factor changes and mortality results.
JAMA 1982;248:1465
-77.
190. Gavin JR III, Alberti KGMM, Davidson MB, DeFronzo RA, Drash A, Gabbe SG, Genuth S, Harris MI, Kahn R, Keen H, Knowler WC, Lebovitz H, Maclaren NK, Palmer JP, Raksin P, Rizza RA, Stern MP. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care1998; 21(suppl):S5 -S19.[CrossRef]
191. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the
Framingham Study. JAMA1979; 241:2035
-8.
192. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study. Diabetes Care 1979;2:120 -6.[Abstract]
193. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, and Bennett PH eds.Diabetes in America , 2nd edition. Bethesda, MD: U.S. Department of Health and Human Services, 1995:429 -48.
194. Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987;3:463 -524.[Medline] [Order article via Infotrieve]
195. Bierman EL. George Lyman Duff Memorial Lecture. Atherogenesis in
diabetes. Arterioscler Thromb1992; 12:647
-56.
196. Herlitz J, Karlson BW, Edrardsson N, Emanuelsson H, Hjalmarson A. Prognosis in diabetics with chest pain or other symptoms suggestive of acute myocardial infarction. Cardiology1992; 80:237 -45.[Medline] [Order article via Infotrieve]
197. Miettinen H, Lehto S, Salomaa V, Mähönen M, Niemelä M, Haffner SM, Pyörälä K, Tuomilehto J, for the FINMONICA Myocardial Infarction Register Study group. Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care1998; 21:69 -75.[Abstract]
198. Diabetes Control and Complications Trial Research Group. The effect
of intensive treatment of diabetes on the development and progression of
long-term complications in insulin-dependent diabetes mellitus. N
Engl J Med 1993;329:977
-86.
199. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet1998; 352:854 -65.[CrossRef][Medline] [Order article via Infotrieve]
200. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998; 352:837 -53.[CrossRef][Medline] [Order article via Infotrieve]
201. UK Prospective Diabetes Study Group. Efficacy of atenolol and
captopril in reducing risk of macrovascular and microvascular complications in
type 2 diabetes: UKPDS 39. BMJ1998; 317:713
-20.
202. UK Prospective Diabetes Study Group. Tight blood pressure control
and risk of macrovascular and microvascular complications in type 2 diabetes:
UKPDS 38. BMJ1998; 317:703
-13.
203. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G, the Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care1997; 20:614 -20.[Abstract]
204. Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA,
Pedersen TR, Kjekshus J, Pyörälä K, for the Scandinavian
Simvastatin Survival Study Group. Reduced coronary events in
simvastatin-treated patients with coronary heart disease and diabetes or
impaired fasting glucose levels: subgroup analyses from the Scandinavian
Simvastatin Survival Study. Arch Intern Med1999; 159:2661
-7.
205. Goldberg RB, Mellies MJ, Sacks FM, Moyé LA, Howard BV,
Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E, for the CARE
Investigators. Cardiovascular events and their reduction with pravastatin in
diabetic and glucose-intolerant myocardial infarction survivors with average
cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events
(CARE) trial. Circulation1998; 98:2513
-9.
206. Long-Term Intervention with Pravastatin in Ischaemic Disease
(LIPID) Study Group. Prevention of cardiovascular events and death with
pravastatin in patients with coronary heart disease and a broad range of
initial cholesterol levels. N Engl J Med1998; 339:1349
-57.
207. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA,
Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr, for the AFCAPS/TexCAPS
Research Group. Primary prevention of acute coronary events with lovastatin in
men and women with average cholesterol levels: results of AFCAPS/TexCAPS.
JAMA 1998;279:1615
-22.
208. Hoogwerf BJ, Waness A, Cressman M, Canner J, Campeau L, Domanski M, Geller N, Herd A, Hickey A, Hunninghake DB, Knatterud GL, White C. Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft trial. Diabetes1999; 48:1289 -94.[Abstract]
209. Koskinen P, Mänttäri M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care1992; 15:820 -5.[Abstract]
210. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K,
Laakso M. Mortality from coronary heart disease in subjects with type 2
diabetes and in nondiabetic subjects with and without prior myocardial
infarction. N Engl J Med1998; 339:229
-34.
211. Haffner SM, D'Agostino RD Jr, Saad MF, O'Leary DH, Savage PJ, Rewers M, Selby J, Bergman RN, Mykkänen L. Carotid artery atherosclerosis in type-2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease: the Insulin Resistance Atherosclerosis Study. Am J Cardiol2000; 85:1395 -400.[CrossRef][Medline] [Order article via Infotrieve]
212. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas
L, Calvin J, Keltai M, Budaj A, for the OASIS Registry Investigators. Impact
of diabetes on long-term prognosis in patients with unstable angina and
non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess
Strategies for Ischemic Syndromes) Registry.
Circulation2000; 102:1014
-9.
213. Hu FB, Stampfer MJ, Solomon C, Willett WC, Manson JE. Diabetes mellitus and mortality from all causes and coronary heart disease in women: 20 years of follow-up. Diabetes2000; 49(suppl 1):A20 .[CrossRef]
214. Simons LA, Simons J. Diabetes and coronary heart disease [Letter].
N Engl J Med1998; 339:1714
-5.
215. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an
independent risk factor for cardiovascular disease: a 26-year follow-up of
participants in the Framingham Heart Study.
Circulation1983; 67:968
-77.
216. Wilcosky T, Hyde J, Anderson JJB, Bangdiwala S, Duncan B. Obesity and mortality in the Lipid Research Clinics Program Follow-Up Study. J Clin Epidemiol1990; 43:743 -52.[CrossRef][Medline] [Order article via Infotrieve]
217. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Monson RR, Speizer FE, Hennekens CH. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med1990; 322:882 -9.[Abstract]
218. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW. Body-mass
index and mortality in a prospective cohort of U.S. adults. N Engl
J Med 1999;341:1097
-105.
219. Olefsky J, Reaven GM, Farquhar JW. Effects of weight reduction on obesity: studies of lipid and carbohydrate metabolism in normal and hyperlipoproteinemic subjects. J Clin Invest1974; 53:64 -76.[Medline] [Order article via Infotrieve]
220. Grundy SM, Mok HYI, Zech L, Steinberg D, Berman M. Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia. J Clin Invest1979; 63:1274 -83.[CrossRef][Medline] [Order article via Infotrieve]
221. Garrison RJ, Wilson PW, Castelli WP, Feinleib M, Kannel WB, McNamara PM. Obesity and lipoprotein cholesterol in the Framingham Offspring Study. Metabolism1980; 29:1053 -60.[CrossRef][Medline] [Order article via Infotrieve]
222. Hartz AJ, Rupley DC, Kalkhoff RD, Rimm AA. Relationship of obesity to diabetes: influence of obesity level and body fat distribution. Prev Med 1983;12:351 -7.[CrossRef][Medline] [Order article via Infotrieve]
223. Stern MP, Haffner SM. Body fat distribution and hyperinsulinemia as
risk factors for diabetes and cardiovascular disease.
Arteriosclerosis1986; 6:123
-30.
224. Berchtold P, Berger M, Jorgens V, Daweke C, Chantelau E, Gries FA, Zimmermann H. Cardiovascular risk factors and HDL-cholesterol levels in obesity. Int J Obes1981; 5:1 -10.[Medline] [Order article via Infotrieve]
225. Berchtold P, Jorgens V, Finke C, Berger M. Epidemiology of obesity and hypertension. Int J Obesity1981; 5(suppl 1):1 -7.[Medline] [Order article via Infotrieve]
226. Blair D, Habicht J-P, Sims EAH, Sylwester D, Abraham S. Evidence
for an increased risk for hypertension with centrally located body fat and the
effect of race and sex on this risk. Am J Epidemiol1984; 119:526
-40.
227. Blair SN, Cooper KH, Gibbons LW, Gettman LR, Lewis S, Goodyear N.
Changes in coronary heart disease risk factors associated with increased
treadmill time in 753 men. Am J Epidemiol1983; 118:352
-9.
228. King H, Kriska AM. Prevention of type II diabetes by physical training: epidemiological considerations and study methods. Diabetes Care1992; 15(suppl 4):1794 -9.[Abstract]
229. Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS Jr. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med1991; 325:147 -52.[Abstract]
230. Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko HR,
Williams PT, Johnstone IM, Champagne MA, Krauss RM, Farquhar JW. Effects of
intensive multiple risk factor reduction on coronary atherosclerosis and
clinical cardiac events in men and women with coronary artery disease: the
Stanford Coronary Risk Intervention Project (SCRIP).
Circulation1994; 89:975
-90.
231. Leon AS, Connett J, Jacobs DR Jr, Rauramaa R. Leisure-time physical
activity levels and risk of coronary heart disease and death: the Multiple
Risk Factor Intervention Trial. JAMA1987; 258:2388
-95.
232. Ekelund LG, Haskell WL, Johnson JL, Whaley FS, Criqui MH, Sheps DS. Physical fitness as a predictor of cardiovascular mortality in asymptomatic North American men: the Lipid Research Clinics Mortality Follow-up Study. N Engl J Med1988; 319:1379 -84.[Abstract]
233. Blair SN, Kohl HW III, Paffenbarger RS Jr, Clark DG, Cooper KH,
Gibbons LW. Physical fitness and all-cause mortality: a prospective study of
healthy men and women. JAMA1989; 262:2395
-401.
234. Morris JN, Clayton DG, Everitt MG, Semmence AM, Burgess EH.
Exercise in leisure time: coronary attack and death rates. Br Heart
J 1990;63:325
-34.
235. Sandvik L, Erikssen J, Thaulow E, Erikssen G, Mundal R, Rodahl K.
Physical fitness as a predictor of mortality among healthy, middle-aged
Norwegian men. N Engl J Med1993; 328:533
-7.
236. Paffenbarger RS Jr, Hyde RT, Wing AL, Lee I-M, Jung DL, Kampert JB.
The association of changes in physical-activity level and other lifestyle
characteristics with mortality among men. N Engl J Med1993; 328:538
-45.
237. Fletcher GF, Balady G, Blair SN, Blumenthal J, Caspersen C,
Chaitman B, Epstein S, Sivarajan Froelicher ES, Froelicher VF, Pina IL,
Pollock ML. Statements on exercise: benefits and recommendations for physical
activity programs for all Americans: a statement for health professionals by
the Committee on Exercise and Cardiac Rehabilitation of the Council on
Clinical Cardiology, American Heart Association.
Circulation1996; 94:857
-62.
238. U.S. Department of Health and Human Services. Physical activity and health: a Report of the Surgeon General. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, 1996. 278 pages.
239. Grundy SM, Blackburn G, Higgins M, Lauer R, Perri MG, Ryan D. Physical activity in the prevention and treatment of obesity and its comorbidities: evidence report of independent panel to assess the role of physical activity in the treatment of obesity and its comorbidities. Med Sci Sports Exerc1999; 31:1493 -500.[Medline] [Order article via Infotrieve]
240. Perseghin G, Price TB, Petersen KF, Roden M, Cline GW, Gerow K,
Rothman DL, Shulman GI. Increased glucose transport-phosphorylation and muscle
glycogen synthesis after exercise training in insulin-resistant subjects.
N Engl J Med1996; 335:1357
-62.
241. U.S. Department of Agriculture and U.S. Department of Health and Human Services. Nutrition and your health: dietary guidelines for Americans, 5th edition. Home and Garden Bulletin no. 232. Washington, D.C.: U.S. Department of Agriculture, 2000;44 pages.
242. Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ,
Erdman JW Jr, Kris-Etherton P, Goldberg IJ, Kotchen TA, Lichtenstein AH, Mitch
WE, Mullis R, Robinson K, Wylie-Rosett J, St. Jeor S, Suttie J, Tribble DL,
Bazzarre TL. AHA Dietary Guidelines: revision 2000: a statement for healthcare
professionals from the Nutrition Committee of the American Heart Association.
Circulation2000; 102:2284
-99.
243. Barrett-Connor E, Khaw K-T. Family history of heart attack as an
independent predictor of death due to cardiovascular disease.
Circulation1984; 69:1065
-9.
244. Shea S, Ottman R, Gabrieli C, Stein Z, Nichols A. Family history as an independent risk factor for coronary artery disease. J Am Coll Cardiol 1984;4:793 -801.[Abstract]
245. Conroy RM, Mulcahy R, Hickey N, Daly L. Is a family history of
coronary heart disease an independent coronary risk factor? Br
Heart J 1985;53:378
-81.
246. Hopkins PN, Williams RR, Kuida H, Stults BM, Hunt SC, Barlow GK, Ash KO. Family history as an independent risk factor for incident coronary artery disease in a high-risk cohort in Utah. Am J Cardiol 1988;62:703 -7.[CrossRef][Medline] [Order article via Infotrieve]
247. Hunt SC, Williams RR, Barlow GK. A comparison of positive family history definitions for defining risk of future disease. J Chron Dis 1986;39:809 -21.[CrossRef][Medline] [Order article via Infotrieve]
248. Jorde LB, Williams RR. Relation between family history of coronary artery disease and coronary risk variables. Am J Cardiol 1988;62:708 -13.[CrossRef][Medline] [Order article via Infotrieve]
249. Colditz GA, Rimm EB, Giovannucci E, Stampfer MJ, Rosner B, Willett WC. A prospective study of parental history of myocardial infarction and coronary artery disease in men. Am J Cardiol1991; 67:933 -8.[CrossRef][Medline] [Order article via Infotrieve]
250. Kekäläinen P, Sarlund H, Pyörälä K, Laakso M. Family history of coronary heart disease is a stronger predictor of coronary heart morbidity and mortality than family history of non-insulin dependent diabetes mellitus. Atherosclerosis1996; 123:203 -13.[CrossRef][Medline] [Order article via Infotrieve]
251. Eaton CB, Bostom AG, Yanek L, Laurino JP, McQuade W, Hume A, Selhub J. Family history and premature coronary heart disease. J Am Board Fam Pract 1996;9:312 -8.[Medline] [Order article via Infotrieve]
252. Pankow JS, Folsom AR, Province MA, Rao DC, Eckfeldt J, Heiss G, Shahar E, Wu KK, on behalf of the Atherosclerosis Risk in Communities Investigators and Family Heart Study Research Group. Family history of coronary heart disease and hemostatic variables in middle-aged adults. Thromb Haemost1997; 77:87 -93.[Medline] [Order article via Infotrieve]
253. Bensen JT, Li R, Hutchinson RG, Province MA, Tyroler HA. Family history of coronary heart disease and pre-clinical carotid artery atherosclerosis in African Americans and whites: the ARIC study. Genet Epidemiol1999; 16:165 -78.[CrossRef][Medline] [Order article via Infotrieve]
254. Li R, Bensen JT, Hutchinson RG, Province MA, Hertz-Picciotto I, Sprafka JM, Tyroler HA. Family risk score of coronary heart disease (CHD) as a predictor of CHD: the Atherosclerosis Risk in Communities (ARIC) Study and the NHLBI Family Heart Study. Genet Epidemiol2000; 18:236 -50.[CrossRef][Medline] [Order article via Infotrieve]
255. Williams RR, Hunt SC, Heiss G, Province MA, Bensen JT, Higgins M, Chamberlain RM, Ware J, Hopkins PN. Usefulness of cardiovascular family history data for population-based preventive medicine and medical research (the Health Family Tree Study and the NHLBI Family Heart Study). Am J Cardiol 2001;87:129 -35.[CrossRef][Medline] [Order article via Infotrieve]
256. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet1969; 2:1380 -2.[CrossRef][Medline] [Order article via Infotrieve]
257. Phillips RL, Lilienfeld AM, Diamond EL, Kagan A. Frequency of
coronary heart disease and cerebrovascular accidents in parents and sons of
coronary heart disease index cases and controls. Am J
Epidemiol 1974;100:87
-100.
258. Rissanen AM. Familial aggregation of coronary heart disease in a
high incidence area (North Karelia, Finland). Br Heart
J 1979;42:294
-303.
259. Pohjola-Sintonen S, Rissanen A, Liskola P, Luomanmaki K. Family
history as a risk factor of coronary heart disease in patients under 60 years
of age. Eur Heart J1998; 19:235
-9.
260. Rissanen AM, Nikkilä E. Coronary artery disease and its risk
factors in families of young men with angina pectoris and in controls.
Br Heart J1977; 39:875
-83.
261. Siegmund KD, Province MA, Higgins M, Williams RR, Keller J, Todorov AA. Modeling disease incidence rates in families. Epidemiology1998; 9:557 -62.[CrossRef][Medline] [Order article via Infotrieve]
262. Sharrett AR, Sorlie PD, Chambless LE, Folsom AR, Hutchinson RG,
Heiss G, Szklo M. Relative importance of various risk factors for asymptomatic
carotid atherosclerosis versus coronary heart disease incidence. The
Atherosclerosis Risk in Communities Study. Am J
Epidemiol 1999;149:843
-52.
263. Snowden CB, McNamara PM, Garrison RJ, Feinleib M, Kannel WB,
Epstein FH. Predicting coronary heart disease in siblings—a multivariate
assessment: the Framingham Heart Study. Am J Epidemiol1982; 115:217
-22.
264. Khaw K-T, Barrett-Connor E. Family history of heart attack: a
modifiable risk factor? Circulation1986; 74:239
-44.
265. Becker DM, Becker LC, Pearson TA, Fintel DJ, Levine DM, Kwiterovich PO. Risk factors in siblings of people with premature coronary heart disease. J Am Coll Cardiol1988; 12:1273 -80.[Abstract]
266. Becker DM, Raqueno JV, Yook RM, Kral BG, Blumenthal RS, Moy TF,
Bezirdjian PJ, Becker LC. Nurse-mediated cholesterol management compared with
enhanced primary care in siblings of individuals with premature coronary
disease. Arch Intern Med1998; 158:1533
-9.
267. Silberberg JS, Wlodarczyk J, Fryer J, Ray CD, Hensley MJ.
Correction for biases in a population-based study of family history and
coronary heart disease: the Newcastle Family History Study I. Am J
Epidemiol 1998;147:1123
-32.
268. Silberberg JS, Wlodarczyk J, Fryer J, Robertson R, Hensley MJ. Risk
associated with various definitions of family history of coronary heart
disease: the Newcastle Family History Study II. Am J
Epidemiol 1998;147:1133
-9.
269. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of
triglyceride-rich lipoprotein families in the progression of atherosclerotic
lesions as determined by sequential coronary angiography from a controlled
clinical trial. Arterioscler Thromb Vasc Biol1997; 17:715
-22.
270. Leary ET, Wang T, Baker DJ, Cilla DD, Zhong J, Warnick GR, Nakajima
K, Havel RJ. Evaluation of an immunoseparation method for quantitative
measurement of remnant-like particle-cholesterol in serum and plasma.
Clin Chem 1998;44:2490
-8.
271. McNamara JR, Shah PK, Nakajima K, Cupples LA, Wilson PWF, Ordovas
JM, Schaefer EJ. Remnant lipoprotein cholesterol and triglyceride reference
ranges from the Framingham Heart Study. Clin Chem1998; 44:1224
-32.
272. Devaraj S, Vega G, Lange R, Grundy SM, Jialal I. Remnant-like particle cholesterol levels in patients with dysbetalipoproteinemia or coronary artery disease. Am J Med1998; 104:445 -50.[CrossRef][Medline] [Order article via Infotrieve]
273. Masuoka H, Kamei S, Wagayama H, Ozaki M, Kawasaki A, Tanaka T, Kitamura M, Katoh S, Shintani U, Misaki M, Sugawa M, Ito M, Nakano T. Association of remnant-like particle cholesterol with coronary artery disease in patients with normal total cholesterol levels. Am Heart J 2000;139:305 -10.[CrossRef][Medline] [Order article via Infotrieve]
274. Moliterno DJ, Lange RA, Meidell RS, Willard JE, Leffert CC, Gerard
RD, Boerwinkle E, Hobbs HH, Hillis LD. Relation of plasma lipoprotein(a) to
infarct artery patency in survivors of myocardial infarction.
Circulation1993; 88:935
-40.
275. Stubbs P, Seed M, Lane D, Collinson P, Kendall F, Noble M.
Lipoprotein(a) as a risk predictor for cardiac mortality in patients with
acute coronary syndromes. Eur Heart J1998; 19:1355
-64.
276. Budde T, Fechtrup C, Bosenberg E, Vielhauer C, Enbergs A, Schulte
H, Assmann G, Breithardt G. Plasma Lp(a) levels correlate with number,
severity, and length-extension of coronary lesions in male patients undergoing
coronary arteriography for clinically suspected coronary atherosclerosis.
Arterioscler Thromb1994; 14:1730
-6.
277. Seman LJ, DeLuca C, Jenner JL, Cupples LA, McNamara JR, Wilson PWF,
Castelli WP, Ordovas JM, Schaefer EJ. Lipoprotein(a)-cholesterol and coronary
heart disease in the Framingham Heart Study. Clin Chem1999; 45:1039
-46.
278. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart
disease: meta-analysis of prospective studies.
Circulation2000; 102:1082
-5.
279. Moliterno DJ, Jokinen EV, Miserez AR, Lange RA, Willard JE,
Boerwinkle E, Hillis LD, Hobbs HH. No association between plasma
lipoprotein(a) concentrations and the presence or absence of coronary
atherosclerosis in African Americans. Arterioscler Thromb Vasc
Biol 1995;15:850
-5.
280. Nishino M, Malloy MJ, Naya-Vigne J, Russell J, Kane JP, Redberg RF.
Lack of association of lipoprotein(a) levels with coronary calcium deposits in
asymptomatic postmenopausal women. J Am Coll Cardiol2000; 35:314
-20.
281. Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol1998; 82:57U -66U.[CrossRef][Medline] [Order article via Infotrieve]
282. Marcovina SM, Hegele RA, Koschinsky ML. Lipoprotein(a) and coronary heart disease risk. Curr Cardiol Rep1999; 1:105 -11.[Medline] [Order article via Infotrieve]
283. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med1989; 226:271 -6.[Medline] [Order article via Infotrieve]
284. Angelin B. Therapy for lowering lipoprotein(a) levels. Curr Opin Lipidol1997; 8:337 -41.[CrossRef][Medline] [Order article via Infotrieve]
285. Su W, Campos H, Judge H, Walsh BW, Sacks FM. Metabolism of Apo(a)
and Apo B-100 of lipoprotein(a) in women: effect of postmenopausal estrogen
replacement. J Clin Endocrinol Metab1998; 83:3267
-76.
286. Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM.
Predominance of dense low-density lipoprotein particles predicts angiographic
benefit of therapy in the Stanford Coronary Risk Intervention Project.
Circulation1996; 94:2146
-53.
287. Gardner CD, Fortmann SP, Krauss RM. Association of small
low-density lipoprotein particles with the incidence of coronary artery
disease in men and women. JAMA1996; 276:875
-81.
288. Mykkänen L, Kuusisto J, Haffner SM, Laakso M, Austin MA. LDL
size and risk of coronary heart disease in elderly men and women.
Arterioscler Thromb Vasc Biol1999; 19:2742
-8.
289. Rader DJ, Hoeg JM, Brewer HB Jr. Quantitation of plasma
apolipoproteins in the primary and secondary prevention of coronary artery
disease. Ann Intern Med1994; 120:1012
-25.
290. Bloch S, Couderc R. Apolipoprotein B and LDL cholesterol: which parameter(s) should be included in the assessment of cardiovascular risk? Ann Biol Clin1998; 56:539 -44.[Medline] [Order article via Infotrieve]
291. Hong MK, Romm PA, Reagan K, Green CE, Rackley CE. Usefulness of the total cholesterol to high-density lipoprotein cholesterol ratio in predicting angiographic coronary artery disease in women. Am J Cardiol 1991;68:1646 -50.[CrossRef][Medline] [Order article via Infotrieve]
292. Castelli WP, Anderson K, Wilson PWF, Levy D. Lipids and risk of coronary heart disease: the Framingham Study. Ann Epidemiol 1992;2:23 -8.[Medline] [Order article via Infotrieve]
293. Kinosian B, Glick H, Preiss L, Puder KL. Cholesterol and coronary heart disease: predicting risks in men by changes in levels and ratios. J Investig Med1995; 43:443 -50.[Medline] [Order article via Infotrieve]
294. Criqui MH, Golomb BA. Epidemiologic aspects of lipid abnormalities. Am J Med 1998;105:48S -57S.[CrossRef][Medline] [Order article via Infotrieve]
295. Kang SS, Wong PWK, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Ann Rev Nutr1992; 12:279 -98.[CrossRef][Medline] [Order article via Infotrieve]
296. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med1998; 49:31 -62.[CrossRef][Medline] [Order article via Infotrieve]
297. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative
assessment of plasma homocysteine as a risk factor for vascular disease:
probable benefits of increasing folic acid intakes.
JAMA 1995;274:1049
-57.
298. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and
cardiovascular diseases: a statement for healthcare professionals from the
Nutrition Committee, American Heart Association.
Circulation1999; 99:178
-82.
299. Stehouwer CDA, Weijenberg MP, van den Berg M., Jakobs C, Feskens
EJM, Kromhout D. Serum homocysteine and risk of coronary heart disease and
cerebrovascular disease in elderly men: a 10-year follow-up.
Arterioscler Thromb Vasc Biol1998; 18:1895
-901.
300. Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH,
Hess DL, Davis CE. Prospective study of coronary heart disease incidence in
relation to fasting total homocysteine, related genetic polymorphisms, and B
vitamins: the Atherosclerosis Risk in Communities (ARIC) Study.
Circulation1998; 98:204
-10.
301. Whincup PH, Refsum H, Perry IJ, Morris R, Walker M, Lennon L,
Thomson A, Ueland PM, Ebrahim SBJ. Serum total homocysteine and coronary heart
disease: prospective study in middle aged men. Heart1999; 82:448
-54.
302. Bostom AG, Rosenberg IH, Silbershatz H, Jacques PF, Selhub J,
D'Agostino RB, Wilson PWF, Wolf PA. Nonfasting plasma total homocysteine
levels and stroke incidence in elderly persons: the Framingham Study.
Ann Intern Med1999; 131:352
-5.
303. Giles WH, Croft JB, Greenlund KJ, Ford ES, Kittner SJ. Association between total homocyst(e)ine and the likelihood for a history of acute myocardial infarction by race and ethnicity: results from the Third National Health and Nutrition Examination Survey. Am Heart J2000; 139:446 -53.[CrossRef][Medline] [Order article via Infotrieve]
304. Clark R, Collins R. Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J Cardiovasc Risk 1998;5:249 -55.[Medline] [Order article via Infotrieve]
305. Tucker KL, Mahnken B, Wilson PWF, Jacques P, Selhub J. Folic acid
fortification of the food supply: potential benefits and risks for the elderly
population. JAMA1996; 276:1879
-85.
306. Tucker KL, Selhub J, Wilson PWF, Rosenberg IH. Dietary intake
patterns relates to plasma folate and homocysteine concentrations in the
Framingham Heart Study. J Nutr1996; 126:3025
-31.
307. Jacques PF, Selhub J, Bostom AG, Wilson PWF, Rosenberg IH. The
effect of folic acid fortification on plasma folate and total homocysteine
concentrations. N Engl J Med1999; 340:1449
-54.
308. Centers for Disease Control and Prevention. Folate status in women of childbearing age—United States, 1999. MMWR2000; 49:962 -5.[Medline] [Order article via Infotrieve]
309. Fuster V, Lewis A. Conner Memorial Lecture. Mechanisms leading to
myocardial infarction: insights from studies of vascular biology.
Circulation1994; 90:2126
-46.
310. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in
cardiovascular disease: a statement for healthcare professionals from the
American Heart Association. Circulation1997; 96:2751
-3.
311. Creager MA. Results of the CAPRIE trial: efficacy and safety of
clopidogrel. Vasc Med1998; 3:257
-60.
312. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S, for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet1998; 351:1755 -62.[CrossRef][Medline] [Order article via Infotrieve]
313. Ernst E. Fibrinogen: its emerging role as a cardiovascular risk factor. Angiology1994; 45:87 -93.[CrossRef][Medline] [Order article via Infotrieve]
314. Meade TW. Fibrinogen in ischaemic heart disease. Eur Heart J 1995;16(suppl A):31 -5.[Abstract]
315. Kannel WB. Influence of fibrinogen on cardiovascular disease. Drugs1997; 54(suppl 3):32 -40.[Medline] [Order article via Infotrieve]
316. Montalescot G, Collet JP, Choussat R, Thomas D. Fibrinogen as a risk factor for coronary heart disease. Eur Heart J1998; 19(suppl H):H11 -H17.[Medline] [Order article via Infotrieve]
317. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M,
Meilahn EN, Kuller LH. Relationship of C-reactive protein to risk of
cardiovascular disease in the elderly: results from the Cardiovascular Health
Study and the Rural Health Promotion Project. Arterioscler Thromb
Vasc Biol 1997;17:1121
-7.
318. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective
study of C-reactive protein and the risk of future cardiovascular events among
apparently healthy women. Circulation1998; 98:731
-3.
319. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the
predictive value of total and HDL cholesterol in determining risk of first
myocardial infarction. Circulation1998; 97:2007
-11.
320. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E, for the
Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of
pravastatin on plasma concentration of C-reactive protein.
Circulation1999; 100:230
-5.
321. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and
other markers of inflammation in the prediction of cardiovascular disease in
women. N Engl J Med2000; 342:836
-43.
322. Koenig W, Sund M, Fröhlich M, Fischer H-G, Löwel H,
Döring A, Hutchinson WL, Pepys MB. C-reactive protein, a sensitive marker
of inflammation, predicts future risk of coronary heart disease in initially
healthy middle-aged men: results from the MONICA (Monitoring Trends and
Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992.
Circulation1999; 99:237
-42.
323. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES,
Kuller LH. Lifetime smoking exposure affects the association of C-reactive
protein with cardiovascular disease risk factors and subclinical disease in
healthy elderly subjects. Arterioscler Thromb Vasc
Biol 1997;17:2167
-76.
324. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated
C-reactive protein levels in over-weight and obese adults.
JAMA 1999;282:2131
-5.
325. Ford ES. Body mass index, diabetes, and C-reactive protein among
U.S. adults. Diabetes Care1999; 22:1971
-7.
326. Cook DG, Mendall MA, Whincup PH, Carey IM, Ballam L, Morris JE, Miller GJ, Strachan DP. C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. Atherosclerosis2000; 149:139 -50.[CrossRef][Medline] [Order article via Infotrieve]
327. Meigs JB, Nathan DM, Wilson PWF, Cupples LA, Singer DE. Metabolic
risk factors worsen continuously across the spectrum of nondiabetic glucose
tolerance: the Framingham Offspring Study. Ann Intern
Med 1998;128:524
-33.
328. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE,
Murphy-Sheehy PM, Lipinska I, D'Agostino RB, Wilson PWF. Hyperinsulinemia,
hyperglycemia, and impaired hemostasis: the Framingham Offspring Study.
JAMA 2000;283:221
-8.
329. Fontbonne AM, Eschwège EM. Insulin and cardiovascular disease: Paris Prospective Study. Diabetes Care1991; 14:461 -9.[Abstract]
330. Haffner SM. Impaired glucose tolerance: is it relevant for cardiovascular disease? Diabetologia1997; 40(suppl):S138 -S140.[CrossRef][Medline] [Order article via Infotrieve]
331. Laakso M, Lehto S. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. Atherosclerosis1998; 137(suppl):S65 -S73.[CrossRef][Medline] [Order article via Infotrieve]
332. Gerstein HC, Pais P, Pogue J, Yusuf S. Relationship of glucose and
insulin levels to the risk of myocardial infarction: a case-control study.
J Am Coll Cardiol1999; 33:612
-9.
333. Smith SC Jr, Amsterdam E, Balady GJ, Bonow RO, Fletcher GF, Froelicher V, Heath G, Limacher MC, Maddahi J, Pryor D, Redberg RF, Roccella E, Ryan T, Smaha L, Wenger NK. AHA Conference Proceedings: Prevention Conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: tests for silent and inducible ischemia: Writing Group II. Circulation2000; 101:E12 -E16.[Medline] [Order article via Infotrieve]
334. Smith SC Jr, Greenland P, Grundy SM. Beyond secondary prevention:
identifying the high-risk patient for primary prevention: executive summary:
AHA Conference Proceedings: Prevention Conference V.
Circulation2000; 101:111
-6.
335. Grundy SM, Bazzarre T, Cleeman J, D'Agostino RB Sr., Hill M, Houston-Miller N, Kannel WB, Krauss R, Krumholz HM, Lauer RM, Ockene IS, Pasternak RC, Pearson T, Ridker PM, Wood D. Prevention Conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: medical office assessment. Circulation2000; 101:E3 -11.[Medline] [Order article via Infotrieve]
336. Greenland P, Abrams J, Aurigemma GP, Bond MG, Clark LT, Criqui MH,
Crouse JR III, Friedman L, Fuster V, Herrington DM, Kuller LH, Ridker PM,
Roberts WC, Stanford W, Stone N, Swan HJ, Taubert KA, Wexler L. Prevention
Conference V: beyond secondary prevention: identifying the high-risk patient
for primary prevention: noninvasive tests of atherosclerotic burden.
Circulation2000; 101:111
-16.
337. Criqui MH, Coughlin SS, Fronek A. Noninvasively diagnosed
peripheral arterial disease as a predictor of mortality: results from a
prospective study. Circulation1985; 72:768
-73.
338. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med1992; 326:381 -6.[Abstract]
339. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR,
Clegg LX. Association of coronary heart disease incidence with carotid
arterial wall thickness and major risk factors: the Atherosclerosis Risk in
Communities (ARIC) Study, 1987-1993. Am J Epidemiol1997; 146:483
-94.
340. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu C, Azen SP. The
role of carotid arterial intima-media thickness in predicting clinical
coronary events. Ann Intern Med1998; 128:262
-9.
341. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK
Jr, for the Cardiovascular Health Study Collaborative Research Group.
Carotid-artery intima and media thickness as a risk factor for myocardial
infarction and stroke in older adults. N Engl J Med1999; 340:14
-22.
342. Detrano RC, Wong ND, Doherty TM, Shavelle RM, Tang W, Ginzton LE,
Budoff MJ, Narahara KA. Coronary calcium does not accurately predict near-term
future coronary events in high-risk adults.
Circulation1999; 99:2633
-8.
343. Raggi P, Callister TQ, Cooil B, He Z-X, Lippolis NJ, Russo DJ,
Zelinger A, Mahmarian JJ. Identification of patients at increased risk of
first unheralded acute myocardial infarction by electron-beam computed
tomography. Circulation2000; 101:850
-5.
344. Arad Y, Spadaro LA, Goodman K, Newstein D, Guerci AD. Prediction of
coronary events with electron beam computed tomography. J Am Coll
Cardiol 2000;36:1253
-60.
345. Wong ND, Hsu JC, Detrano RC, Diamond G, Eisenberg H, Gardin JM. Coronary artery calcium evaluation by electron beam computed tomography and its relation to new cardiovascular events. Am J Cardiol 2000;86:495 -8.[CrossRef][Medline] [Order article via Infotrieve]
346. O'Malley PG, Taylor AJ, Jackson JL, Doherty TM, Detrano RC. Prognostic value of coronary electron-beam computed tomography for coronary heart disease events in asymptomatic populations. Am J Cardiol 2000;85:945 -8.[CrossRef][Medline] [Order article via Infotrieve]
347. O'Rourke RA, Brundage BH, Froelicher VF, Greenland P, Grundy SM,
Hachamovitch R, Pohost GM, Shaw LJ, Weintraub WS, Winters WL Jr. American
College of Cardiology/American Heart Association expert consensus document on
electron-beam computed tomography for the diagnosis and prognosis of coronary
artery disease. J Am Coll Cardiol2000; 36:326
-40.
348. O'Rourke RA, Brundage BH, Froelicher VF, Greenland P, Grundy SM,
Hachamovitch R, Pohost GM, Shaw LJ, Weintraub WS, Winters WL Jr. American
College of Cardiology/American Heart Association expert consensus document on
electron-beam computed tomography for the diagnosis and prognosis of coronary
artery disease. Circulation2000; 102:126
-40.
349. Grundy SM, Cleeman JI, Rifkind BM, Kuller LH, for the Coordinating
Committee of the National Cholesterol Education Program. Cholesterol lowering
in the elderly population. Arch Intern Med1999; 159:1670
-8.
350. Reaven GM. Pathophysiology of insulin resistance in human disease.
Physiol Rev1995; 75:473
-86.
351. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol1999; 83:25F -9F.[Medline] [Order article via Infotrieve]
352. Meigs JB. Invited commentary: insulin resistance syndrome? Syndrome
X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals
patterns in the fabric of correlated metabolic risk factors. Am J
Epidemiol 2000;152:908
-11.
353. Kolaczynski JW, Caro JF. Insulin resistance: site of the primary defect or how the current and the emerging therapies work. J Basic Clin Physiol Pharmacol1998; 9:281 -94.[Medline] [Order article via Infotrieve]
354. Zimmet P, Boyko EJ, Collier GR, de Courten M. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann NY Acad Sci1999; 892:25 -44.[CrossRef][Medline] [Order article via Infotrieve]
355. Haffner SM. Epidemiology of insulin resistance and its relation to coronary artery disease. Am J Cardiol1999; 84:11J -4J.[Medline] [Order article via Infotrieve]
356. Després J-P. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition1993; 9:452 -9.[Medline] [Order article via Infotrieve]
357. Després J-P. The insulin resistance-dyslipidemic syndrome of visceral obesity: effect on patients' risk. Obes Res1998; 6(suppl 1):8S -17S.[Medline] [Order article via Infotrieve]
358. Bjorntorp P. Body fat distribution, insulin resistance, and metabolic diseases. Nutrition1997; 13:795 -803.[CrossRef][Medline] [Order article via Infotrieve]
359. Assmann G, Cullen P, Schulte H. The Münster Heart Study (PROCAM): results of follow-up at 8 years. Eur Heart J1998; 19(suppl A):A2 -A11.[Medline] [Order article via Infotrieve]
360. Eckel RH, Krauss RM, for the AHA Nutrition Committee. American
Heart Association call to action: obesity as a major risk factor for coronary
heart disease. Circulation1998; 97:2099
-100.
361. Groop LC. Insulin resistance: the fundamental trigger of type 2 diabetes. Diabetes Obes Metab1999; 1(suppl 1):S1 -S7.
362. Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest2000; 106:329 -33.[Medline] [Order article via Infotrieve]
363. Dengel DR, Galecki AT, Hagberg JM, Pratley RE. The independent and combined effects of weight loss and aerobic exercise on blood pressure and oral glucose tolerance in older men. Am J Hypertens1998; 11:1405 -12.[CrossRef][Medline] [Order article via Infotrieve]
364. Ahmad F, Considine RV, Bauer TL, Ohannesian JP, Marco CC, Goldstein BJ. Improved sensitivity to insulin in obese subjects following weight loss is accompanied by reduced protein-tyrosine phosphatases in adipose tissue. Metabolism1997; 46:1140 -5.[CrossRef][Medline] [Order article via Infotrieve]
365. Su H-Y, Sheu WH, Chin H-M, Jeng C-Y, Chen Y-D, Reaven GM. Effect of weight loss on blood pressure and insulin resistance in normotensive and hypertensive obese individuals. Am J Hypertens1995; 8:1067 -71.[CrossRef][Medline] [Order article via Infotrieve]
366. Devlin JT. Effects of exercise on insulin sensitivity in humans. Diabetes Care1992; 15:1690-3 .
367. Okosun IS, Liao Y, Rotimi CN, Prewitt TE, Cooper RS. Abdominal adiposity and clustering of multiple metabolic syndrome in White, Black and Hispanic Americans. Ann Epidemiol2000; 10:263-70 .
368. Bjorntorp P. Abdominal obesity and the metabolic syndrome. Ann Med 1992;24:465-8 .
369. Mekki N, Christofilis MA, Charbonnier M, Atlan-Gepner C, Defoort C, Juhel C, Borel P, Portugal H, Pauli AM, Vialettes B, Lairon D. Influence of obesity and body fat distribution on postprandial lipemia and triglyceride-rich lipoproteins in adult women. J Clin Endocrinol Metab 1999;84:184-91 .
370. Bodkin NL, Hannah JS, Ortmeyer HK, Hansen BC. Central obesity in rhesus monkeys: association with hyperinsulinemia, insulin resistance and hypertriglyceridemia? Int J Obes1993; 17:53-61 .
371. Julien P, Vohl M-C, Gaudet D, Gagné C, Lévesque G, Després J-P, Cadelis F, Brun LD, Nadeau A, Ven Murthy MR. Hyperinsulinemia and abdominal obesity affect the expression of hypertriglyceridemia in heterozygous familial lipoprotein lipase deficiency. Diabetes 1997;46:2063-8 .
372. Schaefer EJ, McNamara JR, Genest J Jr, Ordovas JM. Clinical significance of hypertriglyceridemia. Semin Thromb Hemost 1988;14:143-8 .
373. Nilsson PM, Lind L, Pollare T, Berne C, Lithell H. Differences in insulin sensitivity and risk markers due to gender and age in hypertensives. J Hum Hypertens2000; 14:51-6 .
374. Vanhala MJ, Kumpusalo EA, Pitkäjarvi TK, Notkola I-L, Takala JK. Hyperinsulinemia and clustering of cardiovascular risk factors in middle-aged hypertensive Finnish men and women. J Hypertens 1997;15:475-81 .
375. Lind L, Berne C, Lithell H. Prevalence of insulin resistance in essential hypertension. J Hypertens1995; 13:1457-62 .
376. Lender D, Arauz-Pacheco C, Adams-Huet B, Raskin P. Essential
hypertension is associated with decreased insulin clearance and insulin
resistance. Hypertension1997; 29:111-4
.
377. Landsberg L. Insulin resistance and hypertension. Clin Exp Hypertens 1999;21:885-94 .
378. Dyer AR, Liu K, Walsh M, Kiefe C, Jacobs DR Jr, Bild DE. Ten-year incidence of elevated blood pressure and its predictors: the CARDIA study. J Hum Hypertens1999; 13:13-21 .
379. Falkner B, Sherif K, Sumner AE, Kushner H. Blood pressure increase with impaired glucose tolerance in young adult American Blacks. Hypertension1999; 34:1086-90 .
380. Tripathy D, Carlsson M, Almgren P, Isomaa B, Taskinen M-R, Tuomi T, Groop LC. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes2000; 49:975-80 .
381. Haffner SM, Miettinen H, Gaskill SP, Stern MP. Decreased insulin action and insulin secretion predict the development of impaired glucose tolerance. Diabetologia1996; 39:1201-7 .
382. Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, Haffner SM, Pettitt DJ, Sorkin JD, Muller DC, Collins VR, Hamman RF. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes1997; 46:701-10 .
383. Lindahl B, Weinehall L, Asplund K, Hallmans G. Screening for impaired glucose tolerance: results from a population-based study in 21,057 individuals. Diabetes Care1999; 22:1988-92 .
384. Hu FB, Stampfer MJ, Solomon C, Liu S, Colditz GA, Speizer FE, Willett WC, Manson JE. Physical activity and risk for cardiovascular events in diabetic women. Ann Intern Med2001; 134:96-105 .
385. Farrell SW, Kampert JB, Kohl HW III, Barlow CE, Macera CA, Paffenbarger RS Jr, Gibbons LW, Blair SN. Influences of cardiorespiratory fitness levels and other predictors on cardiovascular disease mortality in men. Med Sci Sports Exerc1998; 30:899-905 .
386. de Vreede-Swagemakers JJM, Gorgels APM, Dubois-Arbouw WI, van Ree JW, Daemen MJAP, Houben LGE, Wellens HJJ. Out-of-hospital cardiac arrest in the 1990s: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol1997; 30:1500-5 .
387. Kannel WB, Schatzkin A. Sudden death: lessons from subsets in population studies. J Am Coll Cardiol1985; 5:141B -9B.[Medline] [Order article via Infotrieve]
388. Muller JE, Kaufmann PG, Luepker RV, Weisfeldt ML, Deedwania PC, Willerson JT. Mechanisms precipitating acute cardiac events: review and recommendations of an NHLBI workshop. Circulation1997; 96:3233-9 .
389. American Heart Association. 1999 heart and stroke statistical update. Dallas, TX: American Heart Association,1998; 29 pages.
390. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas A-M, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation1994; 90:583-612 .
391. Marmot MG, Syme SL, Kagan A, Kato H, Cohen JB, Belsky J. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: prevalence of coronary and hypertensive heart disease and associated risk factors. Am J Epidemiol 1975;102:514-25 .
392. Blackburn H. The public health view of the diet and mass hyperlipidemia. Cardiovas Rev Rep1990; 11:25-33 .
393. Krauss RM, Deckelbaum RJ, Ernst N, Fisher E, Howard BV, Knopp RH, Kotchen T, Lichtenstein AH, McGill HC, Pearson TA, Prewitt TE, Stone NJ, Van Horn L, Weinberg R. Dietary guidelines for healthy American adults: a statement for health professionals from the Nutrition Committee, American Heart Association. Circulation1996; 94:1795-800 .
394. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J1998; 19:1434-503 .
395. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K, together with members of the TASK FORCE. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis1998; 140:199-270 .
396. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart1998; 80(suppl 2):S1-S29 .
397. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. BMJ2000; 320:705-8 .
398. Faergeman O. New British recommendations for prevention of coronary
heart disease in clinical practice [Editorial]. Heart1999; 81:335
.
399. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation1999; 100:1481-92 .
400. Grundy SM, D'Agostino RD Sr, Mosca L, Burke GL, Wilson PWF, Rader DJ, Cleeman JI, Roccella EJ, Cutler JA, Friedman LM. Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood Institute workshop. Circulation2001; 104:491-6 .
401. Cullen P, von Eckardstein A, Assmann G. Diagnosis and management of new cardiovascular risk factors. Eur Heart J1998; 19(suppl O):O13-O9 .
402. Dayton S, Pearce ML, Hashimoto S, Dixon WJ, Tomiyasu U. A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation1969; 40(suppl II):II1-II62 .
403. Frantz ID Jr, Dawson EA, Ashman PL, Gatewood LC, Bartsch GE, Kuba K, Brewer ER. Test of effect of lipid lowering by diet on cardiovascular risk: the Minnesota Coronary Survey. Arteriosclerosis1989; 9:129-35 .
404. Miettinen M, Karvonen MJ, Turpeinen O, Elosuo R, Paavilainen E. Effect of cholesterol-lowering diet on mortality from coronary heart-disease and other causes: a twelve-year clinical trial in men and women. Lancet 1972;2:835-8 .
405. Multiple Risk Factor Intervention Trial (MRFIT). A national study of primary prevention of coronary heart disease. JAMA1976; 235:825-7 .
406. Ball KP, Hanington E, McAllen PM, Pilkington TRE, Richards JM, Sharland DE, Sowry GSC, Wilkinson P, Clarke JAC, Murland C, Wood J. Low-fat diet in myocardial infarction: a controlled trial. Lancet 1965;2:501-4 .
407. Singh RB, Rastogi SS, Verma R, Bolaki L, Singh R. An Indian experiment with nutritional modulation in acute myocardial infarction. Am J Cardiol1992; 69:879-85 .
408. Leren P. The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction: a controlled clinical trial. Acta Med Scand Suppl1966; 466:1-92 .
409. Gordon DJ. Cholesterol and mortality: what can meta-analysis tell us? In: Gallo LL, ed. Cardiovascular disease 2: cellular and molecular mechanisms, prevention, and treatment. New York: Plenum Press,1995 : 333-40.
410. Gordon DJ. Cholesterol lowering and total mortality. In: Rifkind BM, ed. Lowering cholesterol in high-risk individuals and populations. New York: Marcel Dekker, Inc., 1995:333-48 .
411. Huttunen JK, Manninen V, Mänttäri M, Koskinen P, Romo M, Tenkanen L, Heinonen OP, Frick MH. The Helsinki Heart Study: central findings and clinical implications. Ann Med1991; 23:155-9 .
412. Huttunen JK, Heinonen OP, Manninen V, Koskinen P, Hakulinen T, Teppo L, Mänttäri M, Frick MH. The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. J Intern Med1994; 235:31 -9.[Medline] [Order article via Infotrieve]
413. Oliver MF. Serum cholesterol-the knave of hearts and the joker. Lancet 1981;2:1090 -5.[Medline] [Order article via Infotrieve]
414. Muldoon MF, Manuck SB, Mathews KA. Lowering cholesterol
concentrations and mortality: a quantitative review of primary prevention
trials. BMJ1990; 301:309
-14.
415. Ravnskov U. Cholesterol lowering trials in coronary heart disease:
frequency of citation and outcome. BMJ1992; 305:15
-9.
416. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW,
McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study
Group. Prevention of coronary heart disease with pravastatin in men with
hypercholesterolemia. N Engl J Med1995; 333:1301
-7.
417. Psaty BM, Furberg CD, Kuller LH, Bild DE, Rautaharju PM, Polak JF,
Bovill E, Gottdiener JS. Traditional risk factors and subclinical disease
measures as predictors of first myocardial infarction in older adults: the
Cardiovascular Health Study. Arch Intern Med1999; 159:1339
-47.
418. Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP, Borhani NO,
Wolfson SK, for the Cardiovascular Health Study (CHS) Collaborative Research
Group. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular
Health Study. Circulation1993; 88:837
-45.
419. Kuller L, Fisher L, McClelland R, Fried L, Cushman M, Jackson S,
Manolio T. Differences in prevalence of and risk factors for subclinical
vascular disease among black and white participants in the Cardiovascular
Health Study. Arterioscler Thromb Vasc Biol1998; 18:283
-93.
420. Frohlich J, Fodor G, McPherson R, Genest J, Langner N, for the Dyslipidemia Working Group of Health Canada. Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim report. Can J Cardiol1998; 14(suppl A):17A -21A.[Medline] [Order article via Infotrieve]
421. Fodor JG, Frohlich JJ, Genest JJ Jr, McPherson PR, for the Working
Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the
management and treatment of dyslipidemia: Report of the Working Group on
Hypercholesterolemia and Other Dyslipidemias. CMAJ2000; 162:1441
-7.
422. U.S. Preventive Services Task Force. Guide to clinical preventive services: Report of the U.S. Preventive Services Task Force, 2nd edition. Baltimore: Williams & Wilkins,1996 . 504 pages.
423. Berenson GS, Wattigney WA, Tracy RE, Newman WP III, Srinivasan SR, Webber LS, Dalferes ER Jr, Strong JP. Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in patients aged 6 to 30 years and studies at necropsy (the Bogalusa Heart Study). Am J Cardiol 1992;70:851 -8.[CrossRef][Medline] [Order article via Infotrieve]
424. Berenson GS, Srinivasan SR, Bao W, Newman WP III, Tracy RE,
Wattigney WA. Association between multiple cardiovascular risk factors and
atherosclerosis in children and young adults. N Engl J
Med 1998;338:1650
-6.
425. Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention
Trial Research Group. Serum cholesterol, blood pressure, cigarette smoking,
and death from coronary heart disease: overall findings and differences by age
for 316,099 white men. Arch Intern Med1992; 152:56
-64.
426. Strong JP, Malcolm GT, Oalmann MC, Wissler RW. The PDAY Study: natural history, risk factors, and pathobiology. Ann NY Acad Sci 1997;811:226 -37.[Medline] [Order article via Infotrieve]
427. Strong JP, Malcom GT, McMahan CA, Tracy RE, Newman WP III,
Herderick EE, Cornhill JF. Prevalence and extent of atherosclerosis in
adolescents and young adults: implications for prevention from the
Pathobiological Determinants of Atherosclerosis in Youth Study.
JAMA 1999;281:727
-35.
428. Umans-Eckenhausen MAW, Defesche JC, Sijbrands EJG, Scheerder RLJM, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet2001; 357:165 -8.[CrossRef][Medline] [Order article via Infotrieve]
429. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol1995; 76:69C -77C.[CrossRef][Medline] [Order article via Infotrieve]
430. Rossouw JE. The effects of lowering serum cholesterol on coronary heart disease risk. Med Clin North Am1994; 78:181 -95.[Medline] [Order article via Infotrieve]
431. Waters D, Higginson L, Gladstsone P, Kimball B, Le May M, Boccuzzi
SJ, Lespérance J. Effects of monotherapy with an HMG-CoA reductase
inhibitor on the progression of coronary atherosclerosis as assessed by serial
quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention
Trial. Circulation1994; 89:959
-68.
432. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, Park J-S, McGovern ME, for the PLAC I Investigators. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol1995; 26:1133 -9.[Abstract]
433. Azen SP, Mack WJ, Cashin-Hemphill L, LaBree L, Shircore AM, Selzer
RH, Blankenhorn DH, Hodis HN. Progression of coronary artery disease predicts
clinical coronary events: long-term follow-up from the Cholesterol Lowering
Atherosclerosis Study. Circulation1996; 93:34
-41.
434. Post Coronary Artery Bypass Graft Trial Investigators. The effect
of aggressive lowering of low-density lipoprotein cholesterol levels and
low-dose anticoagulation on obstructive changes in saphenous-vein
coronary-artery bypass grafts. N Engl J Med1997; 336:153
-62.
435. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994; 344:1383 -9.[CrossRef][Medline] [Order article via Infotrieve]
436. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG,
Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E, for the
Cholesterol and Recurrent Events Trial Investigators. The effect of
pravastatin on coronary events after myocardial infarction in patients with
average cholesterol levels. N Engl J Med1996; 335:1001
-9.
437. Constantinides P. Plaque hemorrhages, their genesis and their role in supra-plaque thrombosis and atherogenesis. In: Giagov S, Newman WP, and Schaffer SA, eds. Pathobiology of the human atherosclerotic plaque. New York: Springer-Verlag, 1990:393 -411.
438. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque
regression: new insights into prevention of plaque disruption and clinical
events in coronary disease. Circulation1993; 87:1781
-91.
439. Falk E, Shah PK, Fuster V. Coronary plaque disruption.
Circulation1995; 92:657
-71.
440. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in
cardiovascular disease: clinical benefits and possible mechanisms.
N Engl J Med1995; 332:512
-21.
441. Ballantyne CM. Clinical trial endpoints: angiograms, events, and plaque instability. Am J Cardiol1998; 82:5M -11M.[CrossRef][Medline] [Order article via Infotrieve]
442. Rossouw JE. Clinical trials of lipid-lowering drugs. In: Rifkind BM, ed. Drug treatment of hyperlipidemia. New York: Marcel Dekker, Inc., 1991: 67-88.
443. Research Committee to the Medical Research Council. Controlled trial of soya-bean oil in myocardial infarction. Lancet 1968;2:693 -9.[Medline] [Order article via Infotrieve]
444. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W, for the Coronary Drug Project Research Group. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol1986; 8:1245 -55.[Abstract]
445. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD Jr, Sawin HS Jr, Campos CT, Hansen BJ, Tuna N, Karnegis JN, Sanmarco ME, Amplatz K, Castaneda-Zuniga WR, Hunter DW, Bissett JK, Weber FJ, Stevenson JW, Leon AS, Chalmers TC, and the POSCH Group. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the Program of the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990;323:946 -55.[Abstract]
446. Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H,
Furberg CD, Mancini GBJ. Reduction in cardiovascular events during pravastatin
therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis
Intervention Program. Circulation1995; 92:2419
-25.
447. Waters D, Higginson L, Gladstone P, Boccuzzi SJ, Cook T,
Lespérance J, for the CCAIT Study Group. Effects of cholesterol
lowering on the progression of coronary atherosclerosis in women: a Canadian
Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy.
Circulation1995; 92:2404
-10.
448. Kjekshus J, Pedersen TR, for the Scandinavian Simvastatin Survival Study Group. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995;76:64C -8C.[CrossRef][Medline] [Order article via Infotrieve]
449. Miettinen TA, Pyörälä K, Olsson AG, Musliner TA,
Cook TJ, Faergeman O, Berg K, Pedersen T, Kjekshus J, for the Scandinavian
Simvastatin Survival Study Group. Cholesterol-lowering therapy in women and
elderly patients with myocardial infarction or angina pectoris: findings from
the Scandinavian Simvastatin Survival Study (4S).
Circulation1997; 96:4211
-8.
450. Crouse JR III, Byington RP, Hoen HM, Furberg CD. Reductase
inhibitor monotherapy and stroke prevention. Arch Intern
Med 1997;157:1305
-10.
451. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering
with statin drugs, risk of stroke, and total mortality: an overview of
randomized trials. JAMA1997; 278:313
-21.
452. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The
effect of cholesterol-lowering and antioxidant therapy on
endothelium-dependent coronary vasomotion. N Engl J
Med 1995;332:488
-93.
453. Aengevaeren WR, Uijen GJ, Jukema JW, Bruschke AV, van der Werf T.
Functional evaluation of lipid-lowering therapy by pravastatin in the
Regression Growth Evaluation Statin Study (REGRESS).
Circulation1997; 96:429
-35.
454. Pedersen TR, Kjekshus J, Pyörälä K, Olsson AG, Cook TJ, Musliner TA, Tobert JA, Haghfelt T. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol1998; 81:333 -5.[CrossRef][Medline] [Order article via Infotrieve]
455. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD.
Cholesterol reduction yields clinical benefit: impact of statin trials.
Circulation1998; 97:946
-52.
456. Knatterud GL, Rosenberg Y, Campeau L, Geller NL, Hunninghake DB, Forman SA, Forrester JS, Gobel FL, Herd JA, Hickey A, Hoogwerf BJ, Terrin ML, White C, and Post CABG Investigators. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the Post Coronary Artery Bypass Graft trial. Circulation2000; 102:157-65 .
457. Holme I. Relationship between total mortality and cholesterol reduction as found by meta-regression analysis of randomized cholesterol-lowering trials. Control Clin Trials1996; 17:13-22 .
458. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ1991; 303:276-82 .
459. Cullen P, Assmann G. Treatment goals for low-density lipoprotein cholesterol in the secondary prevention of coronary heart disease: absolute levels or extent of lowering? Am J Cardiol1997; 80:1287-94 .
460. Grover SA, Abrahamowicz M, Joseph L, Brewer C, Coupal L, Suissa S. The benefits of treating hyperlipidemia to prevent coronary heart disease. JAMA 1992;267:816-22 .
461. Buchwald H. Program on the Surgical Control of the Hyperlipidemias (POSCH) trial: a pivotal 25-year study. In: Grundy SM, ed.Cholesterol-lowering therapy: evaluation of clinical trial evidence . New York: Marcel Dekker, Inc., 2000:117-49 .
462. Grundy SM. Statin trials and goals of cholesterol-lowering therapy [Editorial]. Circulation1998; 97:1436-9 .
463. Sacks FM, Moyé LA, Davis BR, Cole TG, Rouleau JL, Nash DT, Pfeffer MA, Braunwald E. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation1998; 97:1446-52 .
464. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyörälä K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ, for the Scandinavian Simvastatin Survival Study Group. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation1998; 97:1453-60 .
465. Gotto AM Jr, Grundy SM. Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial data: issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, Ninth Council Meeting. Circulation1999; 99:1-7 .[Medline] [Order article via Infotrieve]
466. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer LWV, Mahrer PR, Masteller MJ, Vailas LI, and the MARS Research Group. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993;119:969-76 .
467. Brown BG, Bardsley J, Poulin D, Hillger LA, Dowdy A, Maher VMG, Zhao X-Q, Albers JJ, Knopp RH. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dL in patients with hyperlipidemia and coronary artery disease. Am J Cardiol1997; 80:111-5 .
468. Kroon AA, Aengevaeren WRM, van der WT, Uijen GJH, Reiber JHC, Bruschke AVG, Stalenhoef AF. LDL-Apheresis Atherosclerosis Regression Study (LAARS): effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation1996; 93:1826-35 .
469. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T, for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-8 .
470. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS, for the Atorvastatin Versus Revascularization Treatment Investigators. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999;341:70-6 .
471. Stenestrand U, Wallentin L, for the Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA2001; 285:430-6 .
472. Waters DD, Azar RR. Should intensive cholesterol lowering play a role in the management of acute coronary syndromes? Am J Cardiol 2000;86(suppl):35J -43J.[Medline] [Order article via Infotrieve]
473. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Móye LA, Piller LB, Rutherford J, Simpson LM, Braunwald E, for the CARE Investigators. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) Study. Circulation1999; 99:216-23 .
474. White HD, Simes RJ, Anderson NE, Hankey GJ, Watson JDG, Hunt D, Colquhoun DM, Glasziou P, MacMahon S, Kirby AC, West MJ, Tonkin AM. Pravastatin therapy and the risk of stroke. N Engl J Med 2000;343:317-26 .
475. Crouse JR III, Byington RP, Furberg CD. HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. Atherosclerosis1998; 138:11-24 .
476. Blauw GJ, Lagaay AM, Smelt AHM, Westendorp RGJ. Stroke, statins, and cholesterol: a meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997;28:946-50 .
477. Byington RP, Davis BR, Plehn JF, White HD, Baker J, Cobbe SM, Shepherd J. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation2001; 103:387-92 .
478. Crouse JR. Effects of statins on carotid disease and stroke. Curr Opin Lipidol1999; 10:535-41 .
479. Smith GD, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ 1993;306:1367-73 .
480. Holme I. Relation of coronary heart disease incidence and total
mortality to plasma cholesterol reduction in randomised trials: use of
meta-analysis. Br Heart J1993; 69(suppl):S42
-S7.
481. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: a new look at old data. Circulation1995; 91:2274-82 .
482. Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation1990; 82:1916-24 .
483. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet1994; 344:633-8 .
484. Salonen R, Nyyssönen K, Porkkala E, Rummukainen J, Belder R, Park J-S, Salonen JT. Kuopio Atherosclerosis Prevention Study (KAPS): a population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation1995; 92:1758-64 .
485. Crouse JR III, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol1995; 75:455-9 .
486. Mercuri M, Bond MG, Sirtori CR, Veglia F, Crepaldi G, Feruglio FS, Descovich G, Ricci G, Rubba P, Mancini M, Gallus G, Bianchi G, D'Alo G, Ventura A. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med1996; 101:627-34 .
487. Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, Young B, for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation1994; 90:1679-87 .
488. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LDR, Mann JI, Swan AV. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet1992; 339:563-9 .
489. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease; a meta-analysis of randomized controlled trials. JAMA 1999;282:2340-6 .
490. Law MR, Wald NJ. An ecologic study of serum cholesterol and ischaemic heart disease between 1950 and 1990. Eur J Clin Nutr 1994;48:305-25 .
491. Rosamond WD, Chambless LE, Folsom AR, Cooper LS, Conwill DE, Clegg L, Wang C-H, Heiss G. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 1998;339:861-7 .
492. Tunstall-Pedoe H, Kuulasmaa K, Mähönen M, Tolonen H, Ruokokoski E, Amouyel P, for the WHO MONICA (monitoring trends and determinants in cardiovascular disease) Project. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet 1999;353:1547-57 .
493. Hulley S, Grady S, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff FE, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13 .
494. Feit F, Brooks MM, Sopko G, Keller NM, Rosen A, Krone R, Berger PB, Shemin R, Attubato MJ, Williams DO, Frye R, Detre KM, for the BARI Investigators. Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry: comparison with the randomized trial. Circulation2000; 101:2795-802 .
495. Peduzzi P, Kamina A, Detre K, for the VA Coronary Artery Bypass Surgery Cooperative Study Group. Twenty-two-year follow-up in the VA Cooperative Study of Coronary Artery Bypass Surgery for Stable Angina. Am J Cardiol1998; 81:1393-9 .
496. Leng GC, Fowkes FGR, Lee AJ, Dunbar J, Housley E, Ruckley CV. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ1996; 313:1440-3 .
497. Vogt MT, Cauley JA, Newman AB, Kuller LH, Hulley SB. Decreased
ankle/arm blood pressure index and mortality in elderly women.
JAMA 1993;270:465
-9.
498. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis1991; 87:119 -28.[CrossRef][Medline] [Order article via Infotrieve]
499. Poulias GE, Doundoulakis N, Prombonas E, Haddad H, Papaioannou K, Lymberiades D, Savopoulos G. Aorto-femoral bypass and determinants of early success and late favourable outcome: experience with 1,000 consecutive cases. J Cardiovasc Surg1992; 33:664 -78.[Medline] [Order article via Infotrieve]
500. Ferguson GC, Eliasziw M, Barr HWK, Clagett GP, Barnes RW, Wallace
C, Taylor DW, Haynes RB, Finan JW, Hachinski VC, Barnett HJM, for the North
American Symptomatic Carotid Endarterectomy Trial (NASCET) Collaborators. The
North American Symptomatic Carotid Endarterectomy Trial: surgical results in
1415 patients. Stroke1999; 30:1751
-8.
501. Barnett HJ, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG, Haynes RB,
Rankin RN, Clagett GP, Hachinski VC, Sackett DL, Thorpe KE, Meldrum HE, for
the North American Symptomatic Carotid Endarterectomy Trial Collaborators.
Benefit of carotid endarterectomy in patients with symptomatic moderate or
severe stenosis. N Engl J Med1998; 339:1415
-25.
502. Norris JW, Zhu CZ, Bornstein NM, Chambers BR. Vascular risks of
asymptomatic carotid stenosis. Stroke1991; 22:1485
-90.
503. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998;351:1379 -87.[CrossRef][Medline] [Order article via Infotrieve]
504. Executive Committee for the Asymptomatic Carotid Atherosclerosis
Study. Endarterectomy for Asymptomatic Carotid Artery Stenosis.
JAMA 1995;273:1421
-8.
505. Hobson RW II, Weiss DG, Fields WS, Goldstone J, Moore WS, Towne JB,
Wright CB, and the Veterans Affairs Cooperative Study Group. Efficacy of
carotid endarterectomy for asymptomatic carotid stenosis. N Engl J
Med 1993;328:221
-7.
506. Mayo Asymptomatic Carotid Endarterectomy Study Group. Results of a randomized controlled trial of carotid endarterectomy for asymptomatic carotid stenosis. Mayo Clin Proc1992; 67:513 -8.[Medline] [Order article via Infotrieve]
507. CASANOVA Study Group. Carotid surgery versus medical therapy in
asymptomatic carotid stenosis. Stroke1991; 22:1229
-35.
508. Salonen JT, Salonen R. Ultrasonographically assessed carotid
morphology and the risk of coronary heart disease. Arterioscler
Thromb 1991;11:1245
-9.
509. Hertzer NR. Fatal myocardial infarction following abdominal aortic aneurysm resection: three hundred forty-three patients followed 6-11 years postoperatively. Ann Surg1980; 192:667 -73.[Medline] [Order article via Infotrieve]
510. Heart Outcomes Prevention Evaluation Study Investigators. Effects
of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular
events in high-risk patients. N Engl J Med2000; 342:145
-53.
511. Behar S, Boyko V, Reicher-Reiss H, Goldbourt U, for the Sprint Study Group. Ten-year survival after acute myocardial infarction: comparison of patients with and without diabetes. Am Heart J1997; 133:290 -6.[CrossRef][Medline] [Order article via Infotrieve]
512. Benderly M, Behar S, Reicher-Reiss H, Boyko V, Goldbourt U, for the
Sprint Study Group. Long-term prognosis of women after myocardial infarction.
Am J Epidemiol1997; 146:153
-60.
513. Karlson BW, Wiklund O, Hallgren P, Sjölin M, Lindqvist J, Herlitz J. Ten-year mortality amongst patients with a very small or unconfirmed acute myocardial infarction in relation to clinical history, metabolic screening and signs of myocardial ischaemia. J Intern Med 2000;247:449 -56.[CrossRef][Medline] [Order article via Infotrieve]
514. Gustafsson I, Hildebrandt P, Seibaek M, Melchior T, Torp-Pedersen
C, Kober L, Kaiser-Nielsen P, and the TRACE Study Group. Long-term prognosis
of diabetic patients with myocardial infarction: relation to antidiabetic
treatment regimen. Eur Heart J2000; 21:1937
-43.
515. Thourani VH, Weintraub WS, Stein B, Gebhart SSP, Craver JM, Jones
EL, and Guyton RA. Influence of diabetes mellitus on early and late outcome
after coronary artery bypass grafting. Ann Thorac Surg1999; 67:1045
-52.
516. Herlitz J, Wognsen GB, Karlson BW, Sjöland H, Karlsson T, Caidahl K, Hartford M, Haglid M. Mortality, mode of death and risk indicators for death during 5 years after coronary artery bypass grafting among patients with and without a history of diabetes mellitus. Coron Artery Dis 2000;11:339 -46.[CrossRef][Medline] [Order article via Infotrieve]
517. American Diabetes Association. Type 2 diabetes in children and
adolescents. Pediatrics2000; 105:671
-80.
518. Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T. Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia1987; 30:144 -8.[CrossRef][Medline] [Order article via Infotrieve]
519. Krolewski AS, Kosinksi EJ, Warram JH, Leland OS, Busick EJ, Asmal AC, Rand LI, Christlieb AR, Bradley RF, Kahn CR. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin dependent diabetes mellitus. Am J Cardiol1987; 59:750 -5.[CrossRef][Medline] [Order article via Infotrieve]
520. Pearson TA. The undertreatment of LDL-cholesterol: addressing the challenge. Int J Cardiol2000; 74 (suppl):S23 -S28.[CrossRef][Medline] [Order article via Infotrieve]
521. Bowker TJ, Clayton TC, Ingham J, McLennan NR, Hobson HL, Pyke SD,
Schofield B, Wood DA. A British Cardiac Society survey of the potential for
the secondary prevention of coronary disease: ASPIRE (Action on Secondary
Prevention through Intervention to Reduce Events).
Heart 1996;75:334
-42.
522. Blair TP, Bryant FJ, Bocuzzi S. Treatment of hypercholesterolemia
by a clinical nurse using a stepped-care protocol in a nonvolunteer
population. Arch Intern Med1988; 148:1046
-8.
523. DeBusk RF, Miller NH, Superko HR, Dennis CA, Thomas RJ, Lew HT,
Berger WE III, Heller RS, Rompf J, Gee D, Kraemer HC, Bandura A, Ghandour G,
Clark M, Shah RV, Fisher L, Taylor CB. A case-management system for coronary
risk factor modification after acute myocardial infarction. Ann
Intern Med 1994;120:721
-9.
524. Fonorow GC, Gawlinski A. Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles. Am J Cardiol2000; 85:10A -7A.[Medline] [Order article via Infotrieve]
525. Hoogwerf BJ, Frolkis JP, Pearce GP, Vidt D, Pashkow FJ, Cross JA, Sprecher DL. Use of treatment algorithms by physician extenders in a preventive cardiology clinic for LDL-cholesterol, blood pressure, and HbA1c in diabetic patients. Circulation1999; 100:I -100.
526. LaBresh KA, Owen P, Alteri C, Reilly S, Albright PS, Hordes AR, Shaftel PA, Noonan TE, Stoukides CA, Kaul AF. Secondary prevention in a cardiology group practice and hospital setting after a heart-care initiative. Am J Cardiol2000; 85:23A -9A.[Medline] [Order article via Infotrieve]
527. Schectman G, Wolff N, Byrd JC, Hiatt JG, Hartz A. Physician extenders for cost-effective management of hypercholesterolemia. J Gen Intern Med 1996;11:277 -86.[Medline] [Order article via Infotrieve]
528. Shaffer J, Wexler J. Reducing low-density lipoprotein cholesterol
levels in an ambulatory care system: results of a multidisciplinary
collaborative practice lipid clinic compared with traditional physician-based
care. Arch Intern Med1995; 155:2330
-5.
529. Stuart-Shor E, Skinner SS, Kemper AJ, McCleary NC, Clark SJ, Waldman HM. A nurse-directed, community based, integrated multiple cardiac risk reduction program: physiologic and behavioral outcomes [Abstract]. Circulation1999; 100:I -100.
530. Thomas TS. Improving care with nurse case managers: practical aspects of designing lipid clinics. Am J Cardiol1997; 80:62H -5H.[CrossRef][Medline] [Order article via Infotrieve]
531. Urquhart J. Correlates of variable patient compliance in drug trials: relevance in the new health care environment. Adv Drug Res 1995;26:237 -57.[CrossRef]
532. Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MGM,
Goldman L, Weinstein MC. Cost-effectiveness of cholesterol-lowering therapies
according to selected patient characteristics. Ann Intern
Med 2000;132:769
-79.
533. Neumann PJ, Stone PW, Chapman RH, Sandberg EA, Bell CM. The quality
of reporting in published cost-utility analyses, 1976-1997. Ann
Intern Med 2000;132:964
-872.
534. Stone PW, Teutsch S, Chapman RH, Bell C, Goldie SJ, Neumann PJ. Cost-utility analyses of clinical preventive services: published ratios, 1976-1997. Am J Prev Med2000; 19:15 -23.[Medline] [Order article via Infotrieve]
535. Tengs TO, Adams ME, Pliskin JS, Safran DG, Siegel JE, Weinstein MC, Graham JD. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal1995; 15:369 -90.[CrossRef][Medline] [Order article via Infotrieve]
536. Barosi G, Marchetti M, Dazzi L, Quaglini S. Testing for occult cancer in patients with idiopathic deep vein thrombosis—a decision analysis. Thromb and Haemost1997; 78:1319 -26.[Medline] [Order article via Infotrieve]
537. Boer R, de Koning HJ, van der Maas PJ. A longer breast carcinoma screening interval for women age older than 65 years? Cancer 1999;86:1506 -10.[CrossRef][Medline] [Order article via Infotrieve]
538. Bulgin RH. Comparative costs of various dialysis treatments. Peritoneal Dialysis Bulletin1981; 1:88 -91.
539. Buxton MJ, West RR. Cost-benefit analysis of long-term haemodialysis for chronic renal failure. BMJ1975; 2:376 -9.[Medline] [Order article via Infotrieve]
540. Christie D. Screening for breast cancer: the role of mammography. Med J Aust1977; 47:398 -400.
541. Churchill DN, Lemon BC, Torrance GW. A cost-effectiveness analysis of continuous ambulatory peritoneal dialysis and hospital hemodialysis. Medical Decision Making1984; 4:489 -500.[CrossRef]
542. Croghan IT, Offord KP, Evans RW, Schmidt S, Gomez-Dahl LC,
Schroeder DR, Patten CA, Hurt RD. Cost-effectiveness of treating nicotine
dependence: the Mayo Clinic experience. Mayo Clinic
Proc 1997;72:917
-24.
543. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T.
Cost-effectiveness of the clinical practice recommendations in the AHCPR
guideline for smoking cessation. JAMA1997; 278:1759
-66.
544. Cummings SR, Rubin SM, Oster G. The cost-effectiveness of
counseling smokers to quit. JAMA1989; 261:75
-9.
545. de Koning HJ, van Ineveld BM, van Oortmarssen GJ, de Haes JCJ, Collette HJA, Hendriks JHC, van der Maas PJ. Breast cancer screening and cost-effectiveness: policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer1991; 49:531 -7.[Medline] [Order article via Infotrieve]
546. Douzdjian V, Ferrara D, Silvestri G. Treatment strategies for insulin-dependent diabetics with ESRD: a cost-effectiveness decision analysis model. Am J Kidney Dis1998; 31:794 -802.[Medline] [Order article via Infotrieve]
547. Eccles M, Freemantle N, Mason J, and the North of England Aspirin
Guideline Development Group. North of England evidence based guideline
development project: guideline on the use of aspirin as secondary prophylaxis
for vascular disease in primary care. BMJ1998; 316:1303
-9.
548. Eddy DM, Hasselblad V, McGivney W, Hendee W. The value of
mammography screening in women under age 50 years.
JAMA 1988;259:1512
-9.
549. Edelson JT, Weinstein MC, Tosteson AN, Williams L, Lee TH, Goldman
L. Long-term cost-effectiveness of various initial monotherapies for mild to
moderate hypertension. JAMA1990; 263:407
-13.
550. Fiscella K, Franks P. Cost-effectiveness of the transdermal
nicotine patch as an adjunct to physicians' smoking cessation counseling.
JAMA 1996;275:1247
-51.
551. Gyrd-Hansen D. The relative economics of screening for colorectal cancer, breast cancer and cervical cancer. Crit Rev Oncol Hematol 1999;32:133 -44.[Medline] [Order article via Infotrieve]
552. Harvald B, Christiansen T, Pederson KM, Rasmussen K, Strate M, Thygesen K. Cost-benefit in treatment of mild hypertension. Acta Medica Scandinavia 1983;686:81 -7.
553. Hatziandreu EI, Koplan JP, Weinstein MC, Caspersen CJ, Warner KE. A
cost-effectiveness analysis of exercise as a health promotion activity.
Am J Public Health1988; 78:1417
-21.
554. Hlatky MA, Rogers WJ, Johnstone I, Boothroyd D, Brooks MM, Pitt B,
Reeder G, Ryan T, Smith H, Whitlow P, Wiens R, Mark DB, for the Bypass
Angioplasty Revascularization Investigation (BARI) Investigators. Medical care
costs and quality of life after randomization to coronary angioplasty or
coronary bypass surgery. N Engl J Med1997; 336:92
-9.
555. Hristova L, Hakama M. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017. Acta Oncologica1997; 36(suppl 9):S1 -60.[CrossRef]
556. Johannesson M, Agewall S, Hartford M, Hedner T, Fagerberg B. The cost-effectiveness of a cardiovascular multiple-risk-factor intervention programme in treated hypertensive men. J Int Med1995; 237:19 -26.[Medline] [Order article via Infotrieve]
557. Johannesson M, Dahlöf B, Lindholm LH, Ekbom T, Hansson L, Oden A, Scherstén B, Wester P-O, Jönsson B. The cost-effectiveness of treating hypertension in elderly people—an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). J Int Med 1993;234:317 -23.[Medline] [Order article via Infotrieve]
558. Johannesson M, Meltzer D, O'Conor RM. Incorporating future costs in
medical cost-effectiveness analysis: implications for the cost-effectiveness
of the treatment of hypertension. Med Decis Making1997; 17:382
-9.
559. Johannesson M. The cost-effectiveness of hypertension treatment in Sweden: an analysis of the criteria for intervention and the choice of drug treatment. J Hum Hypertens1996; 10(suppl 2):S23 -S26.[Medline] [Order article via Infotrieve]
560. Johannesson M. The impact of age on the cost-effectiveness of
hypertension treatment: an analysis of randomized drug trials. Med
Decis Making 1994;14:236
-44.
561. Jones TF, Eaton CB. Cost-benefit analysis of walking to prevent
coronary heart disease. Arch Fam Med1994; 3:703
-10.
562. Kerlikowske K, Salzmann P, Phillips KA, Cauley JA, Cummings SR.
Continuing screening mammography in women aged 70 to 79 years: impact on life
expectancy and cost-effectiveness. JAMA1999; 282:2156
-63.
563. Klarman HE, Francis JO, Rosenthal JD. Cost-effectiveness analysis applied to the treatment of chronic renal disease. Medical Care 1968;6:48 -54.[CrossRef]
564. Knox EG. Evaluation of a proposed breast cancer screening regimen.
BMJ 1988;297:650
-4.
565. Kodlin D. A note on the cost-benefit problem in screening for breast cancer. Methods Inform Med1972; 11:242 -7.[Medline] [Order article via Infotrieve]
566. Kristein MM. Economic issues in prevention. Prev Med 1977;6:252 -64.[CrossRef][Medline] [Order article via Infotrieve]
567. Krumholz HM, Cohen BJ, Tsevat J, Pasternak RC, Weinstein MC. Cost-effectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol1993; 22:1697 -702.[Abstract]
568. Lai M-S, Yen M-F, Kuo H-S, Koong S-L, Chen TH, Duffy SW. Efficacy of breast-cancer screening for female relatives of breast-cancer-index cases: Taiwan multicentre cancer screening (TAMCAS). Int J Cancer 1998;78:21 -6.[CrossRef][Medline] [Order article via Infotrieve]
569. Leivo T, Sintonen H, Tuominen R, Hakama M, Pukkala E, Heinonen O-P. The cost-effectiveness of nationwide breast carcinoma screening in Finland, 1987-1992. Cancer1999; 86:638 -46.[CrossRef][Medline] [Order article via Infotrieve]
570. Lindfors KK, Rosenquist CJ. The cost-effectiveness of mammographic
screening strategies. JAMA1995; 274:881
-4.
571. Lindholm LH, Johannesson M. Cost-benefit aspects of treatment of hypertension in the elderly. Blood Pressure1995; 4(suppl 3):11 -4.[Medline] [Order article via Infotrieve]
572. Littenberg B, Garber AM, Sox HC Jr. Screening for hypertension.
Ann Intern Med1990; 112:192
-202.
573. Ludbrook A. A cost-effectiveness analysis of the treatment of chronic renal failure. Applied Economics1981; 13:337 -50.[CrossRef]
574. Mandelblatt J, Freeman H, Winczewski D, Cagney K, Williams S,
Trowers R, Tang J, Gold K, Lin TH, Kerner J. The costs and effects of cervical
and breast cancer screening in a public hospital emergency room.
Amer J Public Health1997; 87:1182
-9.
575. Marks JS, Koplan JP, Hogue CJR, Dalmat ME. A cost-benefit/cost-effectiveness analysis of smoking cessation for pregnant women. Am J Prev Med1990; 6:282 -9.[Medline] [Order article via Infotrieve]
576. Meenan RT, Stevens VJ, Hornbrook MC, La Chance P-A, Glasgow RE, Hollis JF, Lichtenstein E, Vogt TM. Cost-effectiveness of a hospital-based smoking cessation intervention. Med Care1998; 36:670 -8.[CrossRef][Medline] [Order article via Infotrieve]
577. Moskowitz M, Fox S. Cost analysis of aggressive breast cancer
screening. Radiology1979; 130:253
-6.
578. Munro J, Brazier J, Davey R, Nicholl J. Physical activity for the over-65s: could it be a cost-effective exercise for the NHS? J Pub H1th Med 1997;19:397 -402.
579. Okubo I, Glick H, Frumkin H, Eisenberg JM. Cost-effectiveness analysis of mass screening for breast cancer in Japan. Cancer 1991;67:2021 -9.[CrossRef][Medline] [Order article via Infotrieve]
580. Oster G, Huse DM, Delea TE, Colditz GA. Cost-effectiveness of
nicotine gum as an adjunct to physician's advice against cigarette smoking.
JAMA 1986;256:1315
-8.
581. Pearson DA, Stranova TJ, Thompson JD. Patient and program costs associated with chronic hemodialysis care. Inquiry1976; 13:23 -8.[Medline] [Order article via Infotrieve]
582. Roberts SD, Maxwell DR, Gross TL. Cost-effective care of end-stage renal disease: a billion dollar question. Ann Intern Med 1980;92(part 1):243 -8.[Medline] [Order article via Infotrieve]
583. Rosenquist CJ, Lindfors KK. Screening mammography in women aged
40-49 years: analysis of cost-effectiveness. Radiology1994; 191:647
-50.
584. Salzmann P, Kerlikowske K, Phillips K. Cost-effectiveness of
extending screening mammography guidelines to include women 40 to 49 years of
age. Ann Intern Med1997; 127:955
-65.
585. Secker-Walker RH, Worden JK, Holland RR, Flynn BS, Detsky AS. A mass media programme to prevent smoking among adolescents: costs and cost-effectiveness. Tobacco Control1997; 6:207 -12.[Abstract]
586. Shepard DS, Stason WB, Perry HM Jr, Carmen BA, Nagurney JT. Multivariate cost-effectiveness analysis: an application to optimizing ambulatory care for hypertension. Inquiry1995; 32:320 -31.[Medline] [Order article via Infotrieve]
587. Simon DG. A cost-effectiveness analysis of cyclosporine in
cadavernic kidney transplantation. Med Decis Making1986; 6:199
-207.
588. Simpson KN, Snyder LB. Informing the mammography coverage debate: results of meta-analysis, computer modeling, and issue analysis. Int J Technol Assess Health Care1991; 7:616 -31.[Medline] [Order article via Infotrieve]
589. Smith WF. Cost-effectiveness and cost-benefit analyses for public health programs. Public Health Rep1968; 83:899 -906.[Medline] [Order article via Infotrieve]
590. Sollano JA, Rose EA, Williams DL, Thornton B, Quint E, Apfelbaum M, Wasserman H, Cannavale GA, Smith CR, Reemtsma K, Greene RJ. Cost-effectiveness of coronary artery bypass surgery in octogenarians. Ann Surg 1998;228:297 -306.[CrossRef][Medline] [Order article via Infotrieve]
591. Stange PV, Sumner AT. Predicting treatment costs and life expectancy for end-stage renal disease. N Engl J Med1978; 298:372 -8.[Abstract]
592. Stason WB, Weinstein MC. Public-health rounds at the Harvard School of Public Health: allocation of resources to manage hypertension. N Engl J Med 1977;296:732 -9.[Medline] [Order article via Infotrieve]
593. Streitz JM Jr, Ellis FH Jr, Tilden RL, Erickson RV. Endoscopic surveillance of Barrett's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer. Am J Gastroenterol 1998;93:911 -5.[Medline] [Order article via Infotrieve]
594. Tsevat J. Impact and cost-effectiveness of smoking interventions. Am J Med1992; 93(suppl 1A):43S -7S.[CrossRef][Medline] [Order article via Infotrieve]
595. van der Maas PJ, de Koning HJ, van Ineveld BM, van Oortmarssen GJ, Habbema JD, Lubbe KTN, Geerts AT, Collette HJA, Verbeek ALM, Hendriks JH, Rombach JJ. The cost-effectiveness of breast cancer screening. Int J Cancer 1989;43:1055 -60.[Medline] [Order article via Infotrieve]
596. Warner KE, Smith RJ, Smith DG, Fries BE. Health and economic implications of a work-site smoking-cessation program: a simulation analysis. JOEM 1996;38:981 -92.[CrossRef][Medline] [Order article via Infotrieve]
597. Wasley MA, McNagny SE, Phillips VL, Ahluwalia JS. The cost-effectiveness of the nicotine transdermal patch for smoking cessation. Prev Med 1997;26:264 -70.[CrossRef][Medline] [Order article via Infotrieve]
598. Weinstein MC, Stason WB. Cost-effectiveness of coronary artery bypass surgery. Circulation1982; 66(suppl III):III56 -III66.[Medline] [Order article via Infotrieve]
599. Williams A. Economics of coronary artery bypass grafting.
BMJ 1985;291:326
-9.
600. Caro J, Klittich W, McGuire A, Ford I, Norrie J, Pettitt D,
McMurray J, Shepherd J, for the West of Scotland Coronary Prevention Study
Group. The West of Scotland Coronary Prevention Study: economic benefit
analysis of primary prevention with pravastatin. BMJ1997; 315:1577
-82.
601. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care2000; 38:583 -637.[CrossRef][Medline] [Order article via Infotrieve]
602. Weinstein MC. From cost-effectiveness ratios to resource allocation: where to draw the line? In: Sloan FA, ed. Valuing health care: costs, benefits, and effectiveness of pharmaceuticals and other medical technologies. New York: Cambridge University Press, 1995:273 pages.
603. Johannesson M, Jönsson B, Kjekshus J, Olsson AG, Pedersen TR,
Wedel H, for the Scandinavian Simvastatin Survival Study Group.
Cost-effectiveness of simvaststain treatment to lower cholesterol levels in
patients with coronary heart disease. N Engl J Med1997; 336:332
-6.
604. Glasziou PP, Mulray SE, Hall JP, Martin A, Harris P, Thompson P, Tonkin A, Simes RJ. Cost-effectiveness with pravastatin in patients with coronary heart disease and average cholesterol level [Abstract]. Med Decis Making1998; 18:475 .
605. Ashraf T, Hay JW, Pitt B, Wittels E, Crouse J, Davidson M, Furberg CD, Radican L. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol1996; 78:409 -14.[CrossRef][Medline] [Order article via Infotrieve]
606. Grover SA, Coupal L, Paquet S, Zowall H. Cost-effectiveness of
3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary
prevention of cardiovascular disease: forecasting the incremental benefits of
preventing coronary and cerebrovascular events. Arch Intern
Med 1999;159:593
-600.
607. Tsevat J, Kuntz KM, Orav EJ, Weinstein MC, Sacks FM, Goldman L. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J2001; 141:727 -34.[CrossRef][Medline] [Order article via Infotrieve]
608. Pedersen TR, Kjekshus J, Berg K, Olsson AG, Wilhelmsen L, Wedel H,
Pyörälä K, Miettinen T, Haghfelt T, Faergeman O, Thorgeirsson
G, Jönsson B, Schwartz JS, for the Scandinavian Simvastatin Survival
Study Group. Cholesterol lowering and the uses of healthcare resources:
results of the Scandinavian Simvastatin Survival Study.
Circulation1996; 93:1796
-802.
609. Schwartz JS, Boccuzzi SJ, Murray JF, Roehm JB, Cook JR, Glick H, Kinosian B, Pedersen T, Kjekshus J, for the 4S Group. Cost-effectiveness of LDL-C reduction in Medicare managed care CHD patients; implications from the Scandinavian Simvastatin Survival Study (4S) [Abstract]. J Am Coll Cardiol 1997;226A .
610. Goldman L, Coxson P, Hunink MG, Goldman PA, Tosteson AN, Mittleman
M, Williams L, Weinstein MC. The relative influence of secondary versus
primary prevention using the National Cholesterol Education Program Adult
Treatment Panel II guidelines. J Am Coll Cardiol1999; 34:768
-76.
611. Muls E, Van Ganse E, Closon M-C. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model. Atherosclerosis1998; 137(suppl):S111 -S116.[CrossRef][Medline] [Order article via Infotrieve]
612. Glick H, Heyse JF, Thompson D, Epstein RS, Smith ME, Oster G. A model for evaluating the cost-effectiveness of cholesterol-lowering treatment. Int J Tech Assess Health Care1992; 8:719 -34.
613. Morris S. A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy. Health Econ1997; 6:589 -601.[CrossRef][Medline] [Order article via Infotrieve]
614. Shepherd J. Preventing coronary artery disease in the West of Scotland: implications for primary prevention. Am J Cardiol 1998;82:57T -9T.[Medline] [Order article via Infotrieve]
615. Hay JW, Yu WM, Ashraf T. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. Pharmacoeconomics1999; 15:47 -74.[CrossRef][Medline] [Order article via Infotrieve]
616. American Diabetes Association. Clinical practice recommendations 1998: screening for type 2 diabetes. Diabetes Care1998; 21(suppl 1):S1 -98.
617. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem1972; 18:499 -502.[Abstract]
618. National Cholesterol Education Program. Recommendations for improving cholesterol measurement. A Report from the Laboratory Standardization Panel of the National Cholesterol Education Program. NIH Pub. No. 93-2964. (Reprinted 1993). Bethesda, MD: National Heart, Lung, and Blood Institute, 1990; 65 pages.
619. National Cholesterol Education Program. Recommendations on lipoprotein measurement from the Working Group on Lipoprotein Measurement. NIH Pub. No. 95-3044. Bethesda, MD: National Heart, Lung, and Blood Institute, 1995; 186 pages.
620. U.S. Department of Health and Human Services. Healthy People 2010; Conference Edition. Volumes I and II. Washington DC: U.S. Department of Health and Human Services, January2000 . 1200 pages.
621. U.S. Department of Health and Human Services. Treating tobacco use and dependence: a systems approach. Clinical Practice Guideline. Public Health Service, U.S. Department of Health and Human Services, June 2000. 6 pages.
622. Grundy SM, Denke MA. Dietary influences on serum lipids and lipoproteins. J Lipid Res1990; 31:1149 -72.[Abstract]
623. Kris-Etherton PM, Yu S. Individual fatty acid effects on plasma lipids and lipoproteins: human studies. Am J Clin Nutr1997; 65(suppl 5):1628S -44S.[Medline] [Order article via Infotrieve]
624. Mensink RP, Katan MB. Effects of dietary fatty acids on serum
lipids and lipoproteins: a meta-analysis of 27 trials. Arterioscler
Thromb 1992;12:911
-9.
625. Ginsberg HN, Kris-Etherton P, Dennis B, Elmer PJ, Ershow A, Lefevre
M, Pearson T, Roheim P, Ramakrishnan R, Reed R, Stewart K, Stewart P, Phillips
K, Anderson N, for the Delta Research Group. Effects of reducing dietary
saturated fatty acids on plasma lipids and lipoproteins in healthy subjects:
the Delta Study, Protocol 1. Arterioscler Thromb Vasc
Biol 1998;18:441
-9.
626. Walden CE, Retzlaff BM, Buck BL, Wallick S, McCann BS, Knopp RH.
Differential effect of National Cholesterol Education Program (NCEP) Step II
diet on HDL cholesterol, its subfractions, and apoprotein A-I in
hypercholesterolemic women and men after 1 year: the beFIT study.
Arterioscler Thromb Vasc Biol2000; 20:1580
-7.
627. Walden CE, Retzlaff BM, Buck BL, McCann BS, Knopp RH. Lipoprotein
lipid response to the National Cholesterol Education Program Step II diet by
hypercholesterolemic and combined hyperlipidemic women and men.
Arterioscler Thromb Vasc Biol1997; 17:375
-82.
628. Obarzanek E, Hunsberger SA, Van Horn L, Hartmuller VV, Barton BA,
Stevens VJ, Kwiterovich PO, Franklin FA, Kimm SY, Lasser NL, Simons-Morton DG,
Lauer RM. Safety of a fat-reduced diet: the Dietary Intervention Study in
Children (DISC). Pediatrics1997; 100:51
-9.
629. Niinikoski H, Lapinleimu H, Viikari J, Rönnemaa T, Jokinen E,
Seppänen R, Terho P, Tuominen J, Välimäki I, Simell O. Growth
until three years of age in a prospective randomized trial of a diet with
reduced saturated fat and cholesterol. Pediatrics1997; 99:687
-94.
630. Stamler J, Briefel RR, Milas C, Grandits GA, Caggiula AW. Relation of changes in dietary lipids and weight, trial years 1-6, to change in blood lipids in the special intervention and usual care groups in the Multiple Risk Factor Intervention Trial. Am J Clin Nutr1997; 65(suppl):272S -88S.[Medline] [Order article via Infotrieve]
631. Caggiula AW, Christakis G, Farrand M, Hulley SB, Johnson R, Lasser NL, Stamler J, Widdowson G, for the MRFIT. The Multiple Risk Intervention Trial (MRFIT). IV. Intervention on blood lipids. Prev Med 1981;10:443 -75.[CrossRef][Medline] [Order article via Infotrieve]
632. Keys A, Menotti A, Karvonen MJ, Aravanis C, Blackburn H, Buzina R,
Djordjevic BS, Dontas AS, Fidanza F, Keys MH, Kromhout D, Nedeljkovic S,
Punsar S, Seccareccia F, Toshima H. The diet and 15-year death rate in the
Seven Countries Study. Am J Epidemiol1986; 124:903
-15.
633. Brousseau ME, Schaefer EJ. Diet and coronary heart disease: clinical trials. Curr Atheroscler Rep2000; 2:487 -93.[Medline] [Order article via Infotrieve]
634. Lichtenstein AH, Ausman LM, Jalbert SM, Schaefer EJ. Effects of
different forms of dietary hydrogenated fats on serum lipoprotein cholesterol
levels. N Engl J Med1999; 340:1933
-40.
635. Judd JT, Clevidence BA, Muesing RA, Wittes J, Sunkin ME, Podczasy
JJ. Dietary trans fatty acids: effects on plasma lipids and
lipoproteins of healthy men and women. Am J Clin Nutr1994; 59:861
-8.
636. Judd JT, Baer DJ, Clevidence BA, Muesing RA, Chen SC, Weststrate JA, Meijer GW, Wittes J, Lichtenstein AH, Montserrat V-B, Schaefer EJ. Effects of margarine compared with those of butter on blood lipid profiles related to cardiovascular disease risk factors in normolipemic adults fed controlled diets. Am J Clin Nutr1998; 68:768 -77.[Abstract]
637. Noakes M, Clifton PM. Oil blends containing partially hydrogenated or interesterified fats: differential effects on plasma lipids. Am J Clin Nutr 1998;68:242 -7.[Abstract]
638. Aro A, Jauhiainen M, Partanen R, Salminen I, Mutanen M. Stearic
acid, trans-fatty acids, and dairy fat: effects on serum and
lipoprotein lipids, apolipoproteins, lipoprotein(a), and lipid transfer
proteins in healthy subjects. Am J Clin Nutr1997; 65:1419
-26.
639. Almendingen K, Jordal O, Kierulf P, Sandstad B, Pedersen JI. Effects of partially hydrogenated fish oil, partially hydrogenated soybean oil, and butter on serum lipoproteins and Lp[a] in men. J Lipid Res 1995;36:1370 -84.[Abstract]
640. Wood R, Kubena K, O'Brien B, Tseng S, Martin G. Effect of butter, mono-and polyunsaturated fatty acid-enriched butter, trans fatty acid margarine, and zero trans fatty acid margarine on serum lipids and lipoproteins in healthy men. J Lipid Res1993; 34:1 -11.[Abstract]
641. Wood R, Kubena K, Tseng S, Martin G, Crook R. Effect of palm oil, margarine, butter, and sunflower oil on the serum lipids and lipoproteins of normocholesterolemic middle-aged men. J Nutr Biochem1993; 4:286 -97.[CrossRef]
642. Nestel PJ, Noakes M, Belling GB, McArthur R, Clifton PM, Abbey M.
Plasma cholesterol-lowering potential of edible-oil blends suitable for
commercial use. Am J Clin Nutr1992; 55:46
-50.
643. Zock PL, Katan MB. Hydrogenation alternatives: effects of trans fatty acids and stearic acid versus linoleic acid on serum lipids and lipoproteins in humans. J Lipid Res1992; 33:399 -410.[Abstract]
644. Katan MB, Zock PL, Mensink RP. Trans fatty acids and their effects on lipoproteins in humans. Ann Rev Nutr1995; 15:473 -93.[Medline] [Order article via Infotrieve]
645. Mensink RP, Katan MB. Effects of dietary trans fatty acids on high-density and low-density lipoprotein cholesterol levels in healthy subjects. N Engl J Med1990; 323:439 -45.[Abstract]
646. Lichtenstein AH, Ausman LM, Carrasco W, Jenner JL, Ordovas JM,
Schaefer EJ. Hydrogenation impairs the hypolipidemic effect of corn oil in
humans: hydrogenation, trans fatty acids, and plasma lipids.
Arterioscler Thromb1993; 13:154
-61.
647. Ascherio A, Katan MB, Zock PL, Stampfer MJ, Willett WC. Trans fatty
acids and coronary heart disease. N Engl J Med1999; 340:1994
-8.
648. Willett WC, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, Rosner BA, Sampson LA, Hennekens CH. Intake of trans fatty acids and risk of coronary heart disease among women. Lancet1993; 341:581 -5.[CrossRef][Medline] [Order article via Infotrieve]
649. Pietinen P, Ascherio A, Korhonen P, Hartman AM, Willett WC, Albanes
D, Virtamo J. Intake of fatty acids and risk of coronary heart disease in a
cohort of Finnish men: the Alpha-Tocopherol, Beta-Carotene Cancer Prevention
Study. Am J of Epidemiol1997; 145:876
-87.
650. Hu FB, Stampfer MJ, Manson JE, Ascherio A, Colditz GA, Speizer FE,
Hennekens CH, Willett WC. Dietary saturated fats and their food sources in
relation to the risk of coronary heart disease in women. Am J Clin
Nutr 1999;70:1001
-8.
651. Kromhout D, Menotti A, Bloemberg B, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F, Giampaoli S, Jansen A, Karvonen M, Katan M, Nissinen A, Nedeljkovic S, Pekkanen J, Pekkarinen M, Punsar S, Räsänen L, Simic B, Toshima H. Dietary saturated and trans fatty acids and cholesterol and 25-year mortality from coronary heart disease: the Seven Countries Study. Prev Med1995; 24:308 -15.[CrossRef][Medline] [Order article via Infotrieve]
652. Clarke R, Frost C, Collins R, Appleby P, Peto R. Dietary lipids and
blood cholesterol: quantitative meta-analysis of metabolic ward studies.
BMJ 1997;314:112
-7.
653. Hopkins PN. Effects of dietary cholesterol on serum cholesterol: a
meta-analysis and review. Am J Clin Nutr1992; 55:1060
-70.
654. Weggemans RM, Zock PL, Katan MB. Dietary cholesterol from eggs
increases the ratio of total cholesterol to high-density lipoprotein
cholesterol in humans: a meta-analysis. Am J Clin Nutr2001; 73:885
-91.
655. Howell WH, McNamara DJ, Tosca MA, Smith BT, Gaines JA. Plasma lipid
and lipoprotein responses to dietary fat and cholesterol: a meta-analysis.
Am J Clin Nutr1997; 65:1747
-64.
656. Grundy SM, Barrett-Connor E, Rudel LL, Miettinen T, Spector AA.
Workshop on the impact of dietary cholesterol on plasma lipoproteins and
atherogenesis. Arteriosclerosis1988; 8:95
-101.
657. National Research Council. Diet and health: implications for reducing chronic disease risk. Washington, D.C.: National Academy Press, 1989: 171-201.
658. Ernst ND, Sempos CT, Briefel RR, Clark MB. Consistency between U.S. dietary fat intake and serum total cholesterol concentrations: the National Health and Nutrition Examination Surveys. Am J Clin Nutr 1997;66(suppl):965S -72S.[Medline] [Order article via Infotrieve]
659. Tippett KS, Cleveland LE. How current diets stack up: comparison with dietary guidelines. In: America's eating habits: changes and consequences. Washington, D.C.: United States Department of Agriculture, Economic Research Service, 1999:51 -70.
660. Putnam J, Gerrior S. Trends in the U.S. food supply, 1970-97. In:America's eating habits: changes and consequences . Washington, D.C.: United States Department of Agriculture, Economic Research Service,1999 : 133-60.
661. Stamler J, Shekelle R. Dietary cholesterol and human coronary heart disease: the epidemiologic evidence. Arch Pathol Lab Med 1988;112:1032 -40.[Medline] [Order article via Infotrieve]
662. Hu FB, Stampfer MJ, Rimm EB, Manson JE, Ascherio A, Colditz GA,
Rosner BA, Hennekens CH, Spiegelman D, Speizer FE, Sacks FM, Willett WC. A
prospective study of egg consumption and risk of cardiovascular disease in men
and women. JAMA1999; 281:1387
-94.
663. Garg A. High-monounsaturated-fat diets for patients with diabetes mellitus: a meta-analysis. Am J Clin Nutr1998; 67(suppl):577S -82S.[Abstract]
664. Garg A, Grundy SM, Unger RH. Comparison of effects of high and low carbohydrate diets on plasma lipoproteins and insulin sensitivity in patients with mild NIDDM. Diabetes1992; 41:1278 -85.[Abstract]
665. Kris-Etherton PM, Pearson TA, Wan Y, Hargrove RL, Moriarty K,
Fishell V, Etherton TD. High-monounsaturated fatty acid diets lower both
plasma cholesterol and triacylglycerol concentrations. Am J Clin
Nutr 1999;70:1009
-15.
666. Rudel LL, Parks JS, Sawyer JK. Compared with dietary
monounsaturated and saturated fat, polyunsaturated fat protects African green
monkeys from coronary artery atherosclerosis. Arterioscler Thromb
Vasc Biol 1995;15:2101
-10.
667. Astrup A, Toubro S, Raben A, Skov AR. The role of low-fat diets and fat substitutes in body weight management: what have we learned from clinical studies? J Am Diet Assoc1997; 97(suppl 7):S82 -S87.[CrossRef][Medline] [Order article via Infotrieve]
668. Jeffery RW, Hellerstedt WL, French SA, Baxter JE. A randomized trial of counseling for fat restriction versus calorie restriction in the treatment of obesity. Int J Obes Relat Metab Disord1995; 19:132 -7.[Medline] [Order article via Infotrieve]
669. Nelson LH, Tucker LA. Diet composition related to body fat in a multivariate study of 203 men. J Am Dietetic Assoc1996; 96:771 -7.[CrossRef][Medline] [Order article via Infotrieve]
670. Prosperi C, Sparti A, Schutz Y, Di Vetta V, Milon H, Jéquier
E. Ad libitum intake of a high-carbohydrate or high-fat diet in young men:
effects on nutrient balances. Am J Clin Nutr1997; 66:539
-45.
671. Schutz Y. Macronutrients and energy balance in obesity. Metabolism1995; 44(suppl 13):7 -11.[CrossRef][Medline] [Order article via Infotrieve]
672. Astrup A. Obesity and metabolic efficiency. CIBA Found Symp 1996;201:159 -73.[Medline] [Order article via Infotrieve]
673. Leibel RL, Hirsch J, Appel BE, Checani GC. Energy intake required
to maintain body weight is not affected by wide variation in diet composition.
Am J Clin Nutr1992; 55:350
-5.
674. Hirsch J, Hudgins LC, Leibel RL, Rosenbaum M. Diet composition and energy balance in humans. Am J Clin Nutr1998; 67(suppl):551S -5S.[Abstract]
675. Lissner L, Heitmann BL. Dietary fat and obesity: evidence from epidemiology. Eur J Clin Nutr1995; 49:79 -90.[Medline] [Order article via Infotrieve]
676. Heitmann BL, Lissner L, Sorensen TI, Bengtsson C. Dietary fat
intake and weight gain in women genetically predisposed for obesity.
Am J Clin Nutr1995; 61:1213
-7.
677. Willett WC. Is dietary fat a major determinant of body fat? Am J Clin Nutr1998; 67 (suppl):556S -62S.[Abstract]
678. Seidell JC. Dietary fat and obesity: an epidemiologic perspective. Am J Clin Nutr1998; 67 (suppl):546S -50S.[Abstract]
679. Harrison RA, Waterbor JW. Understanding meta-analysis in cancer epidemiology: dietary fat and breast cancer. Cancer Detect Prev 1999;23:97 -106.[CrossRef][Medline] [Order article via Infotrieve]
680. Slattery ML, Berry TD, Potter J, Caan B. Diet diversity, diet composition, and risk of colon cancer (United States). Cancer Causes Control 1997;8:872 -82.[CrossRef][Medline] [Order article via Infotrieve]
681. Slattery ML, Potter JD, Duncan DM, Berry TD. Dietary fats and colon cancer: assessment of risk associated with specific fatty acids. Intl J Cancer1997; 73:670 -7.[CrossRef][Medline] [Order article via Infotrieve]
682. Greenwald P, Sherwood K, McDonald SS. Fat, caloric intake, and obesity: lifestyle risk factors for breast cancer. J Am Diet Assoc 1997;97(suppl):S24 -S30.[CrossRef][Medline] [Order article via Infotrieve]
683. Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clin Trials 1998;19:61 -109.[CrossRef][Medline] [Order article via Infotrieve]
684. Holmes MD, Hunter DJ, Colditz GA, Stampfer MJ, Hankinson SE,
Speizer FE, Rosner B, Willett WC. Association of dietary intake of fat and
fatty acids with risk of breast cancer. JAMA1999; 281:914
-20.
685. Kolonel LN, Nomura AM, Cooney RV. Dietary fat and prostate cancer:
current status. J Natl Cancer Inst1999; 91:414
-28.
686. Rose DP. Dietary fatty acids and cancer. Am J Clin Nutr 1997;66(suppl):998S -1003S.[Medline] [Order article via Infotrieve]
687. Giovannucci E, Goldin B. The role of fat, fatty acids, and total energy intake in the etiology of human colon cancer. Am J Clin Nutr 1997;66(suppl):1564S -71S.
688. Chen Y-D, Coulston AM, Zhou M-Y, Hollenbeck CB, Reaven GM. Why do low-fat high-carbohydrate diets accentuate postprandial lipemia in patients with NIDDM? Diabetes Care1995; 18:10 -6.[Abstract]
689. Knopp RH, Walden CE, Retzlaff BM, McCann BS, Dowdy AA, Albers JJ,
Gey GO, Cooper MN. Long-term cholesterol-lowering effects of 4 fat-restricted
diets in hypercholesterolemic and combined hyperlipidemic men: the Dietary
Alternatives Study. JAMA1997; 278:1509
-15.
690. Grundy SM. Comparison of monounsaturated fatty acids and carbohydrates for lowering plasma cholesterol. N Engl J Med 1986;314:745 -8.[Abstract]
691. Mensink RP, Katan MB. Effects of monounsaturated fatty acids versus complex carbohydrates on high-density lipoproteins in healthy men and women. Lancet 1987;1:122 -5.[Medline] [Order article via Infotrieve]
692. Katan MB, Grundy SM, Willett WC. Should a low-fat, high-carbohydrate diet be recommended for everyone? Beyond low-fat diets. N Engl J Med1997; 337:563 -7.[Medline] [Order article via Infotrieve]
693. Turley ML, Skeaff CM, Mann JI, Cox B. The effect of a low-fat, high-carbohydrate diet on serum high density lipoprotein cholesterol and triglyceride. Eur J Clin Nutr1998; 52:728 -32.[CrossRef][Medline] [Order article via Infotrieve]
694. West CE, Sullivan DR, Katan MB, Halferkamps IL, van der Torre HW.
Boys from populations with high-carbohydrate intake have higher fasting
triglyceride levels than boys from populations with high-fat intake.
Am J Epidemiol1990; 131:271
-82.
695. Knuiman JT, West CE, Katan MB, Hautvast JG. Total cholesterol and
high density lipoprotein cholesterol levels in populations differing in fat
and carboyhydrate intake. Arteriosclerosis1987; 7:612
-9.
696. Vuksan V, Sievenpiper JL, Owen R, Swilley JA, Spadafora P, Jenkins DJA, Vidgen E, Brighenti F, Josse RG, Leiter LA, Xu Z, Novokmet R. Beneficial effects of viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled metabolic trial. Diabetes Care2000; 23:9 -14.[Abstract]
697. Jenkins DJA, Wolever TMS, Rao AV, Hegele RA, Mitchell SJ, Ransom
TPP, Boctor DL, Spadafora PJ, Jenkins AL, Mehling C, Relle LK, Connelly PW,
Story JA, Furumoto EJ, Cory P, Würsch P. Effect on blood lipids of very
high intakes of fiber in diets low in saturated fat and cholesterol.
N Engl J Med1993; 329:21
-6.
698. Levin RJ. Carbohydrates. Shils ME, Olson JA, Shike M, Ross AC, eds. In: Modern nutrition in health and disease, 9th edition. Baltimore: Williams and Wilkins, 1999:49 -65.
699. Anderson JW. Dietary fibre, complex carbohydrate and coronary artery disease. Can J Cardiol1995; 11(suppl G):55G -62G.[Medline] [Order article via Infotrieve]
700. Anderson JW, Hanna TJ. Impact of nondigestible carbohydrates on serum lipoproteins and risk for cardiovascular disease. J Nutr 1999;129:1457S -66S.[Medline] [Order article via Infotrieve]
701. U.S. Department of Health and Human Services. Food and Drug Administration. Food labeling: health claims; soluble fiber from certain foods and coronary heart disease: final rule. Federal Register 1998;63:8103 -21.
702. U.S. Department of Health and Human Services. Food and Drug Administration. Food labeling: health claims; soluble fiber from certain foods and coronary heart disease: proposed rule. Federal Register 1997;62:28234 -45.
703. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering
effects of dietary fiber: a meta-analysis. Am J Clin
Nutr 1999;69:30
-42.
704. U.S. Department of Health and Human Services. Food and Drug Administration. Food labeling: health claims; oats and coronary heart disease: final rule. Federal Register1997; 62:3583 -601.
705. U.S. Department of Health and Human Services. Food and Drug Administration. Food labeling: health claims; oats and coronary heart disease: proposed rule. Federal Register1996; 61:296 -337.
706. Westrate JA, Meijer GW. Plant sterol-enriched margarines and reduction of plasma total- and LDL-cholesterol concentrations in normocholesterolaemic and mildly hypercholesterolaemic subjects. Eur J Clin Nutr1998; 52:334 -43.[CrossRef][Medline] [Order article via Infotrieve]
707. Hallikainen MA, Uusitupa MI. Effects of 2 low-fat stanol
ester-containing margarines on serum cholesterol concentrations as part of a
low-fat diet in hypercholesterolemic subjects. Am J Clin
Nutr 1999;69:403
-10.
708. Gylling H, Miettinen TA. Cholesterol reduction by different plant stanol mixtures and with variable fat intake. Metabolism1999; 48:575 -80.[CrossRef][Medline] [Order article via Infotrieve]
709. Gylling H, Radhakrishnan R, Miettinen TA. Reduction of serum
cholesterol in postmenopausal women with previous myocardial infarction and
cholesterol malabsorption induced by dietary sitostanol ester margarine: women
and dietary sitostanol. Circulation1997; 96:4226
-31.
710. Hendriks HFJ, Weststrate JA, van Vliet T, Meijer GW. Spreads enriched with three different levels of vegetable oil sterols and the degree of cholesterol lowering in normocholesterolaemic and mildly hypercholesterolaemic subjects. Eur J Clin Nutr1999; 53:319 -27.[CrossRef][Medline] [Order article via Infotrieve]
711. Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E.
Reduction of serum cholesterol with sitostanol-ester margarine in a mildly
hypercholesterolemic population. N Engl J Med1995; 333:1308
-12.
712. Vanhanen HT, Blomqvist S, Ehnholm C, Hyvönen M, Jauhiainen M, Torstila I, Miettinen TA. Serum cholesterol, cholesterol precursors, and plant sterols in hypercholesterolemic subjects with different apoE phenotypes during dietary sitostanol ester treatment. J Lipid Res1993; 34:1535 -44.[Abstract]
713. Vuorio AF, Gylling H, Turtola H, Kontula K, Ketonen P, Miettinen
TA. Stanol ester margarine alone and with simvastatin lowers serum cholesterol
in families with familial hypercholesterolemia caused by the FH-North Karelia
mutation. Arterio Thromb Vasc Biol2000; 20:500
-6.
714. Gylling H, Miettinen TA. Serum cholesterol and cholesterol and lipoprotein metabolism in hypercholesterolaemic NIDDM patients before and during sitostanol ester-margarine treatment. Diabetol1994; 37:773 -80.[CrossRef]
715. Gylling H, Siimes MA, Miettinen TA. Sitostanol ester margarine in dietary treatment of children with familial hypercholesterolemia. J Lipid Res 1995;36:1807 -12.[Abstract]
716. Law MR. Plant sterol and stanol margarines and health. West J Med2000; 173:43 -7.[CrossRef][Medline] [Order article via Infotrieve]
717. U.S. Department of Health and Human Services. Food and Drug Administration. Food labeling: health claims; soy protein and coronary heart disease: proposed rule. Federal Register1998; 63:62977 -3015.
718. U.S. Department of Health and Human Services. Food and Drug Administration. Food labeling: health claims; soy protein and coronary heart disease: final rule. Federal Register1999; 64:57699 -733.
719. Jenkins DJ, Kendall CW, Vidgen E, Mehling CC, Parker T, Seyler H, Faulkner D, Garsetti M, Griffin LC, Agarwal S, Rao AV, Cunnane SC, Ryan MA, Connelly PW, Leiter LA, Vuksan V, Josse R. The effect on serum lipids and oxidized low-density lipoprotein of supplementing self-selected low-fat diets with soluble fiber, soy, and vegetable protein foods. Metabolism2000; 49:67 -72.[CrossRef][Medline] [Order article via Infotrieve]
720. Crouse JR III, Morgan T, Terry JG, Ellis J, Vitolins M, Burke GL. A
randomized trial comparing the effect of casein with that of soy protein
containing varying amounts of isoflavones on plasma concentrations of lipids
and lipoproteins. Arch Intern Med1999; 159:2070
-6.
721. Albert CM, Hennekens CH, O'Donnell CJ, Ajani UA, Carey VJ, Willett
WC, Ruskin JN, Manson JE. Fish consumption and risk of sudden cardiac death.
JAMA 1998;279:23
-8.
722. Daviglus ML, Stamler J, Orencia AJ, Dyer AR, Liu K, Greenland P,
Walsh MK, Morris D, Shekelle RB. Fish consumption and the 30-year risk of
fatal myocardial infarction. N Engl J Med1997; 336:1046
-53.
723. Dolecek TA, Grandits G. Dietary polyunsaturated fatty acids and mortality in the Multiple Risk Factor Intervention Trial (MRFIT). World Rev Nutr Diet1991; 66:205 -16.[Medline] [Order article via Infotrieve]
724. Ascherio A, Rimm EB, Stampfer MJ, Giovannucci EL, Willett WC.
Dietary intake of marine n-3 fatty acids, fish intake, and risk of coronary
disease among men. N Eng J Med1995; 332:977
-82.
725. Morris MC, Manson JE, Rosner B, Buring JE, Willett WC, Hennekens
CH. Fish consumption and cardiovascular disease in the Physicians' Health
Study: a prospective study. Am J Epidemiol1995; 142:166
-75.
726. Siscovick DS, Raghunathan TE, King I, Weinmann S, Wicklund KG,
Albright J, Bovbjerg V, Arbogast P, Smith H, Kushi LH, Cobb LA, Copass MK,
Psaty BM, Lemaitre R, Retzlaff B, Childs M, Knopp RH. Dietary intake and cell
membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of
primary cardiac arrest. JAMA1995; 274:1363
-7.
727. Roche HM, Gibney MJ. Effects of long-chain n-3 polyunsaturated
fatty acids on fasting and postprandial triacylglycerol metabolism.
Am J Clin Nutr2000; 71(suppl):232S
-7S.
728. Harris WS. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res1989; 30:785 -807.[Abstract]
729. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr1997; 65(suppl 5):1645S -54S.
730. Rissanen T, Voutilainen S, Nyyssönen K, Lakka TA, Salonen JR.
Fish oil-derived fatty acids, docosahexaenoic acid and docosapentaenoic acid,
and the risk of acute coronary events; the Kuopio Ischaemic Heart Disease Risk
Factor Study. Circulation2000; 102:2677
-9.
731. National Research Council. Toxicological effects of methylmercury. Washington, D.C.: National Academy Press,1999 .
732. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM. Effects of changes in fat, fish and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet 1989;2:757 -61.[Medline] [Order article via Infotrieve]
733. de Lorgeril M, Salen P, Martin J-L, Monjaud I, Delaye J, Mamelle N.
Mediterranean diet, traditional risk factors, and the rate of cardiovascular
complications after myocardial infarction: final report of the Lyon Diet Heart
Study. Circulation1999; 99:779
-85.
734. Singh RB, Niaz MA, Sharma JP, Kumar R, Rastogi V, Moshiri M. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian Experiment of Infarct survival-4. Cardiovasc Drugs Ther1997; 11:485 -91.[CrossRef][Medline] [Order article via Infotrieve]
735. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione Trial. Lancet1999; 354:447 -55.[CrossRef][Medline] [Order article via Infotrieve]
736. Sacks FM, Stone PH, Gibson CM, Silverman DI, Rosner B, Pasternak RC, for the HARP Research Group. Controlled trial of fish oil for regression of human coronary atherosclerosis. J Am Coll Cardiol1995; 25:1492 -8.[Abstract]
737. von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H. The effect
of dietary 
-3 fatty acids on coronary atherosclerosis: a randomized,
double-blind, placebo-controlled trial. Ann Intern Med1999; 130:554
-62.
738. Leaf A, Jorgensen MB, Jacobs AK, Cote G, Schoenfeld DA, Scheer J,
Weiner BH, Slack JD, Kellet MA, Raizner AE, Weber PC, Mahrer PR, Rossouw JE.
Do fish oils prevent restenosis after coronary angioplasty?
Circulation1994; 90:2248
-57.
739. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset
SE. Plasma homocysteine levels and mortality in patients with coronary artery
disease. N Engl J Med1997; 337:230
-6.
740. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE,
Ueland PM, Palma-Reis RJ, Boers GHJ, Sheahan RG, Israelsson B, Uiterwaal CS,
Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC,
deValk HW, Sales Lúis AC, Parrot-Roulaud FM, Tan KS, Higgins I, Garcon
D, Medrano MJ, Candito M, Evans AE, Andria G. Plasma homocysteine as a risk
factor for vascular disease. The European Concerted Action Project.
JAMA 1997;277:1775
-81.
741. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet1995; 346:1395 -8.[CrossRef][Medline] [Order article via Infotrieve]
742. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE.
Serum total homocysteine and coronary heart disease. Int J
Epidemiol 1995;24:704
-9.
743. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann
D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and
risk of myocardial infarction in US physicians. JAMA1992; 268:877
-81.
744. Verhoef P, Kok FJ, Kruyssen DA, Schouten EG, Witteman JCM, Grobbee
DE, Ueland PM, Refsum H. Plasma total homocysteine, B vitamins, and risk of
coronary atherosclerosis. Arterioscler Thromb Vasc
Biol 1997;17:989
-95.
745. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH, for the MRFIT
Research Group. Homocyst(e)ine and risk of cardiovascular disease in the
Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc
Biol 1997;17:1947
-53.
746. Alfthan G, Pekkanen J, Jauhiainen M, Pitkäniemi J, Karvonen M, Tuomilehto J, Salonen JT, Ehnholm C. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis1994; 106:9 -19.[CrossRef][Medline] [Order article via Infotrieve]
747. National Research Council. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. Washington, D.C: National Academy Press,2000 . 567 pages.
748. National Research Council. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. Washington, D.C.: National Academy Press, 2000. 509 pages.
749. Blot WJ, Li J-Y, Taylor PR, Guo W, Dawsey S, Wang G-Q, Yang CS,
Zheng SF, Gail M, Li G-Y, Yu Y, Liu B, Tangrea J, Sun Y, Liu F, Fraumeni JF
Jr, Zhang Y-H, Li B. Nutrition intervention trials in Linxian, China:
supplementation with specific vitamin/mineral combinations, cancer incidence,
and disease-specific mortality in the general population. J Natl
Cancer Inst 1993;85:1483
-92.
750. Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The
effect of vitamin E and beta carotene on the incidence of lung cancer and
other cancers in male smokers. N Engl J Med1994; 330:1029
-35.
751. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR,
Belanger C, LaMotte F, Gaziano JM, Ridker PM, Willett W, Peto R. Lack of
effect of long-term supplementation with beta carotene on the incidence of
malignant neoplasms and cardiovascular disease. N Engl J
Med 1996;334:1145
-9.
752. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A,
Keogh JP, Meyskens FL Jr, Valanis B, Williams JH Jr, Barnhart S, Hammar S.
Effects of a combination of beta carotene and vitamin A on lung cancer and
cardiovascular disease. N Engl J Med1996; 334:1150
-5.
753. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781 -6.[CrossRef][Medline] [Order article via Infotrieve]
754. Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E
supplementation and cardiovascular events in high-risk patients. N
Engl J Med 2000;342:154
-60.
755. Criqui MH. Alcohol and coronary heart disease: consistent relationship and public health implications. Clinica Chimica Acta 1996;246:51 -7.[CrossRef][Medline] [Order article via Infotrieve]
756. Dufour MC. If you drink alcoholic beverages do so in moderation:
what does this mean? J Nutr2001; 131(suppl):552S
-61S.
757. Criqui MH. Alcohol and hypertension: new insights from population studies. Eur Heart J1987; (suppl B):19 -26.
758. Thun MJ, Peto R, Lopez AD, Monaco JH, Henley SJ, Heath CW, Doll R.
Alcohol consumption and mortality among middle-aged and elderly U.S. adults.
N Engl J Med1997; 337:1705
-14.
759. Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate
alcohol intake and lower risk of coronary heart disease: meta-analysis of
effects on lipids and haemostatic factors. BMJ1999; 319:1523
-8.
760. Rimm EB, Klatsky A, Grobbee D, Stampfer MJ. Review of moderate
alcohol consumption and reduced risk of coronary heart disease: is the effect
due to beer, wine or spirits? BMJ1996; 312:731
-6.
761. Fortson MR, Freedman SN, Webster PD III. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol1995; 90:2134 -9.[Medline] [Order article via Infotrieve]
762. Smith-Warner SA, Spiegelman D, Yaun S-S, van den Brandt PA, Folsom
AR, Goldbohm A, Graham S, Holmberg L, Howe GR, Marshall JR, Miller AB, Potter
JD, Speizer FE, Willett WC, Wolk A, Hunter DJ. Alcohol and breast cancer in
women: a pooled analysis of cohort studies. JAMA1998; 279:535
-40.
763. Criqui MH. Alcohol in the myocardial infarction patient. Lancet 1998;352:1873 .[CrossRef][Medline] [Order article via Infotrieve]
764. Chobanian AV, Hill M. National Heart, Lung, and Blood Institute
Workshop on Sodium and Blood Pressure: a critical review of current scientific
evidence. Hypertension2000; 35:858
-63.
765. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM,
Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin P-H, Karanja N. A clinical
trial of the effects of dietary patterns on blood pressure. N Engl
J Med 1997;336:1117
-24.
766. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D,
Obarzanek E, Conlin PR, Miller ER III, Simons-Morton DG, Karanja N, Lin P-H,
for the DASH-Sodium Collaborative Research Group. Effects on blood pressure of
reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH)
diet. N Engl J Med2001; 344:3
-10.
767. Borchers AT, Keen CL, Stern JS, Gershwin ME. Inflammation and
Native American medicine: the role of botanicals. Am J Clin
Nutr 2000;72:339
-47.
768. Jenkins DJ, Kendall CW, Axelsen M, Augustin LS, Vuksan V. Viscous and nonviscous fibres, nonabsorbable and low glycaemic index carbohydrates, blood lipids and coronary heart disease. Curr Opin Lipidol 2000;11:49 -56.[CrossRef][Medline] [Order article via Infotrieve]
769. Hunninghake DB, Stein EA, Dujovne CA, Harris WS, Feldman EB, Miller
VT, Tobert JA, Laskarzewski PM, Quiter E, Held J, Taylor AM, Hopper S, Leonard
SB, Brewer BK. The efficacy of intensive dietary therapy alone or combined
with lovastatin in outpatients with hypercholesterolemia. N Engl J
Med 1993;328:1213
-9.
770. Blair SN, Capuzzi DM, Gottlieb SO, Nguyen T, Morgan JM, Cater NB. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol2000; 86:46 -52.[Medline] [Order article via Infotrieve]
771. Pate RR, Pratt M, Blair SN, Haskell WL, Macera CA, Bouchard C,
Buchner D, Ettinger W, Heath GW, King AC, Kriska A, Leon AS, Marcus BH, Morris
J, Paffenbarger RS Jr, Patrick K, Pollock ML, Rippe JM, Sallis J, Wilmore JH.
Physical activity and public health: a recommendation from the Centers for
Disease Control and Prevention and the American College of Sports Medicine.
JAMA 1995;273:402
-7.
772. Denke MA. Review of human studies evaluating individual dietary responsiveness in patients with hypercholesterolemia. Am J Clin Nutr 1995;62:471S -7S.[Medline] [Order article via Infotrieve]
773. Denke MA, Grundy SM. Individual responses to a cholesterol-lowering
diet in 50 men with moderate hypercholestrolemia. Arch Intern
Med 1994;154:317
-25.
774. Denke MA. Individual responsiveness to a cholesterol-lowering diet
in postmenopausal women with moderate hypercholesterolemia. Arch
Intern Med 1994;154:1977
-82.
775. Current Procedural Terminology: CPT 2001. Chicago, Illinois: American Medical Association, 2000.300 pages.
776. Connor SL, Gustafson JR, Sexton G, Becker N, Artaud-Wild S, Connor WE. The Diet Habit Survey: a new method of dietary assessment that relates to plasma cholesterol changes. J Am Diet Assoc1992; 92:41 -7.[Medline] [Order article via Infotrieve]
777. Gans KM, Sundaram SG, McPhillips JB, Hixson ML, Linnan L, Carleton RA. Rate your plate: an eating pattern assessment and educational tool used at cholesterol screening and education programs. J Nutr Educ 1993;25:29 -36.
778. Kris-Etherton P, Eissenstat B, Jaax S, Srinath U, Scott L, Rader J, Pearson T. Validation for MEDFICTS, a dietary assessment instrument for evaluating adherence to total and saturated fat recommendations of the National Cholesterol Education Program Step 1 and Step 2 diets. J Am Diet Assoc 2001;101:81 -6.[CrossRef][Medline] [Order article via Infotrieve]
779. Kristal AR, Abrams BF, Thornquist MD, Disogra L, Croyle RT,
Shattuck AL, Henry HJ. Development and validation of a food use checklist for
evaluation of community nutrition interventions. Am J Public
Health 1990;80:1318
-22.
780. Retzlaff BM, Dowdy AA, Walden CE, Bovbjerg VE, Knopp RH. The
Northwest Lipid Research Clinic Fat Intake Sale: validation and utility.
Am J Public Health1997; 87:181
-5.
781. Peters JR, Quiter ES, Brekke ML, Admire J, Brekke MJ, Mullis RM, Hunninghake DB. The Eating Pattern Assessment Tool: a simple instrument for assessing dietary fat and cholesterol intake. J Am Diet Assoc 1994;94:1008 -13.[CrossRef][Medline] [Order article via Infotrieve]
782. Ammerman AS, Haines PS, DeVellis RF, Strogatz DS, Keyserling TC, Simpson RJ Jr, Siscovick DS. A brief dietary assessment to guide cholesterol reduction in low-income individuals: design and validation. J Am Diet Assoc 1991;91:1385 -90.[Medline] [Order article via Infotrieve]
783. U.S. Department of Agriculture and U.S. Department of Health and Human Services. Nutritive value of foods. Home and Garden Bulletin no.72. Washington, D.C.: U.S. Department of Agriculture,1981; 399 pages.
784. Lin B-H, Frazão E. Away-from-home foods increasingly important to quality of American diet. Agriculture Information Bulletin no. 749. Washington, D.C.: U.S. Department of Agriculture,1999; 22 pages.
785. Pearson TA, Stone EJ, Grundy SM, McBride PE, Van Horn L, Tobin BW.
Translation of nutritional sciences into medical education: the Nutrition
Academic Award Program. Am J Clin Nutr2001; 74:164
-70.
786. Van Horn L, Kavey R-E. Diet and cardiovascular disease prevention: what works? Ann Behav Med1997; 19:197 -212.[Medline] [Order article via Infotrieve]
787. Shepherd R, Stockley L. Nutrition knowledge, attitudes, and fat consumption. J Am Diet Assoc1987; 87:615 -9.[Medline] [Order article via Infotrieve]
788. Prochaska JO, Velicer WF, Rossi JS, Goldstein MG, Marcus BH, Rakowski W, Fiore C, Harlow LL, Redding CA, Rosenbloom D, Rossi SR. Stages of change and decisional balance for 12 problem behaviors. Health Psychol 1994;13:39 -46.[CrossRef][Medline] [Order article via Infotrieve]
789. Glanz K, Patterson RE, Kristal AR, DiClemente CC, Heimendinger J, Linnan L, McLerran DF. Stages of change in adopting healthy diets: fat, fiber, and correlates of nutrient intake. Health Educ Q1994; 21:499 -519.[Medline] [Order article via Infotrieve]
790. Baranowski T, Smith M, Baranowski J, Wang DT, Doyle C, Lin LS, Hearn MD, Resnicow K. Low validity of a seven-item fruit and vegetable food frequency questionnaire among third-grade students. J Am Diet Assoc 1997;97:66 -8.[CrossRef][Medline] [Order article via Infotrieve]
791. Bandura A. Self-efficacy: the exercise of control. New York: W.H. Freeman and Company, 1997.500 pages.
792. Perri MG. The maintenance of treatment effects in the long-term management of obesity. Clin Psychol Sci Prac1998; 5:526 -43.
793. Ryder RE, Hayes TM, Mulligan IP, Kingswood JC, Williams S, Owens
DR. How soon after myocardial infarction should plasma lipid values be
assessed? BMJ1984; 289:1651
-3.
794. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-Coenzyme A
reductase inhibitor, improves endothelial function within 1 month.
Circulation1997; 95:1126
-31.
795. Stroes ES, Koomans HA, de Bruin TWA, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet1995; 346:467 -71.[CrossRef][Medline] [Order article via Infotrieve]
796. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single
LDL apheresis improves endothelium-dependent vasodilation in
hypercholesterolemic humans. Circulation1997; 95:76
-82.
797. Arntz H, Agrawal R, Wunderlich W, Schnitzer L, Stern R, Fischer F, Schultheiss H. Beneficial effects of pravastatin (±colestyramine/niacin) initiated immediately after a coronary event (the Randomized Lipid-Coronary Artery Disease [L-CAD] Study). Am J Cardiol 2000;86:1293 -8.[CrossRef][Medline] [Order article via Infotrieve]
798. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res1992; 33:1569 -82.[Medline] [Order article via Infotrieve]
799. Tobert JA, Bell GD, Birtwell J, James I, Kukovetz WR, Pryor JS, Buntinx A, Holmes IB, Chao Y-S, Bolognese JA. Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, in healthy volunteers. J Clin Invest1982; 69:913 -9.[Medline] [Order article via Infotrieve]
800. Mabuchi H, Sakai T, Sakai Y, Yoshimura A, Watanabe A, Wakasugi T, Koizumi J, Takeda R. Reduction of serum cholesterol in heterozygeous patients with familial hypercholesterolemia: additive effects of compactin and cholestyramine. N Engl J Med1983; 308:609 -13.[Abstract]
801. Davignon J, Montigny M, Dufour R. HMG-CoA reductase inhibitors: a look back and a look ahead. Can J Cardiol1992; 8:843 -64.[Medline] [Order article via Infotrieve]
802. Mabuchi H, Haba T, Tatami R, Miyamoto S, Sakai Y, Wakasugi T, Watanabe A, Koizumi J, Takeda R. Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. N Engl J Med1981; 305:478 -82.[Abstract]
803. Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and
colestipol stimulate receptor-mediated clearance of low density lipoprotein
from plasma in familial hypercholesterolemia heterozygotes. Proc
Natl Acad Sci USA 1983;80:4124
-8.
804. Broyles FE, Walden CE, Hunninghake DB, Hill-Williams D, Knopp RH. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia. Am J Cardiol 1995;76:129A -35A.[CrossRef][Medline] [Order article via Infotrieve]
805. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn
JW, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM.
Efficacy and safety of new HMG-CoA reductase inhibitor, atorvastatin, in
patients with hypertriglyceridemia. JAMA1996; 275:128
-33.
806. Arad Y, Ramakrishnan R, Ginsberg HN. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism1992; 41:487 -93.[CrossRef][Medline] [Order article via Infotrieve]
807. Arad Y, Ramakrishnan R, Ginsberg HN. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. J Lipid Res1990; 31:567 -82.[Abstract]
808. Twisk J, Gillian-Daniel DL, Tebon A, Wang L, Barrett PHR, Attie AD. The role of the LDL receptor in apolipoprotein B secreation. J Clin Invest 2000;105:521 -32.[Medline] [Order article via Infotrieve]
809. Postiglione A, Montefusco S, Pauciullo P, Mancini M, Piliego T. Effects of atorvastatin in patients with homozygous familial hypercholesterolemia [Letter]. Atherosclerosis1999; 147:423 -4.[CrossRef][Medline] [Order article via Infotrieve]
810. Raal FJ, Pappu AS, Illingworth DR, Pilcher GJ, Marais AD, Firth JC, Kotze MJ, Heinonen TM, Black DM. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis2000; 150:421 -8.[CrossRef][Medline] [Order article via Infotrieve]
811. Marais AD, Naoumova RP, Firth JC, Penny C, Neuwirth CK, Thompson GR. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous famililial hypercholesterolemia. J Lipid Res 1997;38:2071 -8.[Abstract]
812. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol1998; 81:66B -9B.[CrossRef][Medline] [Order article via Infotrieve]
813. Jones P, Kafonek S, Laurora I, Hunninghake D, for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (The CURVES Study). Am J Cardiol1998; 81:582 -7.[CrossRef][Medline] [Order article via Infotrieve]
814. Shepherd J. Fibrates and statins in the treatment of
hyperlipidaemia: an appraisal of their efficacy and safety. Eur
Heart J 1995;16:5
-13.
815. Stein E. Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety. Am J Cardiol1998; 82:40J -6J.[CrossRef][Medline] [Order article via Infotrieve]
816. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin
FA, Gould AL, Hesney M, Higgins J, Hurley DP, Langendorfer A, Nash DT, Pool
JL, Schnaper H. Expanded Clinical Evaluation of Lovastatin (EXCEL) study
results. I. Efficacy in modifying plasma lipoproteins and adverse event
profile in 8245 patients with moderate hypercholesterolemia. Arch
Intern Med 1991;151:43
-9.
817. Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother1995; 29:743 -59.[Abstract]
818. Bradford RH, Shear CL, Chremos AN, Dujovne CA, Franklin FA, Grillo RB, Higgins J, Langendorfer A, Nash DT, Pool JL, Schnaper H. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol1994; 74:667 -73.[CrossRef][Medline] [Order article via Infotrieve]
819. Cressman MD, Hoogwerf BJ, Moodie DS, Olin JW, Weinstein CE. HMG-CoA reductase inhibitors: a new approach to the management of hypercholesterolemia. Cleve Clin J Med1988; 55:93 -100.[Medline] [Order article via Infotrieve]
820. Hunninghake DB. Drug treatment of dyslipoproteinemia. Endocrinol Metab Clin North Am1990; 19:345 -60.[Medline] [Order article via Infotrieve]
821. Insull W Jr, Isaacsohn J, Kwiterovich P, Ma P, Brazg R, Dujovne C, Shan M, Shugrue-Crowley E, Ripa S, Tota R, for the Cerivastatin Study Group. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group. J Int Med Res2000; 28:47 -68.[Medline] [Order article via Infotrieve]
822. Davidson MH, Stein EA, Hunninghake DB, Ose L, Dujovne CA, Insull W Jr, Bertolami M, Weiss SR, Kastelein JJP, Scott RS, Campodonico S, Escobar ID, Schrott HG, Bays H, Stepanavage ME, Wu M, Tate AC, Melino MR, Kush D, Mercuri M, Mitchel YB for the Worldwide Expanded Dose Simvastatin Study Group. Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. Nutr Metab Cardiovasc Dis 2000;10:253 -62.[Medline] [Order article via Infotrieve]
823. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis
associated with lovastatin-gemfibrozil combination therapy.
JAMA 1990;264:71
-5.
824. Goldman JA, Fishman AB, Lee JE, Johnson RJ. The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis [Letter]. Arthritis Rheum1989; 32:358 -9.[Medline] [Order article via Infotrieve]
825. Hanston PD, Horn JR. Drug interactions with HMG CoA reductase inhibitors. Drug Interactions Newsletter1998; 103-6.
826. Wanner C, Krämer-Guth A, Galle J. Use of HMG-CoA reductase inhibitors after kidney and heart transplantation: lipid-lowering and immunosuppressive effects. BioDrugs1997; 8:387 -93.[Medline] [Order article via Infotrieve]
827. Gruer PJK, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol1999; 84:811 -5.[CrossRef][Medline] [Order article via Infotrieve]
828. Davidson MH. Does differing metabolism by cytochrome P450 have clinical importance? Curr Atheroscler Reports2000; 1:14 -9.
829. Hunninghake DB, Stein EA, Bremner WF, Greenland P, Demke DM, Oliphant TH. Dose-response study of colestipol tablets in patients with moderate hypercholesterolemia. Am J Therapeut1995; 2:180 -9.[Medline] [Order article via Infotrieve]
830. Superko HR, Greenland P, Manchester RA, Andreadis NA, Schectman G, West NH, Hunninghake D, Haskell WL, Probstfield JL. Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia. Am J Cardiol1992; 70:135 -40.[Medline] [Order article via Infotrieve]
831. Davidson MH, Dillon MA, Gordon B, Jones P, Samuels J, Weiss S,
Isaacsohn J, Toth P, Burke SK. Colesevelam hydrochloride (cholestagel): a new,
potent bile acid sequestrant associated with a low incidence of
gastrointestinal side effects. Arch Intern Med1999; 159:1893
-900.
832. Insull W Jr, Marquis NR, Tsianco MC. Comparison of the efficacy of Questran Light, a new formulation of cholestyramine powder, to regular Questran in maintaining lowered plasma cholesterol levels. Am J Cardiol 1991;67:501 -5.[CrossRef][Medline] [Order article via Infotrieve]
833. Pravastatin Multicenter Study Group II. Comparative efficacy and
safety of pravastatin and cholestyramine alone and combined in persons with
hypercholesterolemia. Arch Intern Med1993; 153:1321
-9.
834. Heinonen TM, Schrott H, McKenney JM, Sniderman AD, Broyles FE, Zavoral JH, Kivel F, Black DM. Atorvastatin, a new HMG-CoA reductase inhibitor as monotherapy and combined with colestipol. J Cardiovasc Pharamacol Therapeut 1996;1:117 -22.
835. Lovastatin Study Group. A multicenter comparison of lovastatin and
cholestyramine therapy for severe primary hypercholesterolemia.
JAMA 1988;260:359
-66.
836. Rudling MJ, Reihner E, Einarsson K, Ewerth S, Angelin B. Low
density lipoprotein receptor-binding activity in human tissues: quantitative
importance of hepatic receptors and evidence for regulation of their
expression in vivo. Proc Natl Acad USA1990; 87:3469
-73.
837. Beil U, Crouse JR, Einarsson K, Grundy SM. Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density lipoprotein triglycerides. Metabolism1982; 31:438 -44.[CrossRef][Medline] [Order article via Infotrieve]
838. Knopp RH. Drug treatment of lipid disorders. N Engl J
Med 1999;341:498
-511.
839. Knapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano JM, Donovan JM, Burke SK, Davidson MH. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001;110:352 -60.[CrossRef][Medline] [Order article via Infotrieve]
840. Davidson MH, Toth P, Weiss S, McKenney J, Hunninghake D, Isaacsohn J, Donovan JM, Burke SK. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol 2001;24:467 -74.[Medline] [Order article via Infotrieve]
841. Denke MA, Grundy SM. Efficacy of low-dose cholesterol-lowering drug
therapy in men with moderate hypercholesterolemia. Arch Intern
Med 1995;155:393
-9.
842. Gylling H, Miettinen TA. Lipid lowering during concomitant cholesterol synthesis inhibition and cholesterol and bile acid malabsorption in coronary patients [Abstract]. Circulation1999; 100:I -825.
843. Gylling H. Studies of plant stanol esters in different patient populations. European Heart Journal1999; 1(suppl S):S109 -S113.[CrossRef]
844. Crouse JR III. Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am J Med1987; 83:243 -8.[CrossRef][Medline] [Order article via Infotrieve]
845. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in
non-insulin-dependent diabetes mellitus: a short-term, double-blind, crossover
trial. Ann Intern Med1994; 121:416
-22.
846. Knopp RH, Ginsberg J, Albers JJ, Hoff C, Ogilvie JT, Warnick GR, Burrows E, Retzlaff B, Poole M. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism1985; 34:642 -50.[CrossRef][Medline] [Order article via Infotrieve]
847. Guyton JR, Goldberg AC, Kreisberg RA, Sprecker DL, Superko HR, O'Connor CM. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998;82:737 -43.[CrossRef][Medline] [Order article via Infotrieve]
848. Drood JM, Zimetbaum PJ, Frishman WH. Nicotinic acid for the treatment of hyperlipoproteinemia. J Clin Pharmacol1991; 31:641 -50.[Abstract]
849. Luria MH. Effects of low-dose niacin on high density lipoprotein
cholesterol and total cholesterol/high density lipoprotein cholesterol ratio.
Arch Intern Med1988; 148:2493
-5.
850. Grundy SM, Mok HYI, Zech L, Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 1981;22:24 -36.[Abstract]
851. Langer T, Levi RI. The effect of nicotinic acid on the turnover of low density lipoproteins in type II hyperlipoproteinemia. In: Gey KF, Carlson RA, eds. Metabolic effects of nicotinic acid and its derivatives. Bern, Germany: Hans Huber Publishers, 1971:641 -7.
852. Superko HR, Krauss RM. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis1992; 95:69 -76.[CrossRef][Medline] [Order article via Infotrieve]
853. Knopp RH, Alagona P, Davidson M, Goldberg AC, Kafonek SD, Kashyap M, Sprecher D, Superko HR, Jenkins S, Marcovina S. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism1998; 47:1097 -104.[CrossRef][Medline] [Order article via Infotrieve]
854. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of
the efficacy and toxic effects of sustained- vs immediate-release niacin in
hypercholesterolemic patients. JAMA1994; 271:672
-7.
855. Illingworth DR, Stein EA, Mitchel YB, Dujovne CA, Frost PH, Knopp
RH, Tun P, Zupkis RV, Greguski RA. Comparative effects of lovastatin and
niacin in primary hypercholesterolemia: a prospective trial. Arch
Intern Med 1994;154:1586
-95.
856. Capuzzi DM, Guyton JR, Morgan JM, Goldberg AC, Kreisberg RA, Brusco OA, Brody J. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol1998; 82:74U -81U;discussion 85U-86U.[CrossRef][Medline] [Order article via Infotrieve]
857. Guyton JR, Capuzzi DM. Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol1998; 82:82U -4U.[CrossRef][Medline] [Order article via Infotrieve]
858. Tatò F, Vega GL, Grundy SM. Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase. Am J Cardiol 1998;81:805 -7.[CrossRef][Medline] [Order article via Infotrieve]
859. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in
non-insulin-dependent diabetes mellitus. JAMA1990; 264:723
-6.
860. Grundy SM, Vega GL, McGovern ME. Effects of extended-release niacin on lipoproteins and glycemic control in patients with type 2 diabetes mellitus: results of a randomized, double-blind, placebo-controlled multicenter trial [Abstract]. JACC2001; 37(suppl A):249A .
861. Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D,
Kostis JB, Sheps DS, Brinton EA, for the ADMIT Investigators. Effect of niacin
on lipid and lipoprotein levels and glycemic control in patients with diabetes
and peripheral arterial disease: the ADMIT study: a randomized trial.
JAMA 2000;284:1263
-70.
862. Etchason JA, Miller TD, Squires RW, Allison TG, Gau GT, Marttila JK, Kottke BA. Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. Mayo Clinic Proc1991; 66:23 -8.[Medline] [Order article via Infotrieve]
863. Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med1992; 92:77 -81.[CrossRef][Medline] [Order article via Infotrieve]
864. Mullin GE, Greenson JK, Mitchell MC. Fulminant hepatic failure
after ingestion of sustained-release nicotinic acid. Ann Intern
Med 1989;111:253
-5.
865. Gibbons LW, Gonzalez V, Gordon N, Grundy S. The prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med 1995;99:378 -85.[CrossRef][Medline] [Order article via Infotrieve]
866. Pauciullo P, Marotta G, Rubba P, Cortese C, Caruso MG, Gnasso A, Fischetti A, Motti C, Mancini M. Serum lipoproteins, apolipoproteins and very low density lipoprotein subfractions during 6-month-fibrate treatment in primary hypertriglyceridaemia. J Intern Med1990; 228:425 -30.[Medline] [Order article via Infotrieve]
867. Leaf DA, Connor WE, Illingworth DR, Bacon SP, Sexton G. The
hypolipidemic effects of gemfibrozil in type V hyperlipidemia: a double-blind,
crossover study. JAMA1989; 262:3154
-60.
868. Gavish D, Oschry Y, Fainaru M, Eisenberg S. Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIB hyperlipoproteinemia. Eur J Clin Invest 1986;16:61 -8.[Medline] [Order article via Infotrieve]
869. Illingworth DR, Olsen GD, Cook SF, Sexton GJ, Wendel HA, Connor WE. Ciprofibrate in the therapy of type II hypercholesterolemia: a double-blind trial. Atherosclerosis1982; 44:211 -21.[CrossRef][Medline] [Order article via Infotrieve]
870. Kornitzer M, Dramaix M, Vandenbroek MD, Everaert L, Gerlinger C. Efficacy and tolerance of 200 mg micronised fenofibrate administered over a 6-month period in hyperlipidaemic patients: an open Belgian multicenter study. Atherosclerosis1994; 110(suppl):S49 -S54.[CrossRef][Medline] [Order article via Infotrieve]
871. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res1996; 37:907 -25.[Abstract]
872. Fruchart JC, Brewer HB Jr, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol1998; 81:912 -7.[CrossRef][Medline] [Order article via Infotrieve]
873. Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart J-C, Staels B, Auwerx J. Fibrates increase human apolipoprotein A-11 expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest1995; 96:741 -50.[Medline] [Order article via Infotrieve]
874. Eisenberg S, Gavish D, Oschry Y, Fainaru M, Deckelbaum RJ. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia: reversal toward normal with bezafibrate treatment. J Clin Invest1984; 74:470 -82.[Medline] [Order article via Infotrieve]
875. Neve BP, Fruchart J-C, Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol 2000;60:1245 -50.[CrossRef][Medline] [Order article via Infotrieve]
876. Pineda Torra I, Gervois P, Staels B. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr Opin Lipidol1999; 10:151 -9.[CrossRef][Medline] [Order article via Infotrieve]
877. Mahley RW, Rall SC Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds.The metabolic and molecular bases of inherited disease, 7th edition . New York: McGraw-Hill, 1995:1953 -80.
878. Palmer RH. Effects of fibric acid derivatives on biliary lipid composition. Am J Med1987; 83(suppl 5B):37 -43.
879. Coronary Drug Project Research Group. Gallbladder disease as a side effect of drugs influencing lipid metabolism: experience in the Coronary Drug Project. N Engl J Med1977; 296:1185 -90.[Abstract]
880. Duell PB, Connor WE, Illingworth DR. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol1998; 81:368 -9.[CrossRef][Medline] [Order article via Infotrieve]
881. Report of the Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet 1984;2:600 -4.[CrossRef][Medline] [Order article via Infotrieve]
882. Report of the Committee of Principal Investigators. W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Lancet 1980;2:379 -85.[Medline] [Order article via Infotrieve]
883. Rodes J, Cote G, Lespérance J, Bourassa MG, Doucet MG, Doucet S, Bilodeau L, Bertrand OF, Harel F, Gallo R, Tardif J-C. Prevention of restenosis after angioplasty in small coronary arteries with probucol. Circulation1998; 97:429-36 .
884. Tardif J-C, Coté G, Lespérance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, de Guise P, for the Multivitamins and Probucol Study Group. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med1997; 337:365-72 .
885. Rosenberg L, Hennekens CH, Rosner B, Belanger C, Rothman KJ, Speizer FE. Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol1981; 139:47-51 .
886. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med1987; 316:1105-10 .
887. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham Study. Ann Intern Med 1976;85:447-52 .
888. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med2000; 343:522-9 .
889. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, for the Heart and Estrogen/progestin Replacement Study Research Group. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000;132:689-96 .
890. Jensen J, Nilas L, Christiansen C. Cyclic changes in serum cholesterol and lipoproteins following different doses of combined postmenopausal hormone replacement therapy. Br J Obstet Gynaecol 1986;93:613-8 .
891. Granfone A, Campos H, McNamara JR, Schaefer MM, Lamon-Fava S, Ordovas JM, Schaefer EJ. Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in postmenopausal, dyslipidemic women. Metabolism1992; 41:1193-8 .
892. Cauley JA, LaPorte RE, Kuller LH, Bates M, Sandler RB. Menopausal estrogen use, high density lipoprotein cholesterol subfractions and liver function. Atherosclerosis1983; 49:31-9 .[CrossRef][Medline] [Order article via Infotrieve]
893. Steinberg KK, Smith SJ, Thacker SB, Stroup DF. Breast cancer risk and duration of estrogen use: the role of study design in meta-analysis. Epidemiology1994; 5:415-21 .
894. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998;19:55-72 .[Medline] [Order article via Infotrieve]
895. Torgerson DJ. HRT and its impact on the menopause, osteoporosis and breast cancer. Exp Opin Pharmacother2000; 1:1163-9 .
896. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet1997; 350:1047-59 .
897. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993;168:1473-80 .
898. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA1998; 279:1445-51 .
899. Goldberg A, Alagona P Jr, Capuzzi DM, Guyton J, Morgan JM, Rodger J, Sachson R, Samuel P. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol2000; 85:1100-5 .
900. Morgan JM, Capuzzi DM, Guyton JR, Centor RM, Goldberg R, Robbins DC, DiPette D, Jenkins S, Marcovina S. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther1996; 1:195-202 .
901. Kiortisis DN, Millionis H, Bairaktari E, Elisaf MS. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia. Eur J Clin Pharmacol2000; 56:631-5 .
902. Ellen RL, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 1998;81:60B-5B .
903. Leren TP, Hjermann I, Berg K, Leren P, Foss OP, Viksmoen L. Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia. Atherosclerosis1988; 73:135-41 .
904. Sprecher DL, Abrams J, Allen JW, Keane WF, Chrysant SG, Ginsberg H, Fischer JJ, Johnson BF, Theroux P, Jokubaitis L. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med 1994;120:537-43 .
905. Pan HY, DeVault AR, Swites BJ, Whigan D, Ivashkiv E, Willard DA, Brescia D. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther 1990;48:201-7 .
906. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Didangelos TP, Carina MV, Kranitsas DF, Kontopoulos AG. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol1997; 80:608-13 .
907. Yeshurun D, Abukarshin R, Elias N, Lanir A, Naschitz JE. Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination. Clin Ther1993; 15:355-63 .
908. East C, Bilheimer DW, Grundy SM. Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med1988; 109:25-32 .
909. Boccuzzi SJ, Bocanegra TS, Walker JF, Shapiro DR, Keegan ME. Long-term safety and efficacy profile of simvastatin. Am J Cardiol 1991;68:1127-31 .
910. Rosenson RS, Frauenheim WA. Safety of combined pravastatin-gemfibrozil therapy. Am J Cardiol1994; 74:499-500 .
911. Murdock DK, Murdock AK, Murdock RW, Olsen KJ, Frane AM, Kersten ME, Joyce DM, Gantner SE. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment for mixed lipid disorders. Am Heart J1999; 138:151-5 .
912. Iliadis EA, Rosenson RS. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. Clin Cardiol 1999;22:25-8 .
913. Zambón D, Ros E, Rodriguez-Villar C, Laguna JC, Vázquez M, Sanllehy C, Casals E, Sol JM, Hernández G. Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation. Metabolism1999; 48:47-54 .
914. Napoli C, Lepore S, Chiariello P, Condorelli M, Chiariello M. Long-term treatment with pravastatin alone and in combination with gemfibrozil in familial type IIB hyperlipoproteinemia or combined hyperlipidemia. J Cardiovasc Pharmacol Ther1997; 2:17-26 .
915. Farnier M, Dejager S, and the French Fluvastatin Group. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. Am J Cardiol2000; 85:53-7 .
916. Davignon J, Roederer G, Montigny M, Hayden MR, Tan M-H, Connelly PW, Hegele R, McPherson R, Lupien PJ, Gagné C. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol1994; 73:339-45 .
917. Goldstein JL, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic basis of inherited disease. New York: McGraw-Hill, 1995:1981-2030 .
918. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992;1:445-66 .
919. Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet1990; 24:133-70 .[Medline] [Order article via Infotrieve]
920. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA1990; 264:3007-12 .
921. Malloy MJ, Kane JP, Kunitake ST. Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia. Ann Intern Med1987; 107:616-23 .
922. Bilheimer DW, Goldstein JL, Grundy SM, Brown MS. Reduction in cholesterol and low density lipoprotein synthesis after portacaval shunt surgery in a patient with homozygous familial hypercholesterolemia. J Clin Invest1975; 56:1420-30 .
923. Bilheimer DW. Portacaval shunt and liver transplantation in treatment of familial hypercholesterolemia. Arteriosclerosis1989; 9(suppl 1):I158 -I163.[Medline] [Order article via Infotrieve]
924. Starzl TE, Putnam CW, Koep LJ. Portacaval shunt and hyperlipidemia. Arch Surg1978; 113:71-4 .
925. King ME, Breslow JL, Lees RS. Plasma-exchange therapy of homozygous familial hypercholesterolemia. N Engl J Med1980; 302:1457-9 .
926. Eisenhauer T, Armstrong VW, Wieland H, Fuchs C, Nebendahl K, Scheler F, Seidel D. Selective continuous elimination of low density lipoproteins (LDL) by heparin precipitation: first clinical application. ASAIO Trans1986; 32:104-7 .
927. Homma Y, Mikami Y, Tamachi H, Nakaya N, Nakamura H, Araki G, Goto Y. Comparison of selectivity of LDL removal by double filtration and dextransulfate cellulose column plasmapheresis. Atherosclerosis1986; 60:23-7 .[CrossRef][Medline] [Order article via Infotrieve]
928. Mabuchi H, Michishita I, Sakai T, Sakai Y, Watanabe A, Wakasugi T, Takeda R. Treatment of homozygous patients with familial hypercholesterolemia by double-filtration plasmapheresis. Atherosclerosis1986; 61:135 -40.[CrossRef][Medline] [Order article via Infotrieve]
929. Thompson GR, Myant NB. Regression of atherosclerosis [Letter]. Atherosclerosis1980; 35:347 -8.[CrossRef][Medline] [Order article via Infotrieve]
930. Soria LF, Ludwig EH, Clarke HRG, Vega GL, Grundy SM, McCarthy BJ.
Association between a specific apolipoprotein B mutation and familial
defective apolipoprotein B-100. Proc Natl Acad Sci USA1989; 86:587
-91.
931. Innerarity TL, Weisgraber KH, Arnold KS, Mahley RW, Krauss RM, Vega
GL, Grundy SM. Familial defective apolipoprotein B-100: low density
lipoproteins with abnormal receptor binding. Proc Natl Acad Sci
USA 1987;84:6919
-23.
932. Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, Krauss RM, Vega GL, Grundy SM, Friedl W, Davignon J, McCarthy BJ. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res1990; 31:1337 -49.[Abstract]
933. Vega GL, Grundy SM. In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. J Clin Invest1986; 78:1410 -4.[Medline] [Order article via Infotrieve]
934. Raal FJ, Pilcher G, Rubinsztein DC, Lingenhel A, Utermann G. Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects. Atherosclerosis1997; 129:97 -102.[CrossRef][Medline] [Order article via Infotrieve]
935. Vega GL, Denke MA, Grundy SM. Metabolic basis of primary
hypercholesterolemia. Circulation1991; 84:118
-28.
936. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins - an integrated approach to mechanisms and disorders (continued). N Engl J Med 1967;276:94 -103.[Medline] [Order article via Infotrieve]
937. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins - an integrated approach to mechanisms and disorders (continued). N Engl J Med 1967;276:148 -56.[Medline] [Order article via Infotrieve]
938. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins - an integrated approach to mechanisms and disorders (continued). N Engl J Med 1967;276:215 -25.[Medline] [Order article via Infotrieve]
939. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins - an integrated approach to mechanisms and disorders (concluded). N Engl J Med 1967;276:273 -81.[Medline] [Order article via Infotrieve]
940. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins - an integrated approach to mechanisms and disorders. N Engl J Med 1967;276:34 -44.[Medline] [Order article via Infotrieve]
941. Boomsma DI, Kempen HJM, Gevers Leuven JA, Havekes L, de Knijff P, Frants RR. Genetic analysis of sex and generation differences in plasma lipid, lipoprotein, and apolipoprotein levels in adolescent twins and their parents. Genet Epidemiol1996; 13:49 -60.[CrossRef][Medline] [Order article via Infotrieve]
942. Heller DA, de Faire U, Pedersen NL, Dahlén G, McClearn GE.
Genetic and environmental influences on serum lipid levels in twins.
N Engl J Med1993; 328:1150
-6.
943. Humphries SE, Peacock R, Dunning A, Lane A, Green F, Hamsten A. Identification of genetic variation that determines levels of plasma triglycerides and hypercoagulability. Clin Genet1994; 46(1 Spec No):19 -31.[Medline] [Order article via Infotrieve]
944. Galton DJ. Common genetic determinants of dyslipidemia: the hypertriglyceridemia/low-high-density lipoprotein syndrome. J Cardiovasc Pharmacol1995; 25(suppl 4):S35 -S40.
945. Assmann G, Brewer HB Jr. Genetic (primary) forms of hypertriglyceridemia. Am J Cardiol1991; 68:13A -6A.[CrossRef][Medline] [Order article via Infotrieve]
946. Hazzard WR, Goldstein JL, Schrott HG, Motulsky AG, Bierman EL. Hyperlipidemia in coronary heart disease. III. Evaluation of lipoprotein phenotypes of 156 genetically defined survivors of myocardial infarction. J Clin Invest1973; 52:1569 -77.[Medline] [Order article via Infotrieve]
947. Goldstein JL, Hazzard WR, Schrott HG, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. J Clin Invest1973; 52:1533 -43.[Medline] [Order article via Infotrieve]
948. Beil U, Grundy SM, Crouse JR, Zech L. Triglyceride and cholesterol
metabolism in primary hypertriglyceridemia.
Arteriosclerosis1982; 2:44
-57.
949. Venkatesan S, Cullen P, Pacy P, Halliday D, Scott J. Stable
isotopes show a direct relation between VLDL apoB overproduction and serum
triglyceride levels and indicate a metabolically and biochemically coherent
basis for familial combined hyperlipidemia. Arterioscler
Thromb 1993;13:1110
-8.
950. Chait A, Albers JJ, Brunzell JD. Very low density lipoprotein overproduction in genetic forms of hypertriglyceridaemia. Eur J Clin Invest 1980;10:17 -22.[Medline] [Order article via Infotrieve]
951. Kwiterovich PO Jr, White S, Forte T, Bachorik PS, Smith H,
Sniderman A. Hyperapobetalipoproteinemia in a kindred with familial combined
hyperlipidemia and familial hypercholesterolemia.
Arteriosclerosis1987; 7:211
-25.
952. Austin MA, Horowitz H, Wijsman E, Krauss RM, Brunzell J. Bimodality of plasma apolipoprotein B levels in familial combined hyperlipidemia. Atherosclerosis1992; 92:67 -77.[CrossRef][Medline] [Order article via Infotrieve]
953. Teng B, Sniderman AD, Soutar AK, Thompson GR. Metabolic basis of hyperapobetalipoproteinemia: turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholeresterolemia. J Clin Invest1986; 77:663 -72.[CrossRef][Medline] [Order article via Infotrieve]
954. Brunzell JD, Schrott HG, Motulsky AG, Bierman EL. Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism1976; 25:313 -20.[CrossRef][Medline] [Order article via Infotrieve]
955. Austin MA, McKnight B, Edwards KL, Bradley CM, McNeely MJ, Psaty
BM, Brunzell JD, Motulsky AG. Cardiovascular disease mortality in familial
forms of hypertriglyceridemia: a 20-year prospective study.
Circulation2000; 101:2777
-82.
956. Dunn FL, Grundy SM, Bilheimer DW, Havel RJ, Raskin P. Impaired catabolism of very low-density lipoprotein-triglyceride in a family with primary hypertriglyceridemia. Metab1985; 34:316 -24.[CrossRef][Medline] [Order article via Infotrieve]
957. Wilson DE, Emi M, Iverius P-H, Hata A, Wu LL, Hillas E, Williams RR, Lalouel J-M. Phenotypic expression of heterozygous lipoprotein lipase deficiency in the extended pedigree of a proband homozygous for a missense mutation. J Clin Invest1990; 86:735 -50.[Medline] [Order article via Infotrieve]
958. Minnich A, Kessling A, Roy M, Giry C, DeLangavant G, Lavigne J, Lussier-Cacan S, Davignon J. Prevalence of alleles encoding defective lipoprotein lipase in hypertriglyceridemic patients of French Canadian descent. J Lipid Res1995; 36:117 -24.[Abstract]
959. Kesaniemi YA, Grundy SM. Dual defect in metabolism of
very-low-density lipoprotein triglycerides: patients with type 5
hyperlipoproteinemia. JAMA1984; 251:2542
-7.
960. Santamarina-Fojo S. The familial chylomicronemia syndrome. Endocrinol Metab Clin North Am1998; 27:551 -67.[CrossRef][Medline] [Order article via Infotrieve]
961. Ebara T, Ramakrishnan R, Steiner G, Shachter NS. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice: apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J Clin Invest1997; 99:2672 -81.[Medline] [Order article via Infotrieve]
962. Batal R, Tremblay M, Barrett PHR, Jacques H, Fredenrich A, Mamer O,
Davignon J, Cohn JS. Plasma kinetics of apoC-III and apoE in normolipidemic
and hypertriglyceridemic subjects. J Lipid Res2000; 41:706
-18.
963. Aalto-Setala K, Weinstock PH, Bisagaier CL, Wu L, Smith JD, Breslow JL. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice. J Lipid Res 1996;37:1802 -11.[Abstract]
964. Li WW, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T. Common genetic variation in the promoter of the human apoCIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 1995;96:2601 -5.[Medline] [Order article via Infotrieve]
965. Greenberg BH, Blackwelder WC, Levy RI. Primary type V
hyperlipoproteinemia: a descriptive study in 32 families. Ann
Intern Med 1977;87:526
-34.
966. Steiner G, Adelman AG, Silver MD. Early coronary atherosclerosis in primary type V hyperlipoproteinemia. Can Med Assoc J1971; 105:1172 -4.[Medline] [Order article via Infotrieve]
967. Chait A, Brunzell JD. Chylomicronemia syndrome. Adv Intern Med 1992;37:249 -73.[Medline] [Order article via Infotrieve]
968. Vega GL, Grundy SM. Primary hypertriglyceridemia with borderline
high cholesterol and elevated apolipoprotein B concentrations: comparison of
gemfibrozil vs lovastatin therapy. JAMA1990; 264:2759
-63.
969. Connor WE. Fish oil in hypertriglyceridemia: safety and recommendations. Lipids1999; 34 (suppl):S271 .[CrossRef][Medline] [Order article via Infotrieve]
970. Harris WS, Rothrock DW, Fanning A, Inkeles SB, Goodnight SH Jr,
Illingworth DR, Connor WF. Fish oils in hypertriglyceridemia: a dose-response
study. Am J Clin Nutr1990; 51:399
-406.
971. Guyton JR. Treatment of type III hyperlipoproteinemia. Am Heart J1999; 138:17 -8.[CrossRef][Medline] [Order article via Infotrieve]
972. Hoogwerf BJ, Bantle JP, Kuba K, Frantz ID Jr, Hunninghake DB. Treatment of type III hyperlipoproteinemia with four different treatment regimens. Atherosclerosis1984; 51:251 -9.[CrossRef][Medline] [Order article via Infotrieve]
973. East CA, Grundy SM, Bilheimer DW. Preliminary report: treatment of type 3 hyperlipoproteinemia with mevinolin. Metabolism1986; 35:97 -8.[CrossRef][Medline] [Order article via Infotrieve]
974. Garg A, Grundy SM. Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM. Diabetes 1989;38:364 -72.[Abstract]
975. Goldberg AC, Schonfeld G, Feldman EB, Ginsberg HN, Hunninghake DB, Insull W, Knopp RH, Kwiterovich PO, Mellies MJ, Pickering J, Samuel P. Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter U.S. study. Clin Ther 1989;11:69 -83.[Medline] [Order article via Infotrieve]
976. Albrink MJ, Krauss RM, Lindgren FT, von der Groeben J, Pan S, Woo PD. Intercorrelations among plasma high density lipoprotein, obesity and triglycerides in a normal population. Lipids1980; 15:668 -76.[CrossRef][Medline] [Order article via Infotrieve]
977. Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ III, Jones PH, West MS, Gould KL, Gotto AM Jr, for the LCAS Investigators. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol1997; 80:278 -86.[CrossRef][Medline] [Order article via Infotrieve]
978. Sosenko JM, Kato M, Soto R, Goldberg RB. Plasma lipid levels at diagnosis in type 2 diabetic patients. Diabet Med1993; 10:814 -9.[Medline] [Order article via Infotrieve]
979. Barrett-Connor E, Philippi T, Khaw KT. Lipoproteins as predictors of ischemic heart disease in non-insulin-dependent diabetic men. Am J Prev Med 1987;3:206 -10.[Medline] [Order article via Infotrieve]
980. Strandberg TE, Tilvis RS, Lindberg O, Valvanne J, Sairanen S, Ehnholm C, Tuomilehto J. High plasma insulin is associated with lower LDL cholesterol in elderly individuals. Atherosclerosis1996; 121:267 -73.[CrossRef][Medline] [Order article via Infotrieve]
981. Haffner SM, Mykkänen L, Stern MP, Paidi M, Howard BV. Greater effect of diabetes on LDL size in women than in men. Diabetes Care 1994;17:1164 -71.[Abstract]
982. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care2001; 24(suppl 1):S58 -S61.
983. Kahn SE, Beard JC, Schwartz MW, Ward WK, Ding HL, Bergman RN, Taborsky GJ Jr., Porte D Jr. Increased ß-cell secretory capacity as mechanism for islet adaption to nicotinic acid-induced insulin resistance. Diabetes 1989;38:562 -8.[Abstract]
984. Kelly JJ, Lawson JA, Campbell LV, Storlien LH, Jenkins AB, Whitworth JA, O'Sullivan AJ. Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects. J Hum Hypertens 2000;14:567 -72.[CrossRef][Medline] [Order article via Infotrieve]
985. Berlyne GM, Mallick NP. Ischaemic heart-disease as a complication of nephrotic syndrome. Lancet1969; 2:399 -400.[Medline] [Order article via Infotrieve]
986. Mallick NP, Short CD. The nephrotic syndrome and ischaemic heart disease. Nephron1981; 27:54 -7.[Medline] [Order article via Infotrieve]
987. Alexander JH, Schapel GJ, Edwards KD. Increased incidence of coronary heart disease associated with combined elevation of serum triglyceride and cholesterol concentrations in the nephrotic syndrome in man. Med J Aust 1974;2:119 -22.[Medline] [Order article via Infotrieve]
988. Grundy SM. Management of hyperlipidemia of kidney disease [Editorial Review]. Kidney Int1990; 37:847 -53.[Medline] [Order article via Infotrieve]
989. Rabelink AJ, Erkelens DW, Hene RJ, Joles JA, Koomans HA. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. Lancet1988; 2:1335 -8.[Medline] [Order article via Infotrieve]
990. Matzkies FK, Bahner U, Teschner M, Hohage H, Heidland A, Schaefer RM. Efficiency of 1-year treatment with fluvastatin in hyperlipidemic patients with nephrotic syndrome. Am J Nephrol1999; 19:492 -4.[CrossRef][Medline] [Order article via Infotrieve]
991. Toto RD, Grundy SM, Vega GL. Pravastatin treatment of very low density, intermediate density and low density lipoproteins in hypercholesterolemia and combined hyperlipidemia secondary to the nephrotic syndrome. Am J Nephrol2000; 20:12 -7.[CrossRef][Medline] [Order article via Infotrieve]
992. Attman P-O, Alaupovic P, Gustafson A. Serum apolipoprotein profile of patients with chronic renal failure. Kidney Int1987; 32:368 -75.[Medline] [Order article via Infotrieve]
993. Rader DJ, Rosas S. Management of selected lipid abnormalities: hypertriglyceridemia, low HDL cholesterol, lipoprotein(a), in thyroid and renal diseases, and post-transplantation. Med Clin North Am 2000;84:43 -61.[CrossRef][Medline] [Order article via Infotrieve]
994. Bagdade JD, Porte D, Bierman EL. Hypertriglyceridemia: a metabolic consequence of chronic renal failure. N Engl J Med1968; 279:181 -5.[Medline] [Order article via Infotrieve]
995. Gokal R, Mann JI, Moore RA, Morris PJ. Hyperlipidaemia following renal transplantation: a study of the prevalence, natural history, and dietary treatment. Q J Med1979; 48:507 -17.[Medline] [Order article via Infotrieve]
996. Casaretto A, Marchioro TL, Goldsmith R, Bagdade JD. Hyperlipidaemia after successful renal transplantation. Lancet1974; 1:481 -4.[CrossRef][Medline] [Order article via Infotrieve]
997. Penzak SR, Chuck SK. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. Scand J Infect Dis2000; 32:111 -23.[CrossRef][Medline] [Order article via Infotrieve]
998. Graham NM. Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review. J Acquir Immune Defic Syndr 2000;25(suppl 1):S4 -S11.[CrossRef][Medline] [Order article via Infotrieve]
999. Hruz PW, Murata H, Mueckler M. Adverse metabolic consequences of
HIV protease inhibitor therapy: the search for a central mechanism.
Am J Physiol Endocrinol Metab2001; 280:E549
-E553.
1000. Garg A. Lipodystrophies. Am J Med2000; 108:143 -52.[CrossRef][Medline] [Order article via Infotrieve]
1001. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J1986; 111:383 -90.[CrossRef][Medline] [Order article via Infotrieve]
1002. MacMahon SW, Cutler JA, Furberg CD, Payne GH. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Prog Cardiovasc Dis 1986;29(suppl 1):99 -118.[CrossRef][Medline] [Order article via Infotrieve]
1003. Obarzanek E, Sacks FM, Vollmer WM, Bray GA, Miller ER III, Lin P-H,
Karanja NM, Most-Windhauser MM, Moore TJ, Swain JF, Bales CW, Proschan MA, on
behalf of the DASH Research Group. Effects on blood lipids of a blood
pressure-lowering diet: the Dietary Approaches to Stop Hypertension (DASH)
trial. Am J Clin Nutr2001; 74:80
-9.
1004. Reisin E, Frohlich ED, Messerli FH, Dreslinski GR, Dunn FG, Jones
MM, Batson HM. Cardiovascular changes after weight reduction in obesity
hypertension. Ann Intern Med1983; 98:315
-9.
1005. Eckel RH. Obesity and heart disease: a statement for healthcare
professionals from the Nutrition Committee, American Heart Association.
Circulation1997; 96:3248
-50.
1006. Lardinois CK, Neuman SL. The effects of antihypertensive agents on
serum lipids and lipoproteins. Arch Intern Med1988; 148:1280
-8.
1007. Weinberger MH. Antihypertensive therapy and lipids: evidence,
mechanisms, and implications. Arch Intern Med1985; 145:1102
-5.
1008. Glueck CJ, Gordon DJ, Nelson JJ, Davis CE, Tyroler HA. Dietary and
other correlates of changes in total and low density lipoprotein cholesterol
in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary
Prevention trial. Am J Clin Nutr1986; 44:489
-500.
1009. Freis ED. The efficacy and safety of diuretics in treating
hypertension. Ann Intern Med1995; 122:223
-6.
1010. Ames RP. A comparison of the blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. Am J Cardiol1996; 77:12b -6b.[CrossRef][Medline] [Order article via Infotrieve]
1011. ALLHAT Officers and Coodinators for the ALLHAT Collaborative
Research Group. Major cardiovascular events in hypertensive patients
randomized to doxazosin vs chlorthalidone: the Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
JAMA 2000;283:1967
-75.
1012. Savage PJ, Pressel SL, Curb JD, Schron EB, Applegate WB, Black HR,
Cohen J, Davis BR, Frost P, Smith W, Gonzalez N, Guthrie GP, Oberman A, Rutan
G, Probstfield JL, Stamler J, for the SHEP Cooperative Research Group.
Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on
glucose, lipid, uric acid, and potassium levels in older men and women with
isolated systolic hypertension: the Systolic Hypertension in the Elderly
Program. Arch Intern Med1998; 158:741
-51.
1013. Stirling CM, Isles CG. Rhabdomyolysis due to simvastatin in a
transplant patient: are some statins safer than others? Nephrol
Dial Transplant 2001;16:873
-4.
1014. Al Shohaib S. Simvastatin-induced rhabdomyolysis in a patient with chronic renal failure. Am J Nephrol2000; 20:212 -3.[CrossRef][Medline] [Order article via Infotrieve]
1015. Weise WJ, Possidente CJ. Fatal rhabdomyolysis associated with simvastatin in a renal transplant patient [Letter]. Am J Med 2000;108:351 -2.[CrossRef][Medline] [Order article via Infotrieve]
1016. Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B,
Moskowitz MA. Inadequate management of blood pressure in a hypertensive
population. N Engl J Med1998; 339:1957
-63.
1017. Denke MA, Grundy SM. Hypercholesterolemia in elderly persons:
resolving the treatment dilemma. Ann Intern Med1990; 112:780
-92.
1018. Korhonen T, Savolainen MJ, Koistinen MJ, Ikäheimo M, Linnaluoto MK, Kervinen K, Kesäniemi YA. Association of lipoprotein cholesterol and triglycerides with the severity of coronary heart disease in men and women. Atherosclerosis1996; 127:213 -20.[CrossRef][Medline] [Order article via Infotrieve]
1019. LaRosa JC. Triglycerides and coronary risk in women and the
elderly. Arch Intern Med1997; 157:961
-8.
1020. Austin MA. Plasma triglyceride as a risk factor for cardiovascular disease. Can J Cardiol1998; 14(suppl B):14B -7B.[Medline] [Order article via Infotrieve]
1021. Sprecher DL, Pearce GL, Cosgrove DM, Lytle BW, Loop FD, Pashkow FJ. Relation of serum triglyceride levels to survival after coronary artery bypass grafting. Am J Cardiol2000; 86:285 -8.[CrossRef][Medline] [Order article via Infotrieve]
1022. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C,
Judd HL, Sakkinen PA, Tracy RP. Effect of postmenopausal hormones on
inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin
Interventions (PEPI) Study. Circulation1999; 100:717
-22.
1023. Scarabin P-Y, Alhenc-Gelas M, Plu-Bureau, Taisne P, Agher R, Aiach
M. Effects of oral and transdermal estrogen/progesterone regimens on blood
coagulation and fibrinolysis in postmenopausal women: a randomized controlled
trial. Arterioscler Thromb Vasc Biol1997; 17:3071
-8.
1024. Kroon U-B, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost1994; 71:420 -3.[Medline] [Order article via Infotrieve]
1025. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med1991; 325:1196 -204.[Abstract]
1026. Crook D, Cust MP, Gangar KF, Worthington M, Hillard TC, Stevenson JC, Whitehead MI, Wynn V. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol1992; 166:950 -5.[Medline] [Order article via Infotrieve]
1027. Meschia M, Bruschi F, Soma M, Amicarelli F, Paoletti R, Crosignani P. Effects of oral and transdermal hormone replacement therapy on lipoprotein(A) and lipids: a randomized controlled trial. Menopause 1998;5:157-62 .
1028. Walsh BW, Li H, Sacks FM. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res1994; 35:2083-93 .
1029. Do K-A, Green A, Guthrie JR, Dudley EC, Burger HG, Dennerstein L. Longitudinal study of risk factors for coronary heart disease across the menopausal transition. Am J Epidemiol2000; 151:584-93 .
1030. Rossouw JE. What we still need to learn about hormone replacement therapy. Infert Reprod Med Clin North Am1999; 10:189-209 .
1031. Sotelo MM, Johnson SR. The effects of hormone replacement therapy on coronary heart disease. Endocrinol Metab Clin North Am 1997;26:313-28 .
1032. Barrett-Connor E. Hormone replacement therapy. BMJ 1998;317:457-61 .
1033. National Center for Health Statistics, Fulwood R, Kalsbeek W, Rifkind B, et al. Total serum cholesterol levels of adults 20-74 years of age: United States, 1976-80. Vital and Health Statistics. Series 11. No. 236. DHHS Pub. No. (PHS) 86-1686. Public Health Service. Washington: U.S. Government Printing Office, May 1986;59 pages.
1034. Kronmal RA, Cain KC, Ye Z, Omenn GS. Total serum cholesterol levels and mortality risk as a function of age. Arch Intern Med 1993;153:1065-73 .
1035. Zimetbaum P, Frishman WH, Ooi WL, Derman MP, Aronson M, Gidez LI, Eder HA. Plasma lipids and lipoproteins and the incidence of cardiovascular disease in the very elderly: the Bronx Aging Study. Arterioscler Thromb 1992;12:416-23 .
1036. Krumholz HM, Seeman TE, Merrill SS, Mendes de Leon CF, Vaccarino V, Silverman DI, Tsukahara R, Ostfeld AM, Berkman LF. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA1994; 272:135-40 .
1037. Kuller L, Borhani N, Furberg C, Gardin J, Manolio T, O'Leary D, Psaty B, Robbins J. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. Am J Epidemiol1994; 139:1164-79 .
1038. Grundy SM. Early detection of high cholesterol levels in young adults [Editorial]. JAMA2000; 284:365-7 .
1039. Cleeman JI, Grundy SM. National Cholesterol Education Program recommendations for cholesterol testing in young adults: a science-based approach. Circulation1997; 95:1646-50 .
1040. Clark LT, Ferdinand KC, Flack JM, Gavin JR III, Hall WD, Kumanyika SK, Reed JW, Saunders E, Valantine HA, Watson K, Wenger NK, Wright JT. Coronary heart disease in African Americans. Heart Disease 2001;3:97-108 .
1041. Traven ND, Kuller LH, Ives DG, Rutan GH, Perper JA. Coronary heart disease mortality and sudden death among the 35-44-year age group in Allegheny County, Pennsylvania. Ann Epidemiol1996; 6:130-6 .
1042. Gillum RF, Mussolino ME, Madans JH. Coronary heart disease incidence and survival in African-American women and men: the NHANES I Epidemiologic Follow-up Study. Ann Intern Med1997; 127:111-8 .
1043. Gillum RF. Sudden cardiac death in Hispanic Americans and African
Americans. Am J Public Health 1997;87
: 1461-6.
1044. Hutchinson RG, Watson RL, Davis CE, Barnes R, Brown S, Romm F, Spencer JM, Tyroler HA, Wu K, for the ARIC Study Group. Racial differences in risk factors for atherosclerosis: the ARIC Study. Angiology 1997;48:279-90 .
1045. Cutter GR, Burke GL, Dyer AR, Friedman GD, Hilner JE, Hughes GH, Hulley SB, Jacobs DR Jr, Liu K, Manolio TA, Oberman A, Perkins LL, Savage PJ, Serwitz JR, Sidney S, Wagenknecht LE. Cardiovascular risk factors in young adults: the CARDIA baseline monograph. Control Clin Trials 1991;12(suppl):1S -77S.[CrossRef][Medline] [Order article via Infotrieve]
1046. Cooper RS, Liao Y, Rotimi C. Is hypertension more severe among U.S. blacks, or is severe hypertension more common? Ann Epidemiol 1996;6:173-80 .
1047. Liao Y, Cooper RS, McGee DL, Mensah GA, Ghali JK. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 1995;273:1592-7 .
1048. Gavin JR III. Diabetes in minorities: reflections on the medical dilemma and the healthcare crisis. Trans Am Clin Climatol Assoc 1995;107:213-23 .
1049. D'Agostino RB Sr., Grundy S, Sullivan LM, Wilson P, for the CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001;286:180-7 .
1050. Sorlie PD, Backlund E, Johnson NJ, Rogot E. Mortality by Hispanic status in the United States. JAMA1993; 270:2464-8 .
1051. Wei M, Mitchell BD, Haffner SM, Stern MP. Effects of cigarette smoking, diabetes, high cholesterol, and hypertension on all-cause mortality and cardiovascular disease mortality in Mexican Americans: the San Antonio Heart Study. Am J Epidemiol1996; 144:1058-65 .
1052. Liao Y, Cooper RS, Cao G, Kaufman JS, Long AE, McGee DL. Mortality from coronary heart disease and cardiovascular disease among adult U.S. Hispanics: findings from the National Health Interview Survey (1986 to 1994). J Am Coll Cardiol 1997;30 .
1053. Sundquist J, Winkleby MA. Cardiovascular risk factors in Mexican American adults: a transcultural analysis of NHANES III, 1988-1994. Am J Public Health1999; 89:723-30 .
1054. Winkleby MA, Robinson TN, Sundquist J, Kraemer HC. Ethnic variation in cardiovascular disease risk factors among children and young adults: findings from the Third National Health and Nutrition Examination Survey, 1988-1994. JAMA1999; 281:1006-13 .
1055. Sundquist J, Winkleby MA, Pudaric S. Cardiovascular disease risk factors among older black, Mexican-American, and white women and men: an analysis of NHANES III, 1988-1994. J Am Geriatr Soc2001; 49:109-16 .
1056. Markides KS, Coreil J. The health of Hispanics in the southwestern United States: an epidemiologic paradox. Public Health Rep 1986;101:253-65 .[Medline] [Order article via Infotrieve]
1057. Howard BV, Lee ET, Cowan LD, Fabsitz RR, Howard WJ, Oopik AJ, Robbins DC, Savage PJ, Yeh JL, Welty TK. Coronary heart disease prevalence and its relation to risk factors in American Indians: the Strong Heart Study. Am J Epidemiol1995; 142:254-68 .
1058. Oopik AJ, Dorogy M, Devereux RB, Yeh J-L, Okin PM, Lee ET, Cowan L, Fabsitz RR, Howard BV, Welty TK. Major electrocardiographic abnormalities among American Indians aged 45 to 74 years (the Strong Heart Study). Am J Cardiol1996; 78:1400-5 .
1059. Howard BV, Lee ET, Cowan LD, Devereaux RB, Galloway JM, Go OT, Howard WJ, Rhoades ER, Robbins DC, Sievers ML, Welty TK. Rising tide of cardiovascular disease in American Indians: the Stong Heart Study. Circulation1999; 99:2389-95 .
1060. Welty TK, Lee ET, Yeh J, Cowan LD, Go O, Fabsitz RR, Le N-A, Oopik AJ, Robbins DC, Howard BV. Cardiovascular disease risk factors among American Indians: the Strong Heart Study. Am J Epidemiol1995; 142:269-87 .
1061. Goldberg RJ, Burchfiel CM, Benfante R, Chiu D, Reed DM, Yano K. Lifestyle and biologic factors associated with atherosclerotic disease in middle-aged men: 20-year findings from the Honolulu Heart Program. Arch Intern Med1995; 155:686-94 .
1062. Abbott RD, Sharp DS, Burchfiel CM, Curb JD, Rodriguez BL, Hakim AA, Yano K. Cross-sectional and longitudinal changes in total and high-density-lipoprotein cholesterol levels over a 20-year period in elderly men: the Honolulu Heart Program. Ann Epidemiol1997; 7:417-24 .
1063. Enas EA, Yusuf S, Sharma S. Coronary artery disease in South Asians: second meeting of the International Working Group: 16 March 1997, Anaheim, California. Indian Heart J1998; 50:105-13 .
1064. Anand SS, Enas EA, Pogue J, Haffner S, Pearson T, Yusuf S. Elevated lipoprotein(a) levels in South Asians in North America. Metabolism1998; 47:182-4 .
1065. Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med1980; 303:1038-41 .
1066. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J1997; 18:1718-24 .
1067. Harnick DJ, Cohen JL, Schechter CB, Fuster V, Smith DA. Effects of practice setting on quality of lipid-lowering management in patients with coronary artery disease. Am J Cardiol1998; 81:1416-20 .
1068. Frolkis JP, Zyzanski SJ, Schwartz JM, Suhan PS. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATP II) guidelines. Circulation1998; 98:851-5 .
1069. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67 .
1070. Hoerger TJ, Bala MV, Bray JW, Wilcosky TC, LaRosa J. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol1998; 82:61-5 .[CrossRef][Medline] [Order article via Infotrieve]
1071. Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley S, for the HERS Research Group. Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease: the Heart and Estrogen/Progestin Replacement Study (HERS). JAMA1997; 277:1281-6 .
1072. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust1996; 164:208-11 .
1073. Haynes RB, Montague P, Oliver T, McKibbon KA, Brouwers MC, Kanani R. Interventions for helping patients follow prescriptions for medications (Cochrane Review). In: The Cochrane Library, Issue 4,1999 . Oxford: Update Software.
1074. Horwitz RI, Horwitz SM. Adherence to treatment and health outcomes. Arch Intern Med1993; 153:1863-8 .
1075. Baird MG, Bentley-Taylor MM, Carruthers SG, Dawson KG, Laplante LE, Larochelle P, MacCannell KL, Marquez-Julio A, Silverberg LR, Talbot P. A study of efficacy, tolerance and compliance of once-daily versus twice-daily metoprolol (Betaloc) in hypertension: Betaloc Compliance Canadian Cooperative Study Group. Clin Invest Med1984; 7:95 -102.[Medline] [Order article via Infotrieve]
1076. Colcher IS, Bass JW. Penicillin treatment of streptococcal
pharyngitis: a comparison of schedules and the role of specific counseling.
JAMA 1972;222:657
-9.
1077. Sackett DL, Haynes RB, Gibson ES, Hackett BC, Taylor DW, Roberts RS, Johnson AL. Randomised clinical trial of strategies for improving medication compliance in primary hypertension. Lancet1975; 1:1205 -7.[Medline] [Order article via Infotrieve]
1078. Becker LA, Glanz K, Sobel E, Mossey J, Zinn SL, Knott KA. A randomized trial of special packaging of antihypertensive medications. J Fam Pract1986; 22:357 -61.[Medline] [Order article via Infotrieve]
1079. Haynes RB, Sackett DL, Gibson ES, Taylor DW, Hackett BC, Roberts RS, Johnson AL. Improvement of medication compliance in uncontrolled hypertension. Lancet1976; 1:1265 -8.[Medline] [Order article via Infotrieve]
1080. Logan AG, Milne BJ, Achber C, Campbell WP, Haynes RB. Work-site treatment of hypertension by specially trained nurses: a controlled trial. Lancet 1979;2:1175 -8.[Medline] [Order article via Infotrieve]
1081. Peterson GM, McLean S, Millingen KS. A randomized trial of strategies to improve patient compliance with anticonvulsant therapy. Epilepsia 1984;25:412 -7.[Medline] [Order article via Infotrieve]
1082. Kirkman MS, Weinberger M, Landsman PB, Samsa GP, Shortliffe EA, Simel DL, Feussner JR. A telephone-delivered intervention for patients with NIDDM. Diabetes Care1994; 17:840 -6.[Abstract]
1083. Friedman RH, Kazis LE, Jette A, Smith MB, Stollerman J, Torgerson J, Carey K. A telecommunications system for monitoring and counseling patients with hypertension: impact on medication adherence and blood pressure control. Am J Hypertens1996; 9:285 -92.[CrossRef][Medline] [Order article via Infotrieve]
1084. Raynor DK, Booth TG, Blenkinsopp A. Effects of computer generated
reminder charts on patients' compliance with drug regimens.
BMJ 1993;306:1158
-61.
1085. Ornstein SM, Garr DR, Jenkins RG, Rust PF, Arnon A. Computer-generated physician and patient reminders: tools to improve population adherence to selected preventive services. J Fam Pract 1991;32:82 -90.[Medline] [Order article via Infotrieve]
1086. Taylor CB, Houston-Miller N, Killen JD, DeBusk RF. Smoking
cessation after acute myocardial infarction: effects of a nurse-managed
intervention. Ann Intern Med1990; 113:118
-23.
1087. Robinson JG, Conroy C, Wickemeyer WJ. A novel telephone-based
system for management of secondary prevention to a low-density lipoprotein
cholesterol 
100 mg/dL. Am J Cardiol2000; 85:305
-8.[CrossRef][Medline]
[Order article via Infotrieve]
1088. Bovbjerg VE, McCann BS, Brief DJ, Follette WC, Retzlaff BM, Dowdy
AA, Walden CE, Knopp RH. Spouse support and long-term adherence to
lipid-lowering diets. Am J Epidemiol1995; 141:451
-60.
1089. Morisky DE, Levine DM, Green LW, Shapiro S, Russell RP, Smith CR.
Five-year blood pressure control and mortality following health education for
hypertensive patients. Am J Public Health1983; 73:153
-62.
1090. Daltroy LH, Godin G. The influence of spousal approval and patient perception of spousal approval on cardiac patient participation in exercise programs. J Cardiopulmonary Rehabil1989; 9:363 -7.
1091. Baker RC, Kirschenbaum DS. Self-monitoring may be necessary for successful weight control. Behavior Therapy1993; 24:377 -94.[CrossRef]
1092. Edmonds D, Foerster E, Groth H, Greminger P, Siegenthaler W, Vetter W. Does self-measurement of blood pressure improve patient compliance in hypertension? J Hypertens1985; 3(suppl 1):31 -4.[CrossRef][Medline] [Order article via Infotrieve]
1093. Oldridge NB, Jones NL. Improving patient compliance in cardiac exercise rehabilitation: effects of written agreement and self-monitoring. J Cardiopulm Rehabil1983; 3:257 -62.
1094. McBride P, Underbakke G, Plane MB, Massoth K, Brown RL, Solberg LI, Ellis L, Schrott HG, Smith K, Swanson T, Spencer E, Pfeifer G, Knox A. Improving prevention systems in primary care practices: the Health Education and Research Trial (HEART). J Fam Pract2000; 49:115 -25.[Medline] [Order article via Infotrieve]
1095. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud P-A, Rubin
HR. Why don't physicians follow clinical practice guidelines? A framework for
improvement. JAMA1999; 282:1458
-65.
1096. Maly RC, Abrahamse AF, Hirsh SH, Frank FC, Reuben DB. What influences physician practice behavior? An interview study of physicians who received consultative geriatric assessment recommendations. Arch Fam Med Dev 1996;5:448 -54.[CrossRef]
1097. Ockene IS, Hebert JR, Ockene JK, Merriam PA, Hurley TG, Saperia GM. Effect of training and a structured office practice on physician-delivered nutrition counseling: the Worcester-Area Trial for Counseling in Hyperlipidemia (WATCH). Am J Prev Med1996; 12:252 -8.[Medline] [Order article via Infotrieve]
1098. Kottke TE, Solberg LI, Brekke ML, Conn SA, Maxwell P, Brekke MJ. A controlled trial to integrate smoking cessation advice into primary care practice: doctors helping smokers, round III. J Fam Pract 1992;34:701 -8.[Medline] [Order article via Infotrieve]
1099. Ockene IS, Hebert JR, Ockene JK, Saperia GM, Stanek E, Nicolosi R,
Merriam PA, Hurley TG. Effect of physician-delivered nutrition counseling
training and an office-support program on saturated fat intake, weight, and
serum lipid measurements in a hyperlipidemic population. Worcester Area Trial
for Counseling in Hyperlipidemia (WATCH). Arch Intern
Med 1999;159:725
-31.
1100. Davis DA, Thomson MA, Oxman AD, Haynes RB. Changing physician
performance: a systematic review of the effect of continuing medication
education strategies. JAMA1995; 274:700
-5.
1101. Ockene JK, McBride PE, Sallis JF, Bonollo DP, Ockene IS. Synthesis of lessons learned from cardiopulmonary preventive interventions in healthcare practice settings. Ann Epidemiol1997; S7:S32 -S45.
1102. Stamos TD, Shaltoni H, Girard SA, Parillo JE, Calvin JE. Effectiveness of chart prompts to improve physician compliance with the National Cholesterol Education Program guidelines. Am J Cardiol 2001;88:1420 -3.[CrossRef][Medline] [Order article via Infotrieve]
1103. Dietrich AJ, O'Connor GT, Keller A, Carney PA, Levy D, Whaley FS.
Cancer: improving early detection and prevention: a community practice
randomised trial. BMJ1992; 304:687
-91.
1104. Finnerty FA Jr, Shaw LW, Himmelsbach CK. Hypertension in the inner
city. II. Detection and follow-up. Circulation1973; 47:76
-8.